<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006602.pub4" GROUP_ID="ARI" ID="939806081403013795" MERGED_FROM="" MODIFIED="2013-06-13 05:14:31 +0100" MODIFIED_BY="Liz Dooley" REVIEW_NO="A041" REVMAN_SUB_VERSION="5.2.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2013-06-13 05:14:31 +0100" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2011-06-17 05:10:09 +1000" MODIFIED_BY="Tea Andabaka">Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children</TITLE>
<CONTACT MODIFIED="2013-06-13 05:14:31 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="CCE42FE782E26AA20004653063294FAA" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tea</FIRST_NAME><LAST_NAME>Andabaka</LAST_NAME><EMAIL_1>Tea.Andabaka@gmail.com</EMAIL_1><MOBILE_PHONE>+385997373195</MOBILE_PHONE><ADDRESS><ORGANISATION>Ewopharma Ltd</ORGANISATION><ADDRESS_1>Zadarska 80 / 2</ADDRESS_1><CITY>Zagreb</CITY><ZIP>10000</ZIP><COUNTRY CODE="HR">Croatia</COUNTRY><PHONE_1>+38516548553</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-06-13 05:14:31 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="CCE42FE782E26AA20004653063294FAA" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tea</FIRST_NAME><LAST_NAME>Andabaka</LAST_NAME><EMAIL_1>Tea.Andabaka@gmail.com</EMAIL_1><MOBILE_PHONE>+385997373195</MOBILE_PHONE><ADDRESS><ORGANISATION>Ewopharma Ltd</ORGANISATION><ADDRESS_1>Zadarska 80 / 2</ADDRESS_1><CITY>Zagreb</CITY><ZIP>10000</ZIP><COUNTRY CODE="HR">Croatia</COUNTRY><PHONE_1>+38516548553</PHONE_1></ADDRESS></PERSON><PERSON ID="34791097803893750392091105160314" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Jason</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Nickerson</LAST_NAME><POSITION>PhD candidate</POSITION><EMAIL_1>jnick018@uottawa.ca</EMAIL_1><URL>http://www.jasonnickerson.ca</URL><ADDRESS><ORGANISATION>Institute of Population Health</ORGANISATION><ADDRESS_1>1 Stewart Street</ADDRESS_1><CITY>Ottawa</CITY><ZIP>K1N 6N5</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 613 562 5800 x2339</PHONE_1></ADDRESS></PERSON><PERSON ID="EEE82C9782E26AA20126CDD1B6925085" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Maria Ximena</FIRST_NAME><LAST_NAME>Rojas-Reyes</LAST_NAME><SUFFIX>RN</SUFFIX><POSITION>Clinical Epidemiologist, Associate Professor in Clinical Epidemiology</POSITION><EMAIL_1>mxrojas@gmail.com</EMAIL_1><EMAIL_2>mxrojas@javeriana.edu.co</EMAIL_2><ADDRESS><DEPARTMENT>Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine</DEPARTMENT><ORGANISATION>Pontificia Universidad Javeriana</ORGANISATION><ADDRESS_1>Cr. 7 #40-62, 2nd floor</ADDRESS_1><CITY>Bogota</CITY><REGION>DC</REGION><COUNTRY CODE=" CO">Colombia</COUNTRY><PHONE_1>+57 1 320 8320 ext 2811</PHONE_1><PHONE_2>+57 1 320 8320 ext 2812 / 2799</PHONE_2><FAX_1>+57 1 285 6981</FAX_1></ADDRESS></PERSON><PERSON ID="97337423593257210268111207015901" ROLE="AUTHOR"><FIRST_NAME>Juan David</FIRST_NAME><LAST_NAME>Rueda</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Research Assistant</POSITION><EMAIL_1>juandavidruedamd@gmail.com</EMAIL_1><EMAIL_2>cometinrueda@hotmail.com</EMAIL_2><MOBILE_PHONE>+571 31 1440 1922</MOBILE_PHONE><ADDRESS><DEPARTMENT>Departamento de Cirugía</DEPARTMENT><ORGANISATION>Pontificia Universidad Javeriana</ORGANISATION><ADDRESS_1>Carrera 7 No. 40 - 62</ADDRESS_1><CITY>Bogota</CITY><REGION>Cundinamarca</REGION><COUNTRY CODE=" CO">Colombia</COUNTRY><PHONE_1>+571 320 8320 ext 2808</PHONE_1><FAX_1>+571 320 8320 ext 2808</FAX_1></ADDRESS></PERSON><PERSON ID="CCEF1DE082E26AA200046530A1B07E94" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vesna</FIRST_NAME><LAST_NAME>Bacic Vrca</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Head of the Hospital Pharmacy Department</POSITION><EMAIL_1>vesnav@kbd.hr</EMAIL_1><MOBILE_PHONE>+385 91 535 5741</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Hospital Pharmacy</DEPARTMENT><ORGANISATION>University Hospital Dubrava</ORGANISATION><ADDRESS_1>Avenija Gojka ?u?ka 6</ADDRESS_1><CITY>Zagreb</CITY><ZIP>10 000</ZIP><COUNTRY CODE="HR">Croatia</COUNTRY><PHONE_1>+385 1 290 3303</PHONE_1><FAX_1>+385 1 290 2606</FAX_1></ADDRESS></PERSON><PERSON ID="32033528639138622651091112005304" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bruno</FIRST_NAME><LAST_NAME>Barsic</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Professor of Medicine</POSITION><EMAIL_1>bruno.barsic@bfm.hr</EMAIL_1><EMAIL_2>bbarsic@bfm.hr</EMAIL_2><MOBILE_PHONE>+385 91 4012 604</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Intensive Care</DEPARTMENT><ORGANISATION>University of Zagreb, School of Medicine, Hospital for Infectious Diseases</ORGANISATION><ADDRESS_1>Mirogojska 8</ADDRESS_1><CITY>Zagreb</CITY><ZIP>10000</ZIP><COUNTRY CODE="HR">Croatia</COUNTRY><PHONE_1>+385 1 4603 275</PHONE_1><FAX_1>+385 1 4603 255</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-06-03 20:26:05 +1000" MODIFIED_BY="Tea Andabaka">
<UP_TO_DATE>
<DATE DAY="8" MONTH="8" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="8" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="8" MONTH="8" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2013"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2013-06-12 08:04:25 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-12 08:04:25 +1000" MODIFIED_BY="Tea Andabaka">
<DATE DAY="9" MONTH="6" YEAR="2013"/>
<DESCRIPTION>
<P>Results on mortality now included in the Abstract.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MAJOR" MODIFIED="2012-09-26 05:06:49 +1000" MODIFIED_BY="Tea Andabaka">
<DATE DAY="11" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>A new review team took over this previously withdrawn protocol.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>Withdrawn from <I>The Cochrane Library</I> 2010, Issue 1.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-09-07 11:05:56 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-11-21 05:44:56 +1000" MODIFIED_BY="Tea Andabaka">
<INTERNAL_SOURCES MODIFIED="2010-11-21 05:44:20 +1000" MODIFIED_BY="Tea Andabaka">
<SOURCE MODIFIED="2010-11-21 05:44:20 +1000" MODIFIED_BY="Tea Andabaka">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-11-21 05:44:56 +1000" MODIFIED_BY="Tea Andabaka">
<SOURCE MODIFIED="2010-11-21 05:44:56 +1000" MODIFIED_BY="Tea Andabaka">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-06-12 08:29:33 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-06-12 08:29:23 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-09-26 04:17:46 +1000" MODIFIED_BY="[Empty name]">Palivizumab for reducing the risk of severe RSV infection in children</TITLE>
<SUMMARY_BODY MODIFIED="2013-06-12 08:29:23 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory syncytial virus (RSV) infection is a major cause of acute respiratory infections in children. RSV infection can lead to morbidity and mortality in children, resulting in hospitalization, admission to an intensive care unit, the need for intensive medical therapies and death.</P>
<P>Most infected children suffer little consequence. However, children who have other serious health problems are known to be at higher risk of complications from RSV infection. This review examined the use of a passive immunisation - palivizumab - to prevent and modify the severity of RSV infection in these children and to determine if it is cost-effective.</P>
<P>The results from this review are based on data from seven studies (all sponsored by the drug manufacturing company) involving 11,096 participants reporting on efficacy and safety of palivizumab, and 34 studies reporting on its cost-effectiveness.</P>
<P>Our findings suggest a favorable effect of preventive use of palivizumab in children who are at higher risk of acquiring severe RSV infection, when compared to placebo. Children treated with palivizumab were less often hospitalised, spent fewer days in the hospital, were admitted to an intensive care unit less often, and had fewer days of oxygen therapy than children who received a placebo.</P>
<P>Considering the underlying health problems in this population of infants and children, high rates of adverse events are quite expected. Our findings showed that children treated with palivizumab experienced adverse events similarly as often as children treated with placebo.</P>
<P>Palivizumab was shown to be effective in reducing the hospitalisations, but whether it is also cost-effective is not easy to determine. This review found large differences in cost-effectiveness results across the studies. Due to the high costs of the drug, in many countries palivizumab prophylaxis might not be available as a standard treatment.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-06-12 08:29:23 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-06-12 08:29:23 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory syncytial virus (RSV) is one of the most important viral pathogens causing acute respiratory infections, resulting in about 3.4 million hospitalisations annually in children under five. Palivizumab is the only product approved for prevention of serious RSV disease, as motavizumab is no longer being developed for this condition. The efficacy and safety of palivizumab has been evaluated in randomized controlled trials (RCTs) and a large number of economic evaluations (EEs) have tested its cost-effectiveness.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-06-12 08:29:23 +1000" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness and safety of palivizumab prophylaxis in reducing the risk of complications (hospitalization due to RSV infection) in high-risk infants and children. To assess the cost-effectiveness (or cost-utility) of palivizumab prophylaxis in infants and children in different risk groups.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-06-09 19:06:46 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (2012, Issue 7), MEDLINE (1996 to July week 4, 2012), EMBASE (1996 to August 2012), CINAHL (1996 to August 2012) and LILACS (1996 to August 2012) for RCTs. We searched the NHS Economic Evaluations Database (NHS EED 2012, Issue 4), Health Economics Evaluations Database (HEED, 9 August 2012), Paediatric Economic Database Evaluations (PEDE, 1980 to 2009), MEDLINE (1996 to July week 4, 2012) and EMBASE (1996 to August 2012) for EEs.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-06-09 19:48:02 +1000" MODIFIED_BY="[Empty name]">
<P>We included RCTs comparing palivizumab prophylaxis with a placebo or another type of prophylaxis in preventing serious lower respiratory tract disease caused by RSV in paediatric patients at high risk. We included cost-effectiveness analyses and cost-utility analyses comparing palivizumab prophylaxis with no prophylaxis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-06-09 19:10:16 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed risk of bias for the included studies and extracted data for both the RCTs and EEs. We calculated risk ratios (RRs) and their associated 95% confidence intervals (CIs) for dichotomous outcomes and for adverse events (AEs). For continuous outcomes, we provided a narrative summary of results due to missing data on standard deviations. We performed fixed-effect meta-analyses for the estimation of pooled effects whenever there was no indication of heterogeneity between included RCTs. </P>
<P>We summarised the results reported in included EEs, such as incremental costs, incremental effectiveness, and incremental cost-effectiveness and/or cost-utility ratios (ICERs), and we calculated ICER present values in 2011 Euros for all studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-06-09 19:48:10 +1000" MODIFIED_BY="[Empty name]">
<P>Of the seven available RCTs, three compared palivizumab with a placebo in a total of 2831 patients, and four compared palivizumab with motavizumab in a total of 8265 patients. All RCTs were sponsored by the drug manufacturing company. The overall quality of RCTs was good, but most of the outcomes assessed relied on data from only two studies. Palivizumab prophylaxis was associated with a statistically significant reduction in RSV hospitalisations (RR 0.49, 95% CI 0.37 to 0.64) and a statistically non-significant reduction in all-cause mortality (RR 0.69, 95% CI 0.42 to 1.15) when compared to placebo. When compared to motavizumab, palivizumab recipients showed a non-significant increase in the risk of RSV hospitalisations (RR 1.36, 95% CI 0.97 to 1.90) and a non-significant risk reduction in all-cause mortality (RR 0.74, 95% CI 0.38 to 1.43). In both cases, the proportion of children with any AE or any AE related to the study drug was similar between the two groups. </P>
<P>We included 34 studies that reported cost-effectiveness and/or cost-utility data for palivizumab prophylaxis in high-risk children with different underlying medical conditions. The overall quality of EEs was good, but the variations in modelling approaches were considerable across the studies, leading to large differences in the results. The cost-effectiveness of palivizumab prophylaxis depends on the consumption of resources taken into account by the study authors, and on the cost-effectiveness threshold set by the healthcare sector in each country.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-06-09 19:17:31 +1000" MODIFIED_BY="[Empty name]">
<P>There is evidence that palivizumab prophylaxis is effective in reducing the frequency of hospitalisations due to RSV infection, i.e. in reducing the incidence of serious lower respiratory tract RSV disease in children with chronic lung disease, congenital heart disease, or those born preterm. </P>
<P>Results from economic evaluations of palivizumab prophylaxis are inconsistent across studies, ranging from highly cost-effective to not cost-effective, implying that economic findings must be interpreted with caution. The availability of low-cost palivizumab would reduce its inequitable distribution, so that RSV prophylaxis would be available to the poorest countries where children are at greatest risk.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-06-12 08:29:33 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-06-12 08:29:25 +1000" MODIFIED_BY="Liz Dooley">
<CONDITION MODIFIED="2013-06-12 08:29:23 +1000" MODIFIED_BY="Liz Dooley">
<P>Respiratory syncytial virus (RSV) is one of the most important viral pathogens to cause acute respiratory infections (ARIs) in children (<LINK REF="REF-Nair-2010" TYPE="REFERENCE">Nair 2010</LINK>), with virtually all children having been infected with RSV at least once by their second birthday (<LINK REF="REF-Red-Book-2012" TYPE="REFERENCE">Red Book 2012</LINK>). In the United States (US), RSV infection is associated with substantial childhood morbidity, necessitating inpatient and outpatient care (<LINK REF="REF-Hall-2009a" TYPE="REFERENCE">Hall 2009a</LINK>).</P>
<P>RSV infection carries a considerable disease burden, with an estimated 2.1 million children under five years of age requiring medical care in the US each year. Among children with RSV-related illnesses, approximately 3% are hospitalised, 25% are treated in emergency departments and 73% are treated by paediatricians. In the US each year, it is estimated that in children under five, RSV infection accounts for one out of every 334 hospitalisations, one out of 38 visits to an emergency department and one out of 13 visits to a primary care physician (<LINK REF="REF-Hall-2009a" TYPE="REFERENCE">Hall 2009a</LINK>). Globally, it is estimated that RSV causes about 34 million episodes of acute lower respiratory tract infections in children under five, resulting in about 3.4 million hospitalisations each year (<LINK REF="REF-Nair-2010" TYPE="REFERENCE">Nair 2010</LINK>). RSV has also been shown to be the most important viral cause of death in children under five, especially in those younger than one year (<LINK REF="REF-Fleming-2005" TYPE="REFERENCE">Fleming 2005</LINK>; <LINK REF="REF-Shay-2001" TYPE="REFERENCE">Shay 2001</LINK>; <LINK REF="REF-Thompson-2003" TYPE="REFERENCE">Thompson 2003</LINK>). In data compiled by the Centers for Disease Control and Prevention (CDC), RSV pneumonia causes about 2700 adult and paediatric deaths each year in the US (<LINK REF="REF-Thompson-2003" TYPE="REFERENCE">Thompson 2003</LINK>). Globally, it is estimated to result in up to 199,000 deaths per year (<LINK REF="REF-Nair-2010" TYPE="REFERENCE">Nair 2010</LINK>).</P>
<P>The exact timing of the RSV season varies by location and year (<LINK REF="REF-Mullins-2003" TYPE="REFERENCE">Mullins 2003</LINK>). In temperate climates of the US, RSV outbreaks usually begin in November or December, peaking in January or February and end by March or April; whereas in tropical or subtropical climates, RSV activity correlates with rainy seasons and may be present throughout the year (<LINK REF="REF-AAP-2009" TYPE="REFERENCE">AAP 2009</LINK>; <LINK REF="REF-Hall-2009b" TYPE="REFERENCE">Hall 2009b</LINK>; <LINK REF="REF-Simoes-2003" TYPE="REFERENCE">Simoes 2003</LINK>). The most recent RSV season for which data are available in the US was July 2010 to June 2011, and this RSV season had a median duration of 19 weeks (<LINK REF="REF-CDC-2011" TYPE="REFERENCE">CDC 2011</LINK>). Knowledge of RSV seasonality can be used by clinicians and public health officials to determine when to consider RSV as a cause of ARIs and when to provide RSV immunoprophylaxis to children at high risk of serious disease (<LINK REF="REF-Red-Book-2012" TYPE="REFERENCE">Red Book 2012</LINK>).</P>
<P>The incubation period of infection frequently lasts four to six days. Inoculation of the virus happens through the upper respiratory tract (URT), followed by infection of the respiratory epithelium. The mechanism by which the virus spreads along the respiratory tract is not clear, but may occur through cell-to-cell transfer along intracytoplasmic bridges or through the aspiration of nasopharyngeal aspirations, and may involve the conducting airways at all levels (<LINK REF="REF-Domachowske-1999" TYPE="REFERENCE">Domachowske 1999</LINK>; <LINK REF="REF-Hall-2009b" TYPE="REFERENCE">Hall 2009b</LINK>). Transmission of RSV is usually by direct or close contact with RSV-contaminated secretions. The virus can survive for several hours on surfaces, and for approximately half an hour on hands, reinforcing the need for stringent infection control policies within health facilities to reduce nosocomial infections. Transmission of the virus among household and child care contacts is common.</P>
<P>RSV initially manifests in infants as an upper respiratory tract infection, but progresses to a lower respiratory tract infection in approximately 20% to 30% of infants with varying degrees of severity, ranging from mild to life-threatening respiratory failure (<LINK REF="REF-Red-Book-2012" TYPE="REFERENCE">Red Book 2012</LINK>). Bronchiolitis usually develops one to three days following common cold symptoms such as nasal congestion and discharge, mild cough, fever and reduced appetite. As the infection progresses and the small airways are affected, other symptoms may develop, such as rapid breathing, wheezing, persistent cough and difficulty feeding, which can result in dehydration. Apnoea (a pause in breathing for more than 15 or 20 seconds) is the presenting symptom in up to 20% of infants admitted to hospital with RSV and may be the first symptom of bronchiolitis (<LINK REF="REF-Arms-2008" TYPE="REFERENCE">Arms 2008</LINK>; <LINK REF="REF-Hall-1979" TYPE="REFERENCE">Hall 1979</LINK>; <LINK REF="REF-Ralstone-2009" TYPE="REFERENCE">Ralstone 2009</LINK>). While most cases of RSV infection are not severe, in severe cases oxygenation may worsen and a child may develop acute respiratory or ventilatory failure, necessitating mechanical ventilation and admission to an intensive care unit (ICU). Approximately 1% to 3% of all children under 12 months of age will require hospitalization for the treatment of lower respiratory tract infection resulting from RSV (<LINK REF="REF-Red-Book-2012" TYPE="REFERENCE">Red Book 2012</LINK>).</P>
<P>Characteristics that are most frequently associated with RSV illness requiring hospitalization include male sex, chronic co-existing medical conditions, lower socio-economic status, smoke exposure, contact with other children and lack of breast-feeding (<LINK REF="REF-Hall-2009a" TYPE="REFERENCE">Hall 2009a</LINK>). Characteristics that increase the risk of severe RSV illness are preterm birth, cyanotic or complicated congenital heart disease, especially conditions that cause pulmonary hypertension, chronic lung disease of prematurity (formerly called bronchopulmonary dysplasia) and immunodeficiency (<LINK REF="REF-Purcell-2004" TYPE="REFERENCE">Purcell 2004</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-06-12 08:29:25 +1000" MODIFIED_BY="Liz Dooley">
<P>The observation that passively transferred maternal RSV-neutralising antibodies provided some protection from severe lower respiratory tract (LRT) disease has led to the development of passive immunity products to prevent and modify the severity of RSV infection. The first product available for this use was a respiratory syncytial virus immune globulin intravenous (RSV-IVIG, RespiGam), a polyclonal human RSV-neutralising antibody (a combination of different immunoglobulin molecules), administered intravenously during RSV-risk months. RSV-IVIG is no longer available.</P>
<P>In 1996, palivizumab (Synagis) entered into clinical trials. Palivizumab is an anti-RSV monoclonal antibody (a set of identical immunoglobulin molecules), administered intramuscularly at a dose of 15 mg/kg once every 30 days. The efficacy and safety of palivizumab has been evaluated in multicentre randomized controlled trials (RCTs), which in two trials demonstrated 45% and 55% decreases in RSV-related hospitalisations (<LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>; <LINK REF="STD-IMpact_x002d_RSV-1998" TYPE="STUDY">IMpact-RSV 1998</LINK>). In both trials, palivizumab prophylaxis was generally safe and well tolerated. In June 1998, palivizumab was licensed by the US Food and Drug Administration (FDA) for prevention of serious LRT disease caused by RSV in paediatric patients who are at an increased risk of severe disease (<LINK REF="REF-AAP-2009" TYPE="REFERENCE">AAP 2009</LINK>).</P>
<P>In 2008, MedImmune filed for FDA approval of motavizumab (Numax, Rezield), another RSV-neutralising monoclonal antibody intended for the same indication. The efficacy and safety of motavizumab and palivizumab were compared in a multinational non-inferiority RCT (<LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>). However, the FDA did not approve motavizumab for RSV prophylaxis, due to concerns regarding ts safety and efficacy. Serious concerns were raised with regards to non-fatal hypersensitivity adverse events, which were three times higher in the motavizumab group than in the palivizumab group. Additional questions were raised with regards to geographical stratification of study patients, since measures of motavizumab's non-inferiority relied heavily on data obtained from the 9% of participants enrolled in southern hemisphere countries. Removing this population led the FDA to determine that in the US population motavizumab did not meet the non-inferiority criterion relative to palivizumab. In December 2010, the company announced it had discontinued further development of motavizumab for the prophylaxis of serious RSV disease. Therefore, palivizumab is currently the only product approved for prevention of serious RSV disease in infants and children with chronic lung disease, with a history of preterm birth (35 weeks gestation or less), or with haemodynamically significant congenital heart disease (<LINK REF="REF-AAP-2009" TYPE="REFERENCE">AAP 2009</LINK>).</P>
<P>The cost of immunoprophylaxis with palivizumab is high and economic analyses have failed to demonstrate overall savings in healthcare dollars if all infants who are at risk receive prophylaxis (<LINK REF="STD-ElHassan-2006" TYPE="STUDY">ElHassan 2006</LINK>; <LINK REF="STD-Garcia_x002d_Altes-2010" TYPE="STUDY">Garcia-Altes 2010</LINK>; <LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>). In the USA, it is considered that a total of five monthly doses for infants and young children with chronic lung disease, congenital heart disease or preterm birth born before 32 weeks gestation will provide an optimal balance of benefit and cost, even with variation in the season's onset and end (<LINK REF="REF-AAP-2009" TYPE="REFERENCE">AAP 2009</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2012-10-15 13:24:57 +1000" MODIFIED_BY="Tea Andabaka">
<P>Respiratory syncytial virus is a ribonucleic acid (RNA) virus of the <I>Paramyxoviridae</I> family. The virus uses attachment (G) and fusion (F) surface glycoproteins to infect cells. Palivizumab is a humanised mouse monoclonal immunoglobulin G1, produced by recombinant DNA technology and directed to an epitope of the F glycoprotein of RSV. Palivizumab binds to this glycoprotein and prevents viral invasion of the host cells in the airway. This reduces viral activity and cell-to-cell transmission and blocks the fusion of infected cells (<LINK REF="REF-Johnson-1997" TYPE="REFERENCE">Johnson 1997</LINK>). As a result, preventive use of palivizumab may be associated with reduced risk for developing LRT disease (<LINK REF="REF-Hall-2010" TYPE="REFERENCE">Hall 2010</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>In a previous Cochrane systematic review, the pooled effects of RSV-IVIG and palivizumab were assessed together, compared to placebo, with the last search performed in March 1999 (<LINK REF="REF-Wang-1999" TYPE="REFERENCE">Wang 1999</LINK>). That review included three studies with RSV-IVIG and one with palivizumab prophylaxis. The review was withdrawn from <I>The Cochrane Library</I> in 2003, as the authors could not commit time to update it. Since then, RSV-IVIG has been withdrawn from the market, methodologies of performing systematic reviews have changed and additional RCTs with palivizumab have been conducted. A new team of authors took over this review in 2007 and published a protocol which focused on effectiveness and safety of prophylaxis with palivizumab (<LINK REF="REF-Lozano-2007" TYPE="REFERENCE">Lozano 2007</LINK>). The protocol was withdrawn from <I>The Cochrane Library</I> in 2010, as the authors could not commit time to writing a review.</P>
<P>Unlike the review by <LINK REF="REF-Wang-1999" TYPE="REFERENCE">Wang 1999</LINK>, ours focuses on palivizumab prophylaxis, in terms of effectiveness and safety, as well as its cost-effectiveness. We expect that our findings will provide comprehensive and up-to-date evidence on RSV immunoprophylaxis with palivizumab in infants and children at high risk of severe RSV disease.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-06-12 08:29:25 +1000" MODIFIED_BY="Liz Dooley">
<OL>
<LI>To assess the effectiveness and safety of palivizumab prophylaxis compared with placebo, or another type of prophylaxis, in reducing the risk of complications (hospitalization due to RSV infection) in high-risk infants and children.</LI>
<LI>To assess the cost-effectiveness (or cost-utility) of palivizumab prophylaxis compared with no prophylaxis in infants and children in different risk groups.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2013-06-12 08:29:27 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-06-12 08:29:25 +1000" MODIFIED_BY="Liz Dooley">
<CRIT_STUDIES MODIFIED="2013-06-12 08:29:25 +1000" MODIFIED_BY="Liz Dooley">
<P>To study the effectiveness and safety of palivizumab, we included randomized controlled trials (RCTs) comparing palivizumab prophylaxis with a placebo, no prophylaxis or another type of prophylaxis in preventing serious LRT disease caused by RSV in paediatric patients at high risk of RSV disease.</P>
<P>To study cost-effectiveness (or cost-utility), we included full economic evaluation studies (cost-effectiveness analyses and cost-utility analyses) comparing palivizumab prophylaxis with no prophylaxis. We considered for inclusion health economics studies conducted alongside high-quality randomized trials, and economic modelling studies based on data from high-quality randomized trials or based on a comprehensive systematic review of the literature. We excluded partial economic evaluation studies that report cost analyses, or cost-outcome descriptions, due to the large number of available full economic evaluations. We also excluded economic evaluations of prophylaxis with RSV-IVIG, due to the fact that palivizumab is the only approved product for this purpose, and these analyses would be of no importance to health funds or patients.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Liz Dooley">
<P>We included infants and children at high risk of developing LRT disease caused by RSV, i.e. those with chronic lung disease (or bronchopulmonary dysplasia), congenital heart disease, immunodeficiency, chronic neuromuscular disease, congenital anomalies or those born preterm. We excluded children with cystic fibrosis as a related Cochrane Review has already been published on that topic (<LINK REF="REF-Robinson-2012" TYPE="REFERENCE">Robinson 2012</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-10-15 13:25:17 +1000" MODIFIED_BY="[Empty name]">
<P>We compared passive immunisation of palivizumab (15 mg/kg dose, any setting and regimen) with placebo, no prophylaxis or another type of prophylaxis. In the critical assessment of health economics studies, we compared palivizumab prophylaxis with no prophylaxis.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-06-12 08:29:25 +1000" MODIFIED_BY="Liz Dooley">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-09-29 03:19:45 +1000" MODIFIED_BY="Liz Dooley">
<OL>
<LI>Hospitalisation for RSV infection.</LI>
<LI>All-cause mortality.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-06-12 08:29:25 +1000" MODIFIED_BY="Liz Dooley">
<SUBSECTION>
<HEADING LEVEL="4">Effectiveness outcomes</HEADING>
<OL>
<LI>RSV-specific outpatient medically attended lower respiratory tract infection (MALRI).</LI>
<LI>Number of days in hospital attributable to RSV infection per 100 randomized children.</LI>
<LI>Admission to intensive care unit (ICU).</LI>
<LI>Number of days in the ICU per 100 randomized children.</LI>
<LI>Mechanical ventilation for RSV infection.</LI>
<LI>Number of days of mechanical ventilation per 100 randomized children.</LI>
<LI>Supplemental oxygen therapy for RSV infection.</LI>
<LI>Number of days of supplemental oxygen therapy per 100 randomized children.</LI>
<LI>Bronchodilator therapy for RSV infection.</LI>
<LI>Number of days of bronchodilator therapy per 100 randomized children.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety outcomes</HEADING>
<OL>
<LI>Number of children reporting any adverse event (AE).</LI>
<LI>Number of children reporting related AE.</LI>
<LI>Number of children reporting any serious adverse event (SAE).</LI>
<LI>Number of children reporting related SAE.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Economic evaluation outcomes</HEADING>
<OL>
<LI>Effectiveness outcome measures: hospitalization for RSV infection avoided (number of RSV hospitalisations avoided due to the use of prophylaxis), or any other effect measure reported by study authors such as quality-adjusted life-year (QALY), life-year gained (LYG) or life-year lost (LYL).</LI>
<LI>The direct medical costs associated with:</LI>
<UL>
<LI>administration of palivizumab (palivizumab injections, administration by physicians, nurses or both);</LI>
<LI>length of hospital stay;</LI>
<LI>days of mechanical ventilation;</LI>
<LI>days in ICU;</LI>
<LI>need for supplemental oxygen;</LI>
<LI>incidence of complications such as air leak syndrome and aggregated bacterial infections;</LI>
<LI>treatment of adverse events;</LI>
<LI>number of outpatient visits;</LI>
<LI>number of outpatient emergency department visits.</LI>
</UL>
<LI>The indirect medical costs associated with:</LI>
<UL>
<LI>number of days off work (parents or caregivers);</LI>
<LI>patient out-of-pocket expenses;</LI>
<LI>future lost productivity of a child.</LI>
</UL>
<LI>Incremental cost-effectiveness ratios (ICERs) expressed as incremental costs per hospitalization avoided, per quality-adjusted life-years (QALY) and per life-years gained (LYG).</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-06-12 08:29:25 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-06-12 08:29:25 +1000" MODIFIED_BY="[Empty name]">
<P>To identify studies on effectiveness and safety, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2012, Issue 7, part of <I>The Cochrane Library, </I>
<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A> (accessed 8 August 2012), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (1996 to July week 4, 2012), EMBASE (1996 to August 2012), CINAHL (1996 to August 2012) and LILACS (1996 to August 2012).</P>
<P>We searched MEDLINE and CENTRAL using the keywords and MeSH terms in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. We used the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE; sensitivity- and precision-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We adapted this search strategy to search EMBASE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), CINAHL (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>) and LILACS (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). In addition, we ran a search in MEDLINE and EMBASE for adverse effects based on the search strategy developed by Golder (<LINK REF="REF-Golder-2006" TYPE="REFERENCE">Golder 2006</LINK>) (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>). We did not use any language or publication restrictions.</P>
<P>To identify economic studies we based our search strategy on the search strategy in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> and searched the NHS Economic Evaluations Database (NHS EED) 2012, Issue 4, part of <I>The Cochrane Library, </I>
<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A> (accessed 9 August 2012), Health Economics Evaluations Database (HEED, searched 9 August 2012) and Paediatric Economic Database Evaluations (PEDE, 1980 to 2009, searched 29 July 2011). We also searched for economic evaluations in MEDLINE (1996 to July week 4, 2012) and EMBASE (1996 to August 2012) using a filter based on the work of <LINK REF="REF-Glanville-2009" TYPE="REFERENCE">Glanville 2009</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the reference lists of relevant studies and review articles to identify additional eligible studies and trial reports. We searched appropriate clinical trials databases utilising the World Health Organization's (WHO) International Clinical Trials Registry Platform (ICTRP), <A HREF="http://www.who.int/ictrp/">www.who.int/ictrp/</A> (accessed 9 August 2012, search terms: respiratory syncytial virus, palivizumab and synagis). We contacted the drug manufacturer (MedImmune LLC), trial authors and content experts to obtain information on ongoing or unpublished studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-06-12 08:29:27 +1000" MODIFIED_BY="Liz Dooley">
<STUDY_SELECTION MODIFIED="2013-06-12 08:29:27 +1000" MODIFIED_BY="Liz Dooley">
<P>Two review authors (TA, JWN) independently examined titles and abstracts for the selection of eligible studies. We removed records that did not report on RCTs and where palivizumab was used as a prophylaxis. We retrieved the full texts of potentially relevant reports and we linked multiple reports of the same study. Two review authors (TA, JWN) independently examined the full-text reports to determine which studies met the eligibility criteria. We resolved disagreements by discussion and consultation with a third review author (BB).</P>
<P>Two review authors (TA, JDR) independently examined titles and abstracts for the selection of health economics studies to be included in the critical review of economic data. We removed records that were not reporting on cost-effectiveness or cost-utility analysis of palivizumab prophylaxis. We retrieved full texts of potentially relevant reports (i.e. health economics studies conducted alongside randomized trials or economic modelling studies based on a meta-analysis of data from randomized trials or based on a comprehensive systematic review of literature). Two review authors (TA, JDR) independently examined full-text reports to determine which studies met the eligibility criteria. Any disagreements were resolved by discussion and consultation with a third review author (MXRR). Only full economic evaluations with high methodological and reporting quality (see <LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK>) were included.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (TA, JWN) independently extracted data from eligible RCTs using customised data collection forms. The data collection forms were tested on a pilot sample of articles. Details on the source, eligibility and reasons for exclusion, methods, potential source of bias, participants, settings, interventions, outcomes and results were collected. Review authors were not blinded to the names of the authors, institutions, journals or results of a study. We attempted to contact trial authors for any of the missing data from studies. Any disagreements were resolved by discussion or consultation with a third review author (BB). We entered all collected data into the Review Manager (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>) software for analysis.</P>
<P>Two review authors (TA, JDR) independently extracted data on the following aspects of each included economic evaluation study.</P>
<OL>
<LI>General information: population, intervention, comparator, results in clinical outcomes, costs of specific resources, study setting and sources of funding.</LI>
<LI>Methods: type of economic evaluation, study perspective, economic outcome measurements and time horizon.</LI>
<LI>Results: incremental costs, incremental effectiveness, discount rate, currency and price year of the reported values, and the final incremental cost-effectiveness ratios reported.</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (TA, JWN) independently assessed risk of bias in the included RCTs using The Cochrane Collaboration's tool for assessing risk of bias, which addresses the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other biases, such as funding. We recorded each piece of information extracted for the 'Risk of bias' tool, together with the precise source of this information. We tabulated the risk of bias for each included RCT, along with a judgement of 'low', 'high' or 'unclear' risk of bias, as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
<P>Since none of the included economic evaluations (EEs) were conducted alongside a RCT, their quality could not be assessed using The Cochrane Collaboration's standard tool for assessing risk of bias in RCTs. Therefore, we critically appraised the quality of EEs using the Drummond checklist (<LINK REF="REF-Drummond-1996" TYPE="REFERENCE">Drummond 1996</LINK>). We used an adapted Drummond checklist (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>) which addresses the following methodological and reporting aspects.</P>
<OL>
<LI>Was a well-defined question posed?</LI>
<LI>Was a comprehensive description of the competing alternatives given?</LI>
<LI>Does the paper provide evidence that the programme would be effective (i.e. would the programme do more harm than good)?</LI>
<LI>Were all important and relevant resource use (costs) and health outcome consequences for each alternative identified, measured accurately in appropriate units prior to evaluation, and valued credibly?</LI>
<LI>Were costs and health outcomes consequences adjusted for different times at which they occurred (i.e. was discounting applied)?</LI>
<LI>Was an incremental analysis of the consequences and costs of alternatives performed?</LI>
<LI>Was an adequate sensitivity analysis performed?</LI>
</OL>
<P>For each main efficacy and safety outcome in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>, we assessed the overall quality of the evidence using the GRADE approach (<LINK REF="REF-Atkins-2004" TYPE="REFERENCE">Atkins 2004</LINK>), as described in <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-06-12 08:29:27 +1000" MODIFIED_BY="Liz Dooley">
<P>We calculated risk ratios (RRs) and their associated 95% confidence intervals (CIs) for dichotomous outcomes and for adverse events. We planned to report the mean post-intervention value, as well as the mean difference (MD) between treatment groups and their associated 95% CIs for continuous outcomes, but due to the lack of data on measures of dispersion for continuous outcomes (such as standard deviations), only a narrative summary is provided for those results. We analyzed count data in the following way.</P>
<OL>
<LI>Total days of RSV hospitalization per 100 randomized children as continuous data.</LI>
<LI>Total days in the ICU per 100 randomized children as continuous data.</LI>
<LI>Total days of mechanical ventilation per 100 randomized children as continuous data.</LI>
<LI>Total days of supplemental oxygen therapy per 100 randomized children as continuous data.</LI>
</OL>
<P>If it was not clearly stated in the study that total days were expressed as means per 100 randomized children, we contacted the study authors to attempt to clarify whether indexing was used, or not. Total days were expressed as means per 100 randomized children in all studies but one, where they were expressed as means and standard deviations per one child (<LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK>). In order to be consistent across studies, for <LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK> the values per 100 randomized children were calculated and entered into RevMan for analysis.</P>
<P>We summarised the results reported in included economic evaluations, such as incremental cost, incremental effectiveness and incremental cost-effectiveness ratio, in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>, <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> and <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>, and we provided a commentary on tabulated results.</P>
<P>For readers to easily benchmark variations among different studies and settings, the final incremental cost-effectiveness ratios are also reported in 2011 Euros (EUR) as 'ICER present values'. Higher ICER values are indicative of less favorable results for the investigated intervention. The values of ICERs provided by study authors were adjusted for the time value of money, so that the cash flows inter projects over time are expressed on a common basis in terms of their present value. However, the use of these data for extrapolation of results among countries or throughout years is not anticipated, since the costs of the technologies and medical practices may have changed substantially throughout years and settings (the oldest included study <LINK REF="STD-Joffe-1999" TYPE="STUDY">Joffe 1999</LINK> uses the 1995 USD price year). Only the present values of ICERs from similar and closer date studies that have evaluated the same effectiveness measure (e.g. hospitalization avoided, or QALY gained) should be taken into account while assessing the variation of ICER that could be expected if the technology would be adopted in similar settings.</P>
<P>We calculated the present values of ICERs at 2011 EUR in two steps. Firstly, we converted the values reported in the study in their original currency to Euros at the same price year, by multiplying the ICER reported value with the appropriate money exchange rate given in <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>. Secondly, we multiplied those values with the appropriate gross domestic product (GDP) deflator given in <LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>, in order to get the final ICER present values at 2011 EUR.</P>
<P>We expressed all currencies as the currency abbreviation and amount (e.g. EUR 1376.50), using the ISO 4217 currency abbreviations available at <A HREF="http://www.xe.com/iso4217.php/">http://www.xe.com/iso4217.php/</A>. We chose Euros for present value calculations, as the majority of included studies were conducted in Europe. More details about present value calculations are given in <LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK>.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>There are several types of missing data in a systematic review or meta-analysis as described in Table 16.1.a in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). The problem of missing studies and outcomes is addressed in the <LINK TAG="BIAS_ASSESSMENT" TYPE="SECTION">Assessment of reporting biases</LINK> section of this review. A common problem is missing summary data, such as standard deviations (SDs) for continuous outcomes. The methods outlined in section 16.1.3 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>) for imputing missing values were considered. However, because the majority of studies in this review had missing SDs, we decided to not impute them. Studies were not excluded from the review because of missing summary data; rather, we contacted trial authors to attempt to obtain more information. Because authors have not provided the requested information, the results of available continuous data are summarised in a narrative way. The potential impact of missing data on the review's findings are addressed in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> section.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity between included studies using the Chi<SUP>2</SUP> test and I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We considered a Chi<SUP>2</SUP> P value of less than 0.10 to be indicative of statistical heterogeneity of intervention effects. However, if studies have a small sample size, or are few in number, the Chi<SUP>2</SUP> test has low power and should be interpreted with caution. In order to quantify inconsistency across studies, we calculated an I<SUP>2</SUP> statistic. We interpreted the I<SUP>2</SUP> statistic in the following way: heterogeneity might not be important (I<SUP>2</SUP> statistic value of 0% to 40%); heterogeneity may be moderate (I<SUP>2</SUP> statistic of 30% to 60%); heterogeneity may be substantial (I<SUP>2</SUP> statistic of 50% to 90%); and considerable heterogeneity (I<SUP>2</SUP> statistic of 75% to 100%).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Possible reporting biases are assessed on two levels: within-study and between-studies.</P>
<P>We examined within-study selective outcome reporting as a part of the overall 'Risk of bias' assessment (see <LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK>). We attempted to find protocols for included studies and compare the outcomes stated in the protocols with those reported in the publications. If protocols were not found, we compared the outcomes listed in the methods section of a publication with those whose results are reported.</P>
<P>We planned to create a funnel plot of effect estimates against their standard errors (SEs) to assess possible between-studies reporting bias, if there were at least 10 RCTs included in the review. However, this was not the case. We would consider possible explanations if we found asymmetry of the funnel plot, either by inspection or statistical tests, and we would have taken into account the interpretation of the overall estimate of treatment effects.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-03-27 06:59:31 +1000" MODIFIED_BY="[Empty name]">
<P>We performed a fixed-effect meta-analysis for the estimation of pooled effects whenever there was no indication of heterogeneity between included studies (I<SUP>2 </SUP>statistic &lt; 40%). When some indication of heterogeneity between trials was identified (I<SUP>2 </SUP>statistic &gt; 40%), we used a random-effects model.</P>
<P>We did not perform pooled calculations of economic data. Rather, the characteristics and results of included economic studies are presented in a descriptive way in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>, <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> and <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-03-27 15:51:26 +1000" MODIFIED_BY="Liz Dooley">
<P>We planned to perform subgroup analyses for effectiveness and safety data, based on the presence of risk factors (preterm birth, chronic lung disease, congenital heart disease, immunodeficiency, chronic neuromuscular disease and congenital anomalies), in case there were at least three studies per subgroup in a specific comparison. However, that was not the case, and no subgroup analysis was performed.</P>
<P>The economic data (incremental cost, incremental effectiveness and incremental cost-effectiveness ratio) are reported separately for studies that evaluated the impact of passive immunisation given during the neonatal period or within the first six months of life (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>), and for studies that evaluated the impact of passive immunisation given to children aged six months and older (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). In each of the two groups, data are presented separately for three subgroups, according to the baseline risk factors: preterm birth (&#8804; 35 weeks gestation), chronic lung disease of prematurity or bronchopulmonary dysplasia, and congenital heart disease. Additionally, the economic data are reported separately in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> for studies that evaluated the impact of passive immunisation given at any time from birth to five years of age, to a high-risk population of infants and children born preterm, with or without bronchopulmonary dysplasia, or with congenital heart disease.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>The sensitivity analysis takes into account those biases that could significantly impact on the outcomes of the included studies. As previously noted in the <LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK> section, The Cochrane Collaboration's tool for assessing risk of bias in RCTs was used (categorised as 'low', 'high' and 'unclear'), focusing on domains such as random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other biases, such as the source of funding of the included studies.</P>
<P>We had planned to perform a sensitivity analysis to assess how the results of the meta-analysis would be affected by excluding studies determined to be at high risk of bias. However, all of the included efficacy and safety studies were of high overall methodological and reporting quality, and we meta-analysed all of these trials without performing a sensitivity analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-06-12 08:29:33 +1000" MODIFIED_BY="Tea Andabaka">
<STUDY_DESCRIPTION MODIFIED="2013-06-12 08:29:29 +1000" MODIFIED_BY="Tea Andabaka">
<SEARCH_RESULTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>With duplicates removed, the electronic searches identified 630 records for effectiveness studies and 413 records for adverse effects studies. We screened titles and abstracts and 12 studies were identified as potentially eligible for inclusion. We retrieved the full-text articles. After reading the full texts, five studies were excluded and seven were found eligible for inclusion according to <LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK>.</P>
<P>By searching the clinical trials registries, we identified three additional RCTs (<LINK REF="STD-NCT00233064" TYPE="STUDY">NCT00233064</LINK>; <LINK REF="STD-NCT00240929" TYPE="STUDY">NCT00240929</LINK>; <LINK REF="STD-NTR1023" TYPE="STUDY">NTR1023</LINK>). According to available data, the three trials are not eligible for inclusion in this review. However, in an attempt to retrieve more information about them, they are listed under <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
<P>The electronic searches for economic evaluations identified 703 records, with duplicates removed. We screened titles and abstracts and 58 studies were identified as potentially eligible for inclusion. After reading the full texts, 24 studies were excluded and 34 were found eligible for inclusion in this review according to <LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK>. No other potentially eligible economic evaluations were found as a result of searching the reference lists of relevant studies and review articles.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-06-12 08:29:27 +1000" MODIFIED_BY="[Empty name]">
<P>Of the seven included RCTs, three compared palivizumab with placebo (<LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>; <LINK REF="STD-IMpact_x002d_RSV-1998" TYPE="STUDY">IMpact-RSV 1998</LINK>; <LINK REF="STD-Subramanian-1998" TYPE="STUDY">Subramanian 1998</LINK>) and four compared motavizumab with palivizumab (<LINK REF="STD-Abarca-2009" TYPE="STUDY">Abarca 2009</LINK>; <LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>; <LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK>; <LINK REF="STD-Fernandez-2010" TYPE="STUDY">Fernandez 2010</LINK>). In all trials palivizumab was delivered intramuscularly, except in <LINK REF="STD-Subramanian-1998" TYPE="STUDY">Subramanian 1998</LINK> where it was delivered intravenously. One study was a dose-escalation study (<LINK REF="STD-Subramanian-1998" TYPE="STUDY">Subramanian 1998</LINK>) and only data for the recommended approved dose of 15 mg/kg were included in our analyses. From all trials, data extracted for the analyses referred to five monthly injections of the study drug, except for <LINK REF="STD-Abarca-2009" TYPE="STUDY">Abarca 2009</LINK>, where four or five doses were applied, and <LINK REF="STD-Fernandez-2010" TYPE="STUDY">Fernandez 2010</LINK>, where palivizumab and motavizumab were used sequentially, and only safety data after the first two doses were extracted for analysis. In <LINK REF="STD-Abarca-2009" TYPE="STUDY">Abarca 2009</LINK>, only the second year of the study was a RCT eligible for inclusion. In all studies, children were followed up for 150 days after randomization (30 days after the final dose).</P>
<P>Of the 34 included economic evaluation studies, three were conducted in Italy (<LINK REF="STD-Chirico-2009" TYPE="STUDY">Chirico 2009</LINK>; <LINK REF="STD-Chiroli-2005" TYPE="STUDY">Chiroli 2005</LINK>; <LINK REF="STD-Ravasio-2006" TYPE="STUDY">Ravasio 2006</LINK>), six in the US (<LINK REF="STD-ElHassan-2006" TYPE="STUDY">ElHassan 2006</LINK>; <LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>; <LINK REF="STD-Joffe-1999" TYPE="STUDY">Joffe 1999</LINK>; <LINK REF="STD-Lofland-2000" TYPE="STUDY">Lofland 2000</LINK>; <LINK REF="STD-Weiner-2012" TYPE="STUDY">Weiner 2012</LINK>; <LINK REF="STD-Yount-2004" TYPE="STUDY">Yount 2004</LINK>), four in the UK (<LINK REF="STD-Bentley-2011" TYPE="STUDY">Bentley 2011</LINK>; <LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>; <LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>), five in Spain (<LINK REF="STD-Garcia_x002d_Altes-2010" TYPE="STUDY">Garcia-Altes 2010</LINK>; <LINK REF="STD-Lazaro-y-de-Mercado-2006" TYPE="STUDY">Lazaro y de Mercado 2006</LINK>; <LINK REF="STD-Lazaro-y-de-Mercado-2007" TYPE="STUDY">Lazaro y de Mercado 2007</LINK>; <LINK REF="STD-Nuijten-2010" TYPE="STUDY">Nuijten 2010</LINK>; <LINK REF="STD-Raya-Ortega-2006" TYPE="STUDY">Raya Ortega 2006</LINK>), four in Canada (<LINK REF="STD-Harris-2011" TYPE="STUDY">Harris 2011</LINK>; <LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK>; <LINK REF="STD-Smart-2010" TYPE="STUDY">Smart 2010</LINK>; <LINK REF="STD-Tam-2009" TYPE="STUDY">Tam 2009</LINK>), one in France (<LINK REF="STD-Hascoet-2008" TYPE="STUDY">Hascoet 2008</LINK>), one in Korea (<LINK REF="STD-Kang-2009" TYPE="STUDY">Kang 2009</LINK>), two in Mexico (<LINK REF="STD-Mayen_x002d_Herrera-2011" TYPE="STUDY">Mayen-Herrera 2011</LINK>; <LINK REF="STD-Salinas_x002d_Escudero-2012" TYPE="STUDY">Salinas-Escudero 2012</LINK>), one in Sweden (<LINK REF="STD-Neovius-2011" TYPE="STUDY">Neovius 2011</LINK>), two in the Netherlands (<LINK REF="STD-Nuijten-2009a" TYPE="STUDY">Nuijten 2009a</LINK>; <LINK REF="STD-Rietveld-2010" TYPE="STUDY">Rietveld 2010</LINK>), two in Germany (<LINK REF="STD-Nuijten-2009b" TYPE="STUDY">Nuijten 2009b</LINK>; <LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK>), two in Austria (<LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>; <LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>) and one in New Zealand (<LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK>).</P>
<P>
<LINK REF="STD-Lazaro-y-de-Mercado-2006" TYPE="STUDY">Lazaro y de Mercado 2006</LINK> evaluated the economic impact of RSV immunoprophylaxis in children with bronchopulmonary dysplasia, children with congenital heart disease and in preterm infants born at 32 to 35 weeks' gestational age, presenting with two or more of the additional risk factors described by the Spanish Neonatology Society. The authors did not report data separately for any of the subgroups or categories of interest in this review. <LINK REF="STD-Kang-2009" TYPE="STUDY">Kang 2009</LINK> is a study conducted in Korea, with only information from the abstract available. Similarly, for <LINK REF="STD-Bentley-2011" TYPE="STUDY">Bentley 2011</LINK> and <LINK REF="STD-Mayen_x002d_Herrera-2011" TYPE="STUDY">Mayen-Herrera 2011</LINK> only the information from abstracts was available. The trial authors did not respond to e-mails asking for the full text. Characteristics of these four studies are presented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, but the economics results were not included in the related 'Additional tables' (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
<P>Overall, 22 studies evaluated the economic impact of RSV immunoprophylaxis given during the neonatal period or within the first few months of life (<LINK REF="STD-Chirico-2009" TYPE="STUDY">Chirico 2009</LINK>; <LINK REF="STD-ElHassan-2006" TYPE="STUDY">ElHassan 2006</LINK>; <LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>; <LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>; <LINK REF="STD-Hascoet-2008" TYPE="STUDY">Hascoet 2008</LINK>; <LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK>; <LINK REF="STD-Lofland-2000" TYPE="STUDY">Lofland 2000</LINK>; <LINK REF="STD-Neovius-2011" TYPE="STUDY">Neovius 2011</LINK>; <LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>; <LINK REF="STD-Nuijten-2009a" TYPE="STUDY">Nuijten 2009a</LINK>; <LINK REF="STD-Nuijten-2010" TYPE="STUDY">Nuijten 2010</LINK>; <LINK REF="STD-Ravasio-2006" TYPE="STUDY">Ravasio 2006</LINK>; <LINK REF="STD-Raya-Ortega-2006" TYPE="STUDY">Raya Ortega 2006</LINK>; <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>; <LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>; <LINK REF="STD-Rietveld-2010" TYPE="STUDY">Rietveld 2010</LINK>; <LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK>; <LINK REF="STD-Salinas_x002d_Escudero-2012" TYPE="STUDY">Salinas-Escudero 2012</LINK>; <LINK REF="STD-Smart-2010" TYPE="STUDY">Smart 2010</LINK>; <LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>; <LINK REF="STD-Weiner-2012" TYPE="STUDY">Weiner 2012</LINK>); 10 studies evaluated the economic impact of RSV immunoprophylaxis given to children aged six months and older (<LINK REF="STD-Chiroli-2005" TYPE="STUDY">Chiroli 2005</LINK>; <LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>; <LINK REF="STD-Harris-2011" TYPE="STUDY">Harris 2011</LINK>; <LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>; <LINK REF="STD-Nuijten-2009b" TYPE="STUDY">Nuijten 2009b</LINK>; <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>; <LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>; <LINK REF="STD-Tam-2009" TYPE="STUDY">Tam 2009</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>; <LINK REF="STD-Yount-2004" TYPE="STUDY">Yount 2004</LINK>); and three studies evaluated the economic impact of RSV immunoprophylaxis given to a high-risk population of infants and children up to five years of age, either born preterm, with or without bronchopulmonary dysplasia, or with congenital heart disease (<LINK REF="STD-Garcia_x002d_Altes-2010" TYPE="STUDY">Garcia-Altes 2010</LINK>; <LINK REF="STD-Joffe-1999" TYPE="STUDY">Joffe 1999</LINK>; <LINK REF="STD-Lazaro-y-de-Mercado-2007" TYPE="STUDY">Lazaro y de Mercado 2007</LINK>).</P>
<P>The study conducted by <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> reported a set of ICER values obtained when passive immunisation is given to infants and children at different birth ages (up to 24 months of life), with different gestational ages, and with or without other comorbidity (chronic lung disease or congenital heart disease). The results from <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> are presented as ranges of values for the following subgroups of interest in this review.</P>
<UL>
<LI>Infants up to six months of age who were born at 35 weeks of gestation or less, without chronic lung disease or congenital heart disease.</LI>
<LI>Infants up to six months of age who were born at 35 weeks of gestation or less, with chronic lung disease.</LI>
<LI>Infants up to six months of age who were born at more than 35 weeks of gestation, with congenital heart disease.</LI>
<LI>Children from 6 to 24 months of age who were born at 35 weeks of gestation or less, without chronic lung disease or congenital heart disease.</LI>
<LI>Children from 6 to 24 months of age who were born at 35 weeks of gestation or less, with chronic lung disease.</LI>
<LI>Children from 6 to 24 months of age who were born at more than 35 weeks of gestation, with congenital heart disease.</LI>
</UL>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-06-12 08:29:29 +1000" MODIFIED_BY="[Empty name]">
<P>Of the five excluded safety and effectiveness studies, four were not RCTs (<LINK REF="STD-Korbal-2003" TYPE="STUDY">Korbal 2003</LINK>; <LINK REF="STD-Martinez-2002" TYPE="STUDY">Martinez 2002</LINK>; <LINK REF="STD-Parmigiani-2001" TYPE="STUDY">Parmigiani 2001</LINK>; <LINK REF="STD-Takeuchi-2002" TYPE="STUDY">Takeuchi 2002</LINK>), and one did not assess effects of palivizumab prophylaxis (<LINK REF="STD-Meissner-1999" TYPE="STUDY">Meissner 1999</LINK>).</P>
<P>Of the 24 excluded economic studies, most were partial economic evaluations that reported cost analyses or cost-outcome descriptions (<LINK REF="STD-Banerji-2009" TYPE="STUDY">Banerji 2009</LINK>; <LINK REF="STD-Buckley-2010" TYPE="STUDY">Buckley 2010</LINK>; <LINK REF="STD-Chan-2003" TYPE="STUDY">Chan 2003</LINK>; <LINK REF="STD-Clark-2000" TYPE="STUDY">Clark 2000</LINK>; <LINK REF="STD-Datar-2012" TYPE="STUDY">Datar 2012</LINK>; <LINK REF="STD-Farina-2002" TYPE="STUDY">Farina 2002</LINK>; <LINK REF="STD-Krilov-2010" TYPE="STUDY">Krilov 2010</LINK>; <LINK REF="STD-Lapena-Lopez-2003" TYPE="STUDY">Lapena Lopez 2003</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; <LINK REF="STD-Marchetti-1999" TYPE="STUDY">Marchetti 1999</LINK>; <LINK REF="STD-Marques-2010" TYPE="STUDY">Marques 2010</LINK>; <LINK REF="STD-McCormick-2002" TYPE="STUDY">McCormick 2002</LINK>; <LINK REF="STD-Meberg-2006" TYPE="STUDY">Meberg 2006</LINK>; <LINK REF="STD-Rackham-2005" TYPE="STUDY">Rackham 2005</LINK>; <LINK REF="STD-Reeve-2006" TYPE="STUDY">Reeve 2006</LINK>; <LINK REF="STD-Rodriguez-2008" TYPE="STUDY">Rodriguez 2008</LINK>; <LINK REF="STD-Vann-2007" TYPE="STUDY">Vann 2007</LINK>; <LINK REF="STD-Wegner-2004" TYPE="STUDY">Wegner 2004</LINK>; <LINK REF="STD-Wendel-2010" TYPE="STUDY">Wendel 2010</LINK>), two were neither a cost-effectiveness nor a cost-utility analysis (<LINK REF="STD-Numa-2000" TYPE="STUDY">Numa 2000</LINK>; <LINK REF="STD-Shireman-2002" TYPE="STUDY">Shireman 2002</LINK>), one analyzed a combined effect of RSV-IVIG and palivizumab used together as prophylaxis (<LINK REF="STD-Stevens-2000" TYPE="STUDY">Stevens 2000</LINK>), one was a systematic review of economic evaluations, and not a primary analysis (<LINK REF="STD-Strutton-2003" TYPE="STUDY">Strutton 2003</LINK>), and one economic evaluation (<LINK REF="STD-Wang-2008" TYPE="STUDY">Wang 2008</LINK>) was later updated and reported by the same author in a more recent publication (<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-06-12 08:29:29 +1000" MODIFIED_BY="Tea Andabaka">
<P>For efficacy and safety studies, see the 'Risk of bias' tables in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. We performed complete 'Risk of bias' assessment for all included RCTs. The methods used in some included studies were not clearly described; some data and explanations were missing and this could be a source of potential bias. Additionally, all of the included studies were sponsored by, and included authors from, the manufacturer of palivizumab, MedImmune. This does not, in of itself, imply any bias in the results and we have listed this as having an 'unclear' potential impact. Further explanation of these risks of bias is provided in the subsequent sections of this review.</P>
<P>The GRADE quality ratings of evidence for the main outcomes are summarised in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>.</P>
<P>Results of the quality assessment of economic evaluation studies are summarised in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
<ALLOCATION MODIFIED="2012-10-15 13:26:08 +1000" MODIFIED_BY="[Empty name]">
<P>Randomisation was performed in all seven included studies. Methods of random sequence generation were clearly described in all trials except for <LINK REF="STD-Subramanian-1998" TYPE="STUDY">Subramanian 1998</LINK> where insufficient information was given, with 'unclear' risk of bias. Study drugs were identical in appearance and their allocation was concealed in <LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>; <LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>; <LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK>; <LINK REF="STD-IMpact_x002d_RSV-1998" TYPE="STUDY">IMpact-RSV 1998</LINK> and <LINK REF="STD-Subramanian-1998" TYPE="STUDY">Subramanian 1998</LINK>; while methods of allocation concealment were 'unclear' in <LINK REF="STD-Abarca-2009" TYPE="STUDY">Abarca 2009</LINK> and <LINK REF="STD-Fernandez-2010" TYPE="STUDY">Fernandez 2010</LINK>.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Adequate blinding of participants and study personnel was clearly stated in <LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>; <LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>; <LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK>; <LINK REF="STD-IMpact_x002d_RSV-1998" TYPE="STUDY">IMpact-RSV 1998</LINK> and <LINK REF="STD-Subramanian-1998" TYPE="STUDY">Subramanian 1998</LINK>. There were no details available in <LINK REF="STD-Abarca-2009" TYPE="STUDY">Abarca 2009</LINK> and <LINK REF="STD-Fernandez-2010" TYPE="STUDY">Fernandez 2010</LINK>, resulting in an 'unclear' risk of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-09-27 13:21:27 +1000" MODIFIED_BY="[Empty name]">
<P>In six studies, comparable attrition rates were reported in both intervention groups, with reasons for attrition provided, making the risk of bias 'low' (<LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>; <LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>; <LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK>; <LINK REF="STD-Fernandez-2010" TYPE="STUDY">Fernandez 2010</LINK>; <LINK REF="STD-IMpact_x002d_RSV-1998" TYPE="STUDY">IMpact-RSV 1998</LINK>; <LINK REF="STD-Subramanian-1998" TYPE="STUDY">Subramanian 1998</LINK>). In <LINK REF="STD-Abarca-2009" TYPE="STUDY">Abarca 2009</LINK>, the risk of bias was 'high', because the reasons for attrition of patients between season one and season two were not given.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>For three of the seven included trials, protocols were registered in appropriate clinical trials databases, and for all of them the same outcomes were reported in protocols and in final published reports (<LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>; <LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK>; <LINK REF="STD-Fernandez-2010" TYPE="STUDY">Fernandez 2010</LINK>). For all seven included trials, the outcomes listed in the methods were also reported in the results section of the final trial reports. RSV-specific outpatient medically attended lower respiratory tract infection was assessed in two studies (<LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>; <LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK>), and in both of them in just a subset of patients, either in patients from selected study sites (<LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>) or in patients in season two only (<LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK>). No explanations were provided, making the risk of reporting bias in these trials 'high'. In three trials, several outcomes of interest (total RSV-hospital days, days in the ICU, days of mechanical ventilation and days of supplemental oxygen therapy) were reported incompletely; data on standard deviations were missing and the risk of reporting bias in these trials was 'high' (<LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>; <LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>; <LINK REF="STD-IMpact_x002d_RSV-1998" TYPE="STUDY">IMpact-RSV 1998</LINK>). None of the studies had prespecified nor reported the incidence and duration of bronchodilator therapy for RSV infection. Since this was not one of the key outcomes of this review, this does not present a risk of reporting bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-06-12 08:29:29 +1000" MODIFIED_BY="[Empty name]">
<P>All of the seven included randomized controlled trials were sponsored by the drug manufacturing company, and many of the study authors were its employees or consultants, or they received research grants and compensations from the company. This represented an 'unclear' risk of bias for all included RCTs.</P>
<P>Of the 34 economic evaluations eligible for inclusion, conflict of interest was clearly stated in 21 studies that were either funded by the drug manufacturing company, or included authors who were employees of the manufacturing company (<LINK REF="STD-Bentley-2011" TYPE="STUDY">Bentley 2011</LINK>; <LINK REF="STD-Chirico-2009" TYPE="STUDY">Chirico 2009</LINK>; <LINK REF="STD-Chiroli-2005" TYPE="STUDY">Chiroli 2005</LINK>; <LINK REF="STD-Hascoet-2008" TYPE="STUDY">Hascoet 2008</LINK>; <LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK>; <LINK REF="STD-Lazaro-y-de-Mercado-2006" TYPE="STUDY">Lazaro y de Mercado 2006</LINK>; <LINK REF="STD-Lofland-2000" TYPE="STUDY">Lofland 2000</LINK>; <LINK REF="STD-Mayen_x002d_Herrera-2011" TYPE="STUDY">Mayen-Herrera 2011</LINK>; <LINK REF="STD-Neovius-2011" TYPE="STUDY">Neovius 2011</LINK>; <LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>; <LINK REF="STD-Nuijten-2009a" TYPE="STUDY">Nuijten 2009a</LINK>; <LINK REF="STD-Nuijten-2009b" TYPE="STUDY">Nuijten 2009b</LINK>; <LINK REF="STD-Nuijten-2010" TYPE="STUDY">Nuijten 2010</LINK>; <LINK REF="STD-Ravasio-2006" TYPE="STUDY">Ravasio 2006</LINK>; <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>; <LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>; <LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK>; <LINK REF="STD-Salinas_x002d_Escudero-2012" TYPE="STUDY">Salinas-Escudero 2012</LINK>; <LINK REF="STD-Tam-2009" TYPE="STUDY">Tam 2009</LINK>; <LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK>; <LINK REF="STD-Weiner-2012" TYPE="STUDY">Weiner 2012</LINK>). For 10 studies no conflict of interest was declared (<LINK REF="STD-ElHassan-2006" TYPE="STUDY">ElHassan 2006</LINK>; <LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>; <LINK REF="STD-Garcia_x002d_Altes-2010" TYPE="STUDY">Garcia-Altes 2010</LINK>; <LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>; <LINK REF="STD-Joffe-1999" TYPE="STUDY">Joffe 1999</LINK>; <LINK REF="STD-Raya-Ortega-2006" TYPE="STUDY">Raya Ortega 2006</LINK>; <LINK REF="STD-Rietveld-2010" TYPE="STUDY">Rietveld 2010</LINK>; <LINK REF="STD-Smart-2010" TYPE="STUDY">Smart 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>; <LINK REF="STD-Yount-2004" TYPE="STUDY">Yount 2004</LINK>); and for three studies it was not completely clear whether they were funded by the industry or not (<LINK REF="STD-Harris-2011" TYPE="STUDY">Harris 2011</LINK>; <LINK REF="STD-Kang-2009" TYPE="STUDY">Kang 2009</LINK>; <LINK REF="STD-Lazaro-y-de-Mercado-2007" TYPE="STUDY">Lazaro y de Mercado 2007</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-06-12 08:29:33 +1000" MODIFIED_BY="Tea Andabaka">
<SUBSECTION>
<HEADING LEVEL="3">Palivizumab compared to placebo</HEADING>
<P>Three randomized controlled trials (RCTs) compared palivizumab prophylaxis with a placebo in a total of 2831 patients, who were either born preterm and less than six months old, or less than two years old and with bronchopulmonary dysplasia (<LINK REF="STD-IMpact_x002d_RSV-1998" TYPE="STUDY">IMpact-RSV 1998</LINK>; <LINK REF="STD-Subramanian-1998" TYPE="STUDY">Subramanian 1998</LINK>), or were less than two years old and with haemodynamically significant congenital heart disease (<LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>). None of the included RCTs were performed in children with immunodeficiency, chronic neuromuscular disease or congenital anomalies. For all efficacy and safety outcomes, results were expressed as per intention-to-treat (ITT) population, which included all randomly assigned patients eligible for inclusion into the study. There was no indication of statistical heterogeneity across studies for most of the assessed outcomes, with the exceptions being the total days in the intensive care unit (ICU), and the incidence and total number of days of mechanical ventilation.</P>
<P>Palivizumab recipients had a statistically significant 51% relative risk reduction in respiratory syncytial virus (RSV) hospitalisations compared with placebo recipients (risk ratio (RR) was 0.49, 95% confidence interval (CI) 0.37 to 0.64) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), as well as a statistically significant 50% relative risk reduction in admissions to the ICU (RR 0.50, 95% CI 0.30 to 0.81) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>), while the number of patients requiring mechanical ventilation for RSV infection seemed similar in the two groups (RR 1.10, 95% CI 0.20 to 6.09) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). However, in case of mechanical ventilation, statistical heterogeneity between the two trials may be substantial (I<SUP>2</SUP> statistic 60%; random-effects model applied) and results should be interpreted with caution.</P>
<P>In both efficacy trials, total days were expressed as means per 100 randomized children (<LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>; <LINK REF="STD-IMpact_x002d_RSV-1998" TYPE="STUDY">IMpact-RSV 1998</LINK>). However, since data on days were reported incompletely, meta-analysis was not possible. Children randomly assigned to placebo had approximately twice as many days of hospitalization due to RSV infection (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), and two to three times more days of supplemental oxygen therapy per 100 randomized children (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), compared to palivizumab recipients. Results for total days in the ICU (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) and total days of mechanical ventilation per 100 randomized children (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) were quite heterogenous across the two trials. <LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>, which included children with congenital heart disease, showed significantly fewer days in the ICU, and lower incidence and fewer days of mechanical ventilation in children treated with palivizumab compared with placebo. On the other hand, <LINK REF="STD-IMpact_x002d_RSV-1998" TYPE="STUDY">IMpact-RSV 1998</LINK>, which included children born preterm with or without bronchopulmonary dysplasia, reported results with the opposite trend.</P>
<P>In all trials, mortality was reported as an all-cause mortality expressed per ITT population. Monthly prophylaxis with palivizumab, when compared to placebo, was associated with a statistically non-significant 31% relative risk reduction in all-cause mortality (RR 0.69, 95% CI 0.42 to 1.15) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Overall, rates of adverse events (AEs) and serious adverse events (SAEs) were consistent with the underlying medical conditions in this high-risk population. The proportion of children with any AE was similar between the two groups (RR 0.99, 95% CI 0.97 to 1.01) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>), as well as the proportion of children with AE related to the study drug (RR 1.09, 95% CI 0.85 to 1.38) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). On the other hand, palivizumab recipients had a statistically significant 12% relative risk reduction in any SAE compared with placebo (RR 0.88, 95% CI 0.80 to 0.96) (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), and a statistically non-significant 86% relative risk reduction in SAE related to study drug (RR 0.14, 95% CI 0.01 to 2.80) (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>). However, only one study assessed these two outcomes (<LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>). Common adverse events (when reported) included fever, injection site reactions and upper respiratory infections.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Palivizumab compared to motavizumab</HEADING>
<P>Four RCTs compared motavizumab prophylaxis with palivizumab prophylaxis in a total of 8265 patients, who were either born preterm and less than six months old, or less than two years old and with chronic lung disease of prematurity (<LINK REF="STD-Abarca-2009" TYPE="STUDY">Abarca 2009</LINK>; <LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>; <LINK REF="STD-Fernandez-2010" TYPE="STUDY">Fernandez 2010</LINK>), or were less than two years old and had haemodynamically significant congenital heart disease (<LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK>). None of the included RCTs were performed in children with immunodeficiency, chronic neuromuscular disease or congenital anomalies. Efficacy outcomes were assessed in two studies (<LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>; <LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK>) and their results were expressed as per ITT population; while for safety outcomes (adverse events) results were expressed per safety population, which included all patients who received any study medication and had any safety follow-up. In order to be consistent with the objectives of this review, palivizumab was considered an intervention and motavizumab a control in all further analyses. There was no indication of statistical heterogeneity of intervention effects across studies.</P>
<P>Palivizumab recipients had a statistically non-significant 36% relative increase in the risk of hospitalization due to RSV infection, when compared with motavizumab recipients (RR 1.36, 95% CI 0.97 to 1.90) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). In a subset of patients, RSV-specific outpatient medically attended lower respiratory tract infections (MALRIs) were assessed. The risk of outpatient MALRI specific for RSV infection in the palivizumab group was twice that of the motavizumab group (RR 1.98, 95% CI 1.25 to 3.13) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). Palivizumab recipients had a statistically non-significant 68% relative risk increase in admission to the ICU compared with motavizumab recipients (RR 1.68, 95% CI 0.89 to 3.19) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>), as well as a statistically non-significant 49% relative risk increase in incidence of supplemental oxygen therapy for RSV infection (RR 1.49, 95% CI 0.98 to 2.26) (<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>), while the risk of mechanical ventilation in the palivizumab group was almost four times that of the motavizumab group (RR 3.79, 95% CI 1.26 to 11.42) (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
<P>In all trials but one (<LINK REF="STD-Abarca-2009" TYPE="STUDY">Abarca 2009</LINK>), mortality was reported as all-cause mortality. In order to be consistent, for <LINK REF="STD-Abarca-2009" TYPE="STUDY">Abarca 2009</LINK> we reported the all-cause deaths, and for all four studies we expressed mortality per ITT population. Children randomly assigned to palivizumab had a statistically non-significant 26% relative risk reduction in all-cause mortality compared with motavizumab recipients (RR 0.74, 95% CI 0.38 to 1.43) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<P>In <LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK> total days were expressed as means per 100 randomized children, while for <LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK> we calculated the means and standard deviations per 100 randomized children from the data originally reported per one child, and entered them in analyses. Since data on standard deviations are missing in <LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>, only data from <LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK> contributed to the meta-analysis, and results should be interpreted with caution. Children randomly assigned to palivizumab prophylaxis had approximately twice as many total RSV-hospital days, with a statistically non-significant mean difference (MD) of 24.95 days per 100 randomized children (MD 24.95, 95% CI -21.59 to 71.49) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>), three to five times more days in the ICU, MD being 21.34 days per 100 randomized children (MD 21.34, 95% CI -13.69 to 56.37) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>), seven to eight times more days of mechanical ventilation (MD 16.06, 95% CI -16.60 to 48.72) (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>), and two to three times more days of supplemental oxygen therapy per 100 randomized children (MD 28.42, 95% CI -13.64 to 70.48) (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>), compared to motavizumab recipients.</P>
<P>Again, rates of AEs and SAEs were consistent with the underlying medical conditions in this high-risk population. No significant differences were found in the proportion of children with any AE (RR 1.00, 95% CI 0.99 to 1.02) (<LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>), with AE related to study drug (RR 0.98, 95% CI 0.73 to 1.32) (<LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>), with any SAE (RR 1.04, 95% CI 0.96 to 1.13) (<LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>), or with SAE related to study drug (RR 0.88, 95% CI 0.32 to 2.43) (<LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>) between palivizumab and motavizumab recipients. Common adverse events (when reported) included fever, upper respiratory infections, cough and rhinitis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Economic impact of immunoprophylaxis given at neonatal period or within the first six months of life</HEADING>
<P>Out of the 22 studies that evaluated the economic impact of RSV immunoprophylaxis given during the neonatal period or within the first few months of life, 18 studies reported on preterm infants born at or before 35 weeks gestational age without other co-morbidities (<LINK REF="STD-Chirico-2009" TYPE="STUDY">Chirico 2009</LINK>; <LINK REF="STD-ElHassan-2006" TYPE="STUDY">ElHassan 2006</LINK>; <LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>; <LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>; <LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK>; <LINK REF="STD-Neovius-2011" TYPE="STUDY">Neovius 2011</LINK>; <LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>; <LINK REF="STD-Nuijten-2010" TYPE="STUDY">Nuijten 2010</LINK>; <LINK REF="STD-Ravasio-2006" TYPE="STUDY">Ravasio 2006</LINK>; <LINK REF="STD-Raya-Ortega-2006" TYPE="STUDY">Raya Ortega 2006</LINK>; <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>; <LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>; <LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK>; <LINK REF="STD-Salinas_x002d_Escudero-2012" TYPE="STUDY">Salinas-Escudero 2012</LINK>; <LINK REF="STD-Smart-2010" TYPE="STUDY">Smart 2010</LINK>; <LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>; <LINK REF="STD-Weiner-2012" TYPE="STUDY">Weiner 2012</LINK>); nine studies reported on preterm infants with bronchopulmonary dysplasia or chronic lung disease (<LINK REF="STD-Chirico-2009" TYPE="STUDY">Chirico 2009</LINK>; <LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>; <LINK REF="STD-Hascoet-2008" TYPE="STUDY">Hascoet 2008</LINK>; <LINK REF="STD-Lofland-2000" TYPE="STUDY">Lofland 2000</LINK>; <LINK REF="STD-Nuijten-2009a" TYPE="STUDY">Nuijten 2009a</LINK>; <LINK REF="STD-Ravasio-2006" TYPE="STUDY">Ravasio 2006</LINK>; <LINK REF="STD-Rietveld-2010" TYPE="STUDY">Rietveld 2010</LINK>; <LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>); and three studies reported on infants with congenital heart disease (<LINK REF="STD-Hascoet-2008" TYPE="STUDY">Hascoet 2008</LINK>; <LINK REF="STD-Nuijten-2009a" TYPE="STUDY">Nuijten 2009a</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>).</P>
<P>Of the studies evaluating immunoprophylaxis in preterm infants without other co-morbidities, 12 (<LINK REF="STD-Chirico-2009" TYPE="STUDY">Chirico 2009</LINK>; <LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>; <LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK>; <LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>; <LINK REF="STD-Nuijten-2010" TYPE="STUDY">Nuijten 2010</LINK>; <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>; <LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>; <LINK REF="STD-Ravasio-2006" TYPE="STUDY">Ravasio 2006</LINK>; <LINK REF="STD-Raya-Ortega-2006" TYPE="STUDY">Raya Ortega 2006</LINK>; <LINK REF="STD-Salinas_x002d_Escudero-2012" TYPE="STUDY">Salinas-Escudero 2012</LINK>; <LINK REF="STD-Smart-2010" TYPE="STUDY">Smart 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>) reported costs from the payer's perspective, or from both the payer's and societal perspectives. Six studies (<LINK REF="STD-ElHassan-2006" TYPE="STUDY">ElHassan 2006</LINK>; <LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>; <LINK REF="STD-Ravasio-2006" TYPE="STUDY">Ravasio 2006</LINK>; <LINK REF="STD-Raya-Ortega-2006" TYPE="STUDY">Raya Ortega 2006</LINK>; <LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK>; <LINK REF="STD-Salinas_x002d_Escudero-2012" TYPE="STUDY">Salinas-Escudero 2012</LINK>) reported a time horizon different than the lifetime (e.g. one year, eight years, 14 years, 18 years). In studies where evaluation was conducted from the payer's perspective and with a lifetime horizon (<LINK REF="STD-Chirico-2009" TYPE="STUDY">Chirico 2009</LINK>; <LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK>; <LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>; <LINK REF="STD-Nuijten-2010" TYPE="STUDY">Nuijten 2010</LINK>; <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>; <LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>; <LINK REF="STD-Smart-2010" TYPE="STUDY">Smart 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>), the incremental cost-effectiveness ratio (ICER) present values at 2011 EUR expressed per quality-adjusted life-year (QALY) or life-year gained (LYG), vary widely across the studies (from EUR 7282 to EUR 27,068 per QALY, and from EUR 10,724 to EUR 36,098 per LYG). All of those studies considered different mortality rates for the intervention and non-intervention groups in the economic models, making the assumption that palivizumab prophylaxis has an effect on mortality, since there is evidence suggesting that palivizumab modifies the RSV hospitalization rates. <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> reported a range of ICERs in this population (from EUR 133,478 to EUR 1,651,357 per QALY); lower ICERs were obtained when passive immunisation is given during the neonatal period to preterm infants born at less than 24 weeks of gestational age, and higher ICERs (less favorable for the use of palivizumab) were obtained when prophylaxis was given to infants three to six months of age, born at 32 to 34 weeks of gestational age.</P>
<P>In studies evaluating preterm infants without other co-morbidities, with a one-year time horizon (<LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>; <LINK REF="STD-Raya-Ortega-2006" TYPE="STUDY">Raya Ortega 2006</LINK>; <LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK>; <LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK>), the effectiveness outcome measure was averted hospitalization. While <LINK REF="STD-Raya-Ortega-2006" TYPE="STUDY">Raya Ortega 2006</LINK> adopted the payer's perspective, <LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>, <LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK> and <LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK> reported results from the societal perspective. The incremental costs per hospitalization averted for palivizumab prophylaxis were rather high in <LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK> (EUR 72,780); while the ICERs reported by <LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK> and <LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK> were quite lower, and similar between them (EUR 29,199 and EUR 24,617 respectively). <LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK> included the mortality benefits for the use of palivizumab prophylaxis and <LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK> did not. However, <LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK> considered a much lower total amount of the drug in the economic model.</P>
<P>Economic evaluations reporting incremental costs per LYG or QALY in preterm infants with bronchopulmonary dysplasia (or chronic lung disease), adopting the payer's perspective (<LINK REF="STD-Chirico-2009" TYPE="STUDY">Chirico 2009</LINK>; <LINK REF="STD-Ravasio-2006" TYPE="STUDY">Ravasio 2006</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>), showed rather favorable cost-effectiveness results for the use of palivizumab (from EUR 2968 to EUR 3317 per QALY, and from EUR 4707 to EUR 6253 per LYG). <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> reported a range of ICERs for this population (from EUR 17,113 to EUR 112,943 per QALY). All three studies allowed a mortality difference and difference in the risk of long-term sequelae in their models. ICER values reported in preterm infants with bronchopulmonary dysplasia (or chronic lung disease) were systematically lower than those reported in preterm infants without other comorbidity, indicating that palivizumab prophylaxis is more cost-effective in infants with bronchopulmonary dysplasia than in those born preterm without other comorbidity.</P>
<P>All three studies that evaluated the economic impact of RSV prophylaxis in infants with congenital heart disease (<LINK REF="STD-Hascoet-2008" TYPE="STUDY">Hascoet 2008</LINK>; <LINK REF="STD-Nuijten-2009a" TYPE="STUDY">Nuijten 2009a</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>) adopted a lifetime time horizon. However, analyses were conducted from different perspectives, and they included different mortality rates and different risks of sequelae (asthma or recurrent wheezing) in their models, which finally made them incomparable. The ICERs expressed per QALY or LYG showed big variations across studies. <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> reported on infants with acyanotic and cyanotic congenital heart disease, adopting the payer's perspective. The range of ICER values obtained in infants with acyanotic congenital heart disease was lower (more favorable) than the range of ICER values in infants with cyanotic congenital heart disease. In both cases, ICER values were dramatically higher than those reported by the other two studies in infants with congenital heart disease, which adopted the societal perspective. All three studies that reported results for infants with congenital heart disease also reported results for preterm infants with bronchopulmonary dysplasia (or chronic lung disease) and within-study comparisons were possible. In <LINK REF="STD-Hascoet-2008" TYPE="STUDY">Hascoet 2008</LINK> and <LINK REF="STD-Nuijten-2009a" TYPE="STUDY">Nuijten 2009a</LINK>, ICERs reported for infants with congenital heart disease showed to be systematically lower than the ICERs reported for infants with bronchopulmonary dysplasia (or chronic lung disease), while <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> showed the opposite trend in results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Economic impact of immunoprophylaxis given to children aged six months and older</HEADING>
<P>Out of 10 studies that evaluated the economic impact of RSV immunoprophylaxis given to children aged six months and older, two studies reported on children born at or before 35 weeks of gestational age without other co-morbidities (<LINK REF="STD-Tam-2009" TYPE="STUDY">Tam 2009</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>); nine studies reported on children with congenital heart disease (<LINK REF="STD-Chiroli-2005" TYPE="STUDY">Chiroli 2005</LINK>; <LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>; <LINK REF="STD-Harris-2011" TYPE="STUDY">Harris 2011</LINK>; <LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>; <LINK REF="STD-Nuijten-2009b" TYPE="STUDY">Nuijten 2009b</LINK>; <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>; <LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>; <LINK REF="STD-Yount-2004" TYPE="STUDY">Yount 2004</LINK>); and five studies reported on children with bronchopulmonary dysplasia or chronic lung disease (<LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>; <LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>; <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>; <LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>).</P>
<P>
<LINK REF="STD-Tam-2009" TYPE="STUDY">Tam 2009</LINK> and <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> performed evaluations from the payer's perspective in children born at or before 35 weeks of gestation without other co-morbidities, adopting a lifetime time horizon, and allowing the mortality benefits for the use of palivizumab prophylaxis. The ICER values expressed per QALYs varied across the studies substantially; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> reported dramatically higher values than <LINK REF="STD-Tam-2009" TYPE="STUDY">Tam 2009</LINK> (EUR 655,409 and EUR 29,663 respectively).</P>
<P>From the studies that analyzed the economic impact of passive immunisation given to children with congenital heart disease, six studies adopted a lifetime time horizon and a payer's perspective (<LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>; <LINK REF="STD-Nuijten-2009b" TYPE="STUDY">Nuijten 2009b</LINK>; <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>; <LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>; <LINK REF="STD-Yount-2004" TYPE="STUDY">Yount 2004</LINK>). All six studies allowed a mortality difference and difference in the risk of long-term sequelae between the interventions. The ICER values expressed per QALYs reported in <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> and <LINK REF="STD-Yount-2004" TYPE="STUDY">Yount 2004</LINK> were dramatically higher than those reported in other studies. Also, <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> and <LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK> reported on children with acyanotic and cyanotic congenital heart disease. The range of ICER values obtained in children with acyanotic congenital heart disease was lower than the range of ICER values in children with cyanotic congenital heart disease, indicating that palivizumab prophylaxis is more cost-effective among the first ones.</P>
<P>
<LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK> and <LINK REF="STD-Harris-2011" TYPE="STUDY">Harris 2011</LINK> used the RSV hospitalization averted, and one day of RSV hospitalization averted as the effectiveness outcome measures, respectively. <LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK> adopted a payer's perspective, and did not include the mortality benefits for the use of palivizumab into the model. <LINK REF="STD-Harris-2011" TYPE="STUDY">Harris 2011</LINK> adopted a societal perspective, and included the mortality benefits into the model. Finally, the ICERs in the two studies differed substantially (EUR 689,645 per hospitalization averted and EUR 11,669 per one day of hospitalization averted, respectively).</P>
<P>All five studies that performed analyses in children with bronchopulmonary dysplasia or chronic lung disease adopted the payer's perspective. <LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK> reported values of ICERs per hospitalization avoided, and did not allow a mortality difference or a difference in the risk of long-term sequelae between the interventions. <LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>; <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>; <LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK> and <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> reported ICERs per LYGs and/or QALYs, thereby adopting a lifetime time horizon, and allowing the mortality benefits for the use of palivizumab prophylaxis. The ICERs from these analyses are quite consistent across studies (from EUR 25,459 to EUR 36,794 per QALY, and from EUR 36,774 to EUR 50,557 per LYG). Again, the range of ICER values reported in <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> was very wide.</P>
<P>
<LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK> reported on the same patient populations as <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>, and conducted the analysis in the same country (Austria), by adopting a similar modelling approach. However, it incorporated changes in the total amount of the drug used, the medication costs and overall consumption of resources, and it included some new country-specific epidemiologic data. These changes led to obtaining more favorable ICERs as compared to ICERs reported in <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>, both in children with congenital heart disease, and in children with bronchopulmonary dysplasia (or chronic lung disease).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Economic impact of immunoprophylaxis given to high-risk infants and children (born preterm, with or without bronchopulmonary dysplasia, or with congenital heart disease) up to five years of age</HEADING>
<P>Three studies evaluated the economic impact of RSV immunoprophylaxis given to a mixed population of high-risk infants and children (preterm infants with or without bronchopulmonary dysplasia, infants with congenital heart disease, preterm children with or without bronchopulmonary dysplasia, and children with congenital heart disease) (<LINK REF="STD-Garcia_x002d_Altes-2010" TYPE="STUDY">Garcia-Altes 2010</LINK>; <LINK REF="STD-Joffe-1999" TYPE="STUDY">Joffe 1999</LINK>; <LINK REF="STD-Lazaro-y-de-Mercado-2007" TYPE="STUDY">Lazaro y de Mercado 2007</LINK>). <LINK REF="STD-Garcia_x002d_Altes-2010" TYPE="STUDY">Garcia-Altes 2010</LINK> reported results from the payer's perspective, adopting a lifetime time horizon, and allowing for mortality difference between the treatments. <LINK REF="STD-Lazaro-y-de-Mercado-2007" TYPE="STUDY">Lazaro y de Mercado 2007</LINK> reported results from the societal perspective, adopting a lifetime time horizon, and allowing the mortality difference as well as the difference in the risk of long-term sequelae between the treatments. Both studies were conducted in Spain. The final results of ICERs expressed per LYGs differ immensely (EUR 174,642 and EUR 6256 respectively). We could not calculate the ICER present values at 2011 EUR for results reported in <LINK REF="STD-Joffe-1999" TYPE="STUDY">Joffe 1999</LINK>, since exchange rates for Euros are not available for 1995.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Funding and results in economic evaluations</HEADING>
<P>Overall, of the 34 included economic evaluations, 21 studies were funded by the drug manufacturing company, 10 studies had no conflict of interest declared and three studies were unclear as to whether they were industry funded or not (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>All of the industry-sponsored economic evaluations supported the cost-effectiveness of palivizumab prophylaxis, except for <LINK REF="STD-Lofland-2000" TYPE="STUDY">Lofland 2000</LINK>, which gave ranges of ICER values and left the conclusions at reader's discretion, <LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK> which suggested a more restrictive policy, and <LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK> that reported no cost savings with palivizumab prophylaxis.</P>
<P>All of the economic evaluations that were not industry-sponsored suggested within their final conclusions that palivizumab was not cost-effective in the analyzed settings, according to the established threshold values, and that a more restrictive passive immunisation policy should be used. The only exception was <LINK REF="STD-Smart-2010" TYPE="STUDY">Smart 2010</LINK>, which had the methodology based on <LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK> (industry-funded) and reported that palivizumab prophylaxis is cost-effective. <LINK REF="STD-Yount-2004" TYPE="STUDY">Yount 2004</LINK> suggested that the routine use of palivizumab should be further evaluated.</P>
<P>Regarding the three studies where funding was questionable, <LINK REF="STD-Harris-2011" TYPE="STUDY">Harris 2011</LINK> reported receiving a very small honorarium from the sponsoring company, and suggested that palivizumab was not cost-effective. For <LINK REF="STD-Kang-2009" TYPE="STUDY">Kang 2009</LINK> only an abstract was available, suggesting that the use of palivizumab was cost-effective, with no details provided about the funding. In <LINK REF="STD-Lazaro-y-de-Mercado-2007" TYPE="STUDY">Lazaro y de Mercado 2007</LINK> no conflict of interest was declared, and cost-effectiveness of palivizumab was suggested, but should be noted that for the economic evaluation performed on the same topic by the same authors in 2006 (<LINK REF="STD-Lazaro-y-de-Mercado-2006" TYPE="STUDY">Lazaro y de Mercado 2006</LINK>), the authors received a grant from the drug manufacturing company.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-06-12 08:29:33 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-06-12 08:29:33 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Efficacy and safety evidence</HEADING>
<P>The primary objective of this review was to assess the effects of palivizumab prophylaxis compared to placebo, or another type of prophylaxis (e.g. motavizumab), in reducing the risk of hospitalization due to respiratory syncytial virus (RSV) infection in high-risk infants and children.</P>
<P>Palivizumab prophylaxis was associated with a statistically significant reduction in RSV hospitalisations, when compared to placebo. The magnitude of this effect is considerable; palivizumab reduced the risk of RSV hospitalization by half. Children treated with palivizumab prophylaxis spent fewer days in hospital, were admitted to the intensive care unit (ICU) less often, and had fewer days of supplemental oxygen therapy for RSV infection than the placebo recipients. These results suggest a favorable effect of palivizumab prophylaxis on the incidence of serious lower respiratory tract RSV disease in children at high risk.</P>
<P>Results for the total days spent in the ICU and the incidence and total days of mechanical ventilation were inconsistent between the two trials, possibly due to different severity of underlying medical conditions in children included in the trials. Children with haemodynamically significant congenital heart disease experienced fewer days in the ICU, and lower incidence and fewer days of mechanical ventilation when treated with palivizumab prophylaxis compared with placebo, while children born preterm, with or without bronchopulmonary dysplasia, having less severe baseline risk factors for RSV disease, showed the opposite trend in results. It could be that a drug has a larger relative effect in sicker populations. But also, medical practices, guidelines and recommendations on when to discharge from an ICU, and when to initiate and wean mechanical ventilation, differ substantially in different settings.</P>
<P>When palivizumab was compared to motavizumab prophylaxis, there was an obvious trend of increase in the risk of acquiring severe lower respiratory tract RSV disease in patients receiving palivizumab. The risk of hospitalization due to RSV infection was increased by one-third in palivizumab patients. Children treated with palivizumab had more admissions to intensive care, a higher need for supplemental oxygen therapy and more instances of mechanical ventilation than the children treated with motavizumab prophylaxis.</P>
<P>However, the results of trials comparing palivizumab and motavizumab should be interpreted with caution. The US Food and Drug Administration (FDA) cited methodological concerns (among others) in its review of a licensing application for motavizumab, specifically with regards to the laboratory testing of RSV, which may have biased the results toward motavizumab over palivizumab. The FDA also expressed concerns regarding both motavizumab's safety and efficacy. The non-fatal hypersensitivity adverse events were found to be three times higher in the motavizumab group than in the palivizumab group. Also, motavizumab's non-inferiority results are largely driven by data obtained from southern hemisphere countries, representing only about 9% of the total patient population. Removing this population led the FDA to determine that in the US population motavizumab did not meet the non-inferiority criterion relative to palivizumab (<LINK REF="REF-FDA-2010" TYPE="REFERENCE">FDA 2010</LINK>). These issues have implications for assessing the risk of bias in <LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>, and the results should be interpreted with this in mind.</P>
<P>Total days in the hospital due to RSV infection, days spent in the ICU, receiving mechanical ventilation or with supplemental oxygen therapy were all much higher in palivizumab than in motavizumab-treated patients.</P>
<P>Data on days were summarised and presented as days per 100 randomized children in a study arm, and not as days per one child. That is why they are expected to be proportional to the number (or better, to the rate) of patients hospitalised from that study arm. For example, if two children out of 100 are hospitalised in one group, and one child out of 100 is hospitalised in the other group, and if each child from both groups stays in the hospital for five days, in the first group we would have 10 hospital days per 100 randomized children, and in the second five hospital days per 100 randomized children. The larger the incidence of RSV hospitalisations, the bigger are the numbers of days. This is a common problem in almost all RCTs in this review: results on total days presented in this way could be misleading. We cannot interpret them as a measure of severity of the disease, once a child has acquired an RSV infection. For both clinicians and patients it would be more beneficial for study authors to express the mean number of days per one child in future studies.</P>
<P>Another common problem of almost all studies reporting data on days is their incomplete reporting. Measures of dispersion were not provided and we cannot be confident about the precision of the results.</P>
<P>RSV-specific outpatient medically attended lower respiratory tract infections were assessed for motavizumab and palivizumab patients in two studies. Motavizumab was associated with statistically significant reduction in RSV-specific outpatient MALRIs when compared to palivizumab; the risk in the palivizumab group was twice that of the motavizumab group. However, this outcome was assessed in just a subset of patients, either in patients from selected study sites or in patients in season two only, making the risk of bias in these results high.</P>
<P>Palivizumab-treated children had lower mortality rates than children treated with placebo or motavizumab. However, it was hard to draw any conclusions since all studies expressed mortality as deaths due to any cause, regardless of their relation to study drug or to RSV infection. We were surprised to find that within-study mortality rates differed substantially between the studies (e.g. <LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK> reports an all-cause mortality rate 30 times that of <LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>). The difference could be attributed to different sample sizes and different underlying medical conditions in patient populations in the two studies.</P>
<P>For both comparisons we analyzed the proportion of children with adverse events in four categories, depending on the seriousness of the adverse event (AE) and its relatedness to the study drug. Unfortunately, we could not analyse a specific adverse event or adverse events grouped by organ systems, due to different reporting methodologies in studies.</P>
<P>As we expected, considering the underlying medical conditions in this high-risk population, rates of AEs and SAEs were high in all treated patients. Palivizumab was associated with a statistically significant reduction in the proportion of children reporting any SAE compared to placebo. After having confirmed the efficacy of palivizumab prophylaxis, these results are self explanatory. Palivizumab reduces the risk of severe RSV disease after the RSV infection has occurred, and thereby minimises hospitalisations, or possibly some life-threatening conditions or significant disabilities, which are all considered serious adverse events. It should also be noted that this result came from one study only. The proportion of children reporting any adverse event related to study drug, or any adverse event at all, was similar in palivizumab and placebo patients. Post-marketing surveillance data included in the Synagis (palivizumab) product leaflet provide additional insight into potential adverse events encountered, specifically: severe acute hypersensitivity reactions and anaphylaxis, which are described as rare and very rare (respectively) (<LINK REF="REF-FDA-2009" TYPE="REFERENCE">FDA 2009</LINK>).</P>
<P>We did not find any differences in the proportion of children reporting AE when palivizumab was compared to motavizumab in any of the four categories assessed. The proportion of children reporting any AE was similar between the two groups, and additional analyses of other groupings of AEs did not demonstrate any significant difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Economic evidence</HEADING>
<P>In all included economic studies, a cost-effectiveness or a cost-utility analysis was conducted that compared the clinical and financial consequences of palivizumab prophylaxis and no prophylaxis in infants and children at high risk. In this section, the Drummond definitions of the types of economic evaluations were followed (<LINK REF="REF-Drummond-1996" TYPE="REFERENCE">Drummond 1996</LINK>) and all studies were classified into a health sector (payer's) or a societal perspective.</P>
<P>In general, costs and outcomes can be combined in three different ways, resulting in three different types of analyses: cost&#8211;benefit analysis (where both inputs and outcomes are considered in monetary terms); cost&#8211;utility analysis (where inputs are considered in terms of costs, and outcomes are measured in utility measures, such as quality-adjusted life-years (QALYs)); and cost&#8211;effectiveness analysis (where inputs are measured in terms of costs, and outcomes are measured using measures specific to the disease). A QALY is estimated in terms of a year of life, adjusted by the amount of quality that the life is lived at. Therefore, one year lived at full quality is 1 QALY, but one year lived at half quality equates to 0.5 QALYs, and half a year at full quality is also 0.5 QALYs. Different diseases and conditions can be compared using the cost&#8211;utility analysis and, therefore, these types of analyses are especially used by governmental approval groups, such as the UK National Institute for Health and Clinical Excellence, which often sets a threshold of utility gains per cost for all drugs and health technologies. A cost&#8211;effectiveness analysis usually compares the costs and outcomes of similar treatments for specific conditions. However, it would not provide data on the incremental cost&#8211;effectiveness ratio (ICER) per QALY, and if such data are required, would need to be modelled from the cost&#8211;effectiveness data.</P>
<P>Whether an intervention is cost-effective or not, and whether it should be provided or not, depends on the cost-effectiveness threshold established by the decision makers in a particular country. Following the recommendations of the Commission on Macroeconomics and Health, the World Health Organization (WHO) has derived three categories of cost-effectiveness using the nominal gross domestic product (GDP) per capita as a measure:</P>
<UL>
<LI>highly cost-effective (ICER is less than one GDP per capita);</LI>
<LI>cost-effective (ICER is between one and three times GDP per capita); and</LI>
<LI>not cost-effective (ICER is more than three times GDP per capita).</LI>
</UL>
<P>The nominal GDP per capita for the European Union (EU) for year 2011, as calculated by the World Bank, was USD 34,848 (EUR 24,621.37) (available at <A HREF="http://data.worldbank.org/">http://data.worldbank.org/</A>). Using this GDP to calculate the cost-effectiveness threshold, the immunoprophylaxis would be cost-effective for the EU countries if the ICER present value at 2011 EUR is lower than EUR 73,864.11 per QALY. However, this threshold is substantially higher than the thresholds established by particular EU countries, e.g. the United Kingdom's cost-effectiveness threshold has been in the range of GBP 20,000 to GBP 30,000 for over 10 years now (EUR 22,791.74 to EUR 34,187.61 respectively, using the 2011 exchange rates).</P>
<P>As Peter Jacobson (<LINK REF="REF-Jacobson-2001" TYPE="REFERENCE">Jacobson 2001</LINK>) stated: "Cost control is a primary objective of the managed care environment. It is no longer possible to provide health care without regard to cost or patient demand. The question is not whether there will be cost containment, but how to structure and oversee its implementation. The use of cost-effectiveness analysis (CEA) in making clinical and payment decisions has become a significant cost containment approach, however CEA should be treated as one piece of evidence to be considered by health care sector to define way of action rather than being used to determine the standard of care."</P>
<P>We presented and discussed economic data separately according to age and subgrouped data according to underlying medical conditions because, clinically, these patients are likely to have different baseline risks for serious complications due to RSV infection. We further classified the economic evaluations by whether they adopted the payer's or the societal perspective. We also debated about the main economic results obtained from the included studies and about variations in methodological approaches among studies that may justify the differences in cost-effectiveness results.</P>
<P>Data on cost&#8211;effectiveness of RSV immunoprophylaxis with palivizumab versus no prophylaxis are based on simulation modelling, rather than the direct collection of costs and outcomes. Data for the evaluations were drawn from a wide variety of sources, including the palivizumab clinical trials, published literature, hospital databases, country-specific price/tariff lists and national population statistics. Country-specific data sources were also used for economic measures and information on therapeutic choices. Clinical events and utilities in the majority of analyses are not country-specific and therefore were derived from international studies.</P>
<P>The main outcomes considered for cost-effectiveness analyses in the included economic studies were hospitalization due to RSV infection (ordinary ward or ICU) and life-years gained (LYGs). For cost-utility analysis, outcomes considered were QALYs. Challenges in the cost&#8211;utility approach for this specific problem lie in modelling of costs and QALY gains in the lifetime follow-up period to capture the impact of palivizumab on long-term morbidity and mortality, resulting from severe RSV infection beyond the RSV hospitalization period. Under the assumption that RSV hospitalisations are associated with clinical and economic consequences beyond the clinical trial period; a proportion of children may develop long-term sequelae (e.g. wheezing or asthma) leading to a reduction of QALYs and additional medical costs. It is known that the rates used to populate the economic models will drive the final results of the analyses towards higher or lower ICER values. The reduction in RSV hospitalization rate due to palivizumab prophylaxis corresponds to data available from the palivizumab clinical trials (e.g. <LINK REF="STD-IMpact_x002d_RSV-1998" TYPE="STUDY">IMpact-RSV 1998</LINK>) that considered only one season period of follow-up, which is 150 days from the point of randomization (30 days after the last scheduled palivizumab injection). Therefore, for the economic models that adopted the lifetime time horizon it was necessary to extrapolate the efficacy data from the palivizumab clinical trials (reduction in the rate of RSV hospitalisations) to calculate the likely number of LYGs and QALYs gained from the use of palivizumab prophylaxis. Regardless of the time horizon considered in the analysis, if authors assumed that differences in RSV hospitalization rates allow for differences in mortality rates between the palivizumab prophylaxis and non-prophylaxis group, and thus populated the models from the beginning with differential mortality rates, the final results will favour palivizumab use, particularly if the societal perspective was adopted.</P>
<P>Modelling costs depend on the perspective of the analysis. The analyses performed from the societal perspective included not only the direct medical costs, but also costs for management of wheezing or asthma, and future lost productivity of a child resulting from mortality (a small proportion of children will die, which will lead to a lifetime loss of productivity benefits). The analyses that adopted the payer's perspective considered only direct medical costs. Generally, analyses that included direct medical costs associated with asthma (i.e. when asthma was included into the disease pathway modelled) showed moderately more favorable ICERs for palivizumab prophylaxis, while analyses that included the long-term indirect costs due to lost lifetime productivity following childhood mortality, showed a substantial improvement in the cost-effectiveness of prophylaxis with palivizumab. It means that palivizumab prophylaxis is more cost-effective if it has a long-term effect on the incidence of asthma and mortality.</P>
<P>A very important consideration that should be taken into account while interpreting the economic results presented in this review is that effectiveness data used to populate the models come from follow-up studies performed in hospitalised children, RSV-infected or not, with or without the underlying medical conditions (such as bronchopulmonary dysplasia or congenital heart disease); none of the studies measured the long-term impact that palivizumab prophylaxis could have on asthma and mortality in these high-risk populations. So, data used by study authors to populate the economic models are based on unsupported assumptions. Whether or not these assumptions and modelling practices lead to underestimation or overestimation of the mortality rates in children born preterm or with underlying heart or lung disease, that have received immunoprophylaxis with palivizumab, is unclear.</P>
<P>Currently there are no longitudinal trials providing robust data on long-term effects of palivizumab prophylaxis on a child's morbidity and mortality beyond the standard follow-up period. The forthcoming results from one investigator-initiated RCT (<LINK REF="STD-NTR1023" TYPE="STUDY">NTR1023</LINK>) that assessed the number of wheezing days in preterm children during the first year of life, and the quality of life and asthmatic symptoms up to six years of age, might be offering some answers to this question.</P>
<P>Owing to particular problems described above, and due to the fact that mortality rates could drive the final cost-effectiveness ratios, it is important to discuss the methodological approaches used by the authors to model this outcome in their economic analyses. Methods that were used for reporting, calculating and adjusting the probabilities of death that entered the models differed considerably across studies. In most cases, the absolute values of probabilities of death were not reported and the exact organisation of decision tree models was not presented. Some study authors directly modelled different mortality rates for patients receiving palivizumab prophylaxis and no prophylaxis. In some of the studies, models included difference in life-years gained between the two intervention groups, and this fact necessarily implies that a difference in mortality was also allowed. Some study authors assumed different mortality rates for hospitalised versus non-hospitalised patients. In other instances, different mortality rates were assumed for patients hospitalised with or without the RSV infection. Again, some other studies assumed the same mortality rates for the two intervention groups, but calculated the probabilities of death according to the related hospitalization rates in the two groups. The bottom line is that all these studies took into account that palivizumab prophylaxis reduces the rate of RSV-related hospitalisations, and this directly translates into reduced mortality risk in palivizumab group compared to no intervention group. Rare authors did not model a mortality benefit associated to the use of prophylaxis, but this was the case only in studies with a short time horizon (one year), and with final costs expressed per hospitalization avoided (the exception being the <LINK REF="STD-ElHassan-2006" TYPE="STUDY">ElHassan 2006</LINK> study).</P>
<P>Other important differences in economic models included in this review are the different total amount of the drug, different resources and services consumed (depending on a healthcare system in a particular country), different overall costs (dependent on the costs that specific services/resources have in a specific country), different time horizons and different discount rates.</P>
<P>Each of the factors described could easily account for large differences in cost-effectiveness results across studies. An additional aspect that we have studied, while interpreting the economic results presented in this review, is whether the analysis was funded by the drug manufacturing company or not. Almost all included studies that were sponsored by the industry supported the cost-effectiveness of palivizumab prophylaxis, while practically all included studies that were not sponsored by the industry suggested that palivizumab was not cost-effective.</P>
<P>We made attempts to classify studies according to all these differing assumptions included in economic models, in an effort to identify premises that would be necessary for palivizumab prophylaxis to be regarded as acceptably cost-effective. However, by analysing the information available from the study reports, it became obvious that a huge problem lies in the lack of standardisation of the modelling approaches adopted in economic studies, and these differences can easily lead to big variations in cost-effectiveness results, making them almost incomparable. The use of palivizumab prophylaxis for reducing the risk of severe RSV infection might not be cost-effective enough to be considered a standard healthcare policy in the majority of low- and middle-income countries, because of the high costs of the drug. However, patient needs and individual risks should be considered in each case that physicians encounter in their everyday clinical practice.</P>
<SUBSECTION>
<HEADING LEVEL="4">Economic impact of immunoprophylaxis given at neonatal period or within the first six months of life</HEADING>
<P>In an attempt to find systematic differences that could explain the variations in results of the studies reporting on preterm infants without other comorbidity, we analyzed patient populations, effectiveness outcomes, perspective taken and other methodological parameters. The doses of palivizumab varied across studies (from 3 to 6 doses at 15 mg/kg); gestational ages of preterm infants entered into the models differed between the studies; incremental effectiveness of palivizumab prophylaxis varied substantially across studies (i.e. RSV hospitalisations avoided, risk of asthma included, lower mortality rates due to palivizumab use). Finally, the included studies reported significant differences in economic results, coming primarily from the consumption of resources taken into account, and from the modelling approaches adopted. Many analyses considered a lifetime follow-up period to capture the impact of palivizumab on a long-term morbidity and mortality resulting from severe RSV infection. Since the available data from palivizumab clinical trials are all limited to a single RSV season, the way of modelling the evaluations presents an important source of variations leading to such differences in ICERs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Economic impact of immunoprophylaxis given to children aged six months and older</HEADING>
<P>Two studies evaluated the economic impact of RSV immunoprophylaxis in preterm children without other co-morbidities. The ICER values expressed per QALYs varied across these two studies substantially, making it difficult for decision-makers to identify the real magnitude of the economic impact that the palivizumab prophylaxis has in this population.</P>
<P>In the studies evaluating the economic impact of passive immunisation given to children with congenital heart disease, substantially higher ICER values expressed per QALYs and LYGs were reported by <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK> and <LINK REF="STD-Yount-2004" TYPE="STUDY">Yount 2004</LINK>. These studies had comparable methodological characteristics to other studies, and they both included mortality benefits and lower risk of long-term sequelae for children receiving palivizumab prophylaxis. We did not find any clear explanations for this variation, other than that these two studies were the only ones not funded by the drug manufacturer.</P>
<P>Results from studies performed in children with bronchopulmonary dysplasia (or chronic lung disease) aged six months and older are quite consistent and rather high. Whether palivizumab prophylaxis is a cost-effective alternative, and whether it should be adopted as part of routine care in this population, depends on the threshold value set by the decision-makers in a particular country.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Economic impact of immunoprophylaxis given to high-risk infants and children (born preterm, with or without bronchopulmonary dysplasia, or with congenital heart disease) up to five years of age</HEADING>
<P>From the evidence presented in the three included studies, it is very difficult to define the real economic impact that the RSV prophylaxis strategy has in a mixed population of high-risk infants and children.</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-06-12 08:29:33 +1000" MODIFIED_BY="[Empty name]">
<P>The review includes all relevant RCTs and economic evaluations identified by an up to date literature search, making this evidence report up to date and current. We had prespecified RSV hospitalization and mortality as the primary efficacy and safety outcomes, and they were reported by most of the RCTs included.</P>
<P>This report presents evidence about the effects of palivizumab prophylaxis in infants and children at high risk for the development of serious RSV disease, in terms of its efficacy, safety and cost-effectiveness.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-06-12 08:29:33 +1000" MODIFIED_BY="[Empty name]">
<P>A total of seven RCTs and 34 economic evaluations were included in this review. The quality of evidence reflects the extent to which we are confident that an estimate of the effect is correct.</P>
<P>The quality of evidence was assessed and summarised for each main efficacy and safety outcome in this review by using the GRADE approach implemented in the GRADEpro software (<LINK REF="REF-GRADEpro-2008" TYPE="REFERENCE">GRADEpro 2008</LINK>). The GRADE quality rating was high or moderate for all outcomes assessed, with minor exceptions. Data on several important outcomes were not reported in all included studies. Some measurements were missing standard deviations and meta-analysis was not possible.</P>
<P>When palivizumab was compared to placebo, the quality of the evidence was high for RSV hospitalization, admission to ICU and for number of children reporting any serious adverse events. We downgraded the quality for all-cause mortality to moderate, due to imprecision of results; for mechanical ventilation the quality rating was very low, due to very serious heterogeneity and imprecision of data; while for total RSV hospital days, standard deviations were missing and meta-analysis was not possible, and we downgraded the quality of evidence to moderate. When palivizumab was compared to motavizumab, the quality of evidence was high for mechanical ventilation and for the number of children reporting any serious adverse events. For RSV hospitalization, all-cause mortality, admission to ICU and supplemental oxygen therapy, the quality of evidence was moderate due to imprecision of results; while for total RSV hospital days a standard deviation was missing in one study and could not be provided by the authors, and data were imprecise in the other study; we downgraded the quality of evidence to low.</P>
<P>It should be noted that there are methodological and other concerns raised by the US Food and Drug Administration (FDA), with regards to some studies in which motavizumab was evaluated (<LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK> among others), which resulted in rejecting a license application for motavizumab in 2010. A concern raised by the FDA was that the <LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK> study may have utilised laboratory testing procedures which may have biased the study toward motavizumab over palivizumab. Another concern was related to hypersensitivity reactions which were more prevalent in children who received motavizumab compared to palivizumab. Further concerns were raised with regards to the geographic distribution of patients enrolled in <LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>. Namely, motavizumab's efficacy results relative to palivizumab were largely driven by data from southern hemisphere countries, representing roughly 9% of the total data set. When compared with the northern hemisphere results, a substantial geographic heterogeneity of the treatment effect was observed (<LINK REF="REF-FDA-2010" TYPE="REFERENCE">FDA 2010</LINK>).</P>
<P>Results of the quality assessment of economic evaluation studies are summarised in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>. We assessed all included economic evaluations according to their full-text publications, except for <LINK REF="STD-Bentley-2011" TYPE="STUDY">Bentley 2011</LINK>; <LINK REF="STD-Kang-2009" TYPE="STUDY">Kang 2009</LINK> and <LINK REF="STD-Mayen_x002d_Herrera-2011" TYPE="STUDY">Mayen-Herrera 2011</LINK>, where only abstracts were available. In general, the included economic evaluations met the methodological and reporting aspects evaluated, and their results can be considered valid. In economic evaluations conducted by <LINK REF="STD-Chiroli-2005" TYPE="STUDY">Chiroli 2005</LINK>; <LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>; <LINK REF="STD-Lofland-2000" TYPE="STUDY">Lofland 2000</LINK>; <LINK REF="STD-Rietveld-2010" TYPE="STUDY">Rietveld 2010</LINK> and <LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK> the discounting was not applied to costs and consequences. However, it is considered to be methodologically correct since the time horizon used in these analyses was one year, making the discounting unnecessary. Studies conducted by <LINK REF="STD-Raya-Ortega-2006" TYPE="STUDY">Raya Ortega 2006</LINK> and <LINK REF="STD-Lofland-2000" TYPE="STUDY">Lofland 2000</LINK> were the only economic evaluations that did not meet three or more of methodological criteria assessed. The authors did not identify, measure accurately and value credibly relevant costs and consequences, and we cannot be confident in the final results presented in these studies.</P>
<P>Overall, the methodological and reporting quality of included economic evaluations was good, which is consistent with the criteria that we set for considering types of studies for inclusion. However, variations in the consumption of resources and in modelling approaches taken into account by a specific study appear to be a big drive for significant differences in the cost-effectiveness results.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-06-12 08:29:33 +1000" MODIFIED_BY="[Empty name]">
<P>Given our comprehensive search strategy and contact with the study authors and the drug manufacturer, it is unlikely that we missed any relevant studies. Two authors independently screened and selected studies, and extracted all data for RCTs and for economic evaluations. This we believe minimises errors in data extraction and biases. The quality of RCTs and economic evaluations was very good, although some studies did not report certain quality characteristics.</P>
<P>However, our review has several limitations, besides the fact that all included randomized controlled trials and two-thirds of the included economic evaluations were funded by the drug manufacturing company. We were limited in that palivizumab versus placebo, and palivizumab versus motavizumab comparisons only had three and four studies, respectively. Out of the total of seven RCTs, three were just safety studies (<LINK REF="STD-Abarca-2009" TYPE="STUDY">Abarca 2009</LINK>; <LINK REF="STD-Fernandez-2010" TYPE="STUDY">Fernandez 2010</LINK>; <LINK REF="STD-Subramanian-1998" TYPE="STUDY">Subramanian 1998</LINK>), without having evaluated the efficacy outcomes (except for one study where RSV hospitalisations were reported). That means that for most of the outcomes we assessed, we only had data from two studies that contributed to our analyses. Also, in one of the RCTs that we included (<LINK REF="STD-Subramanian-1998" TYPE="STUDY">Subramanian 1998</LINK>), the study drug was applied intravenously and not in the recommended approved dosing regimen, intramuscularly. In another study (<LINK REF="STD-Fernandez-2010" TYPE="STUDY">Fernandez 2010</LINK>), we presented safety information after two doses and not after the regular five doses of the study drug.</P>
<P>Two RCTs were conducted in children with haemodynamically significant congenital heart disease, and five RCTs in children born preterm, with or without chronic lung disease. We performed analyses in this review for all high-risk patient populations combined. In case we had three or more studies for each patient subpopulation, and for each comparison, we would have performed a subgroup analysis according to the presence of risk factors.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Our results agree with a previous Cochrane systematic review (<LINK REF="REF-Wang-1999" TYPE="REFERENCE">Wang 1999</LINK>) performed in children born preterm, with congenital heart disease or with bronchopulmonary dysplasia. However, in <LINK REF="REF-Wang-1999" TYPE="REFERENCE">Wang 1999</LINK> the pooled effects of polyclonal (RSV-IVIG) and monoclonal (palivizumab) RSV-neutralising antibodies were assessed, in comparison to placebo. The review included four studies in a pooled analysis, three with RSV-IVIG and one (<LINK REF="STD-IMpact_x002d_RSV-1998" TYPE="STUDY">IMpact-RSV 1998</LINK>) with palivizumab prophylaxis. <LINK REF="REF-Wang-1999" TYPE="REFERENCE">Wang 1999</LINK> reports practically identical relative risk reduction in RSV hospitalisations (RR 0.48, 95% CI 0.37 to 0.64) and in admissions to ICU (RR 0.47, 95% CI 0.29 to 0.77); similar results in the incidence of mechanical ventilation (RR 0.99, 95% CI 0.48 to 2.07) and the opposite trend of a relative risk increase in mortality (RR 1.15, 95% CI 0.63 to 2.11), for RSV prophylaxis compared to placebo.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-06-12 08:29:33 +1000" MODIFIED_BY="Tea Andabaka">
<IMPLICATIONS_PRACTICE MODIFIED="2013-06-12 08:29:33 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis is effective in reducing the frequency of hospitalisations due to respiratory syncytial virus (RSV) infection, i.e. in reducing the incidence of serious lower respiratory tract RSV disease in children with chronic lung disease, congenital heart disease or those born preterm. Even though our search also included children with immunodeficiency, chronic neuromuscular disease or congenital anomalies, no studies were found for those patient populations, and no conclusions can be drawn for them. Also, it would be beneficial to have longitudinal studies that could demonstrate the long-term effects of RSV prophylaxis on a child's morbidity and mortality beyond the standard follow-up period of 30 days after completion of the prophylaxis regimen.</P>
<P>The results of incremental costs per hospitalization averted, life-year gained (LYG) or quality-adjusted life-year (QALY gained) showed substantial variations across the included economic evaluations, not only due to the differences in baseline risks of studied patient populations. Several sources of variation, including the source of funding, have led to incomparable cost-effectiveness results in evaluations performed in similar populations. How cost-effective palivizumab prophylaxis actually is in a high-risk population of infants and children is unclear. The use of palivizumab prophylaxis for reducing the risk of severe RSV infection might not be cost-effective enough to be considered a standard healthcare policy in the majority of low- and middle-income countries, because of the high costs of the drug. However, patient needs and individual risks should be considered individually by the attending physician.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>A more precise definition of underlying medical conditions in the patient population at highest risk of severe RSV infection is necessary. Having a small number of efficacy studies for a specific subgroup of patients limited our ability to analyse data in that way. There are no published studies performed in children with immunodeficiency, chronic neuromuscular disease or congenital anomalies, all of whom may derive some benefit from RSV prophylaxis. Cohort studies are needed to determine the long-term effects of immunoprophylaxis on asthma, mortality and other important clinical outcomes. Conducting investigator-initiated studies would be beneficial, since all of the RCTs included in this review were sponsored by the manufacturer.</P>
<P>Evidence on the efficacy and safety of palivizumab prophylaxis in each subgroup of patients, together with the data about its cost-effectiveness in a specific population and setting, could be used for reconsidering current recommendations and developing national guidelines on when to provide RSV immunoprophylaxis. Also, the introduction of a low-cost vaccine against RSV would reduce the inequitable distribution and would make RSV prophylaxis available to the poorest countries where severe lower respiratory tract infections carry a substantial disease burden.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>The review authors wish to acknowledge Juan Manuel Lozano, Catalina Escovar and Verónica Vásquez, authors of the original protocol on which our review was based. The review authors also wish to thank Dario Sambunjak, Anne Lyddiatt, Karl Gallegos, Teresa Neeman, Ludovic Reveiz, Amina Foda, Nancy Banasiak, Charles Woods, Annabelle Enriquez, Cody Meissner,<B> </B>Theresa Wrangham and Michael Adena for commenting on the draft protocol/review. Author MXRR is a PhD candidate of the doctoral programme in <I>Salud Pública y Metodología de la Investigación Biomédica</I> of the <I>Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva, Universitat Autònoma de Barcelona</I>, Spain.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>This review is in no way funded by commercial entities that could possibly benefit financially from its results. The review authors have no financial interest in the subject matter of the review (e.g. private clinical practice, stocks, legal advice, consultancies, employment).</P>
<P>TA is employed at Allergan.<BR/>BB is involved in consultancies for an international epidemiological study on the incidence and characteristics of RSV infections sponsored by Abbott (H09 - 116: RSV Survey in CEE).<BR/>MXRR has participated as co-investigator of independent clinical research studies supported in part by Abbott Laboratories, MSD, Astra-Zeneca, GlaxoSmithKline and Sanofi-Aventis.<BR/>JWN has received scholarships from the Canadian Society of Respiratory Therapists, Ikaria and the Ontario Graduate Scholarship program (none of which had any role in this review).<BR/>JDR and VBV have no potential conflicts of interest to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>TA conceived the idea for the review and searched for articles for the background section. TA and JWN completed the literature search and extracted the data for the efficacy and safety analysis. TA and BB conducted the statistical analysis of the efficacy and safety data, and interpreted the results from RCTs. BB contributed to the conception of the idea for the review, defined the statistical methods for efficacy and safety data, and contributed to analysing the results from RCTs. TA and JDR completed the literature search and extracted the data for the economic analysis. MXRR defined the methods for the review of economic evidence, verified study selection and data extraction from economic evaluations, and contributed to analysis of economics data. TA and MXRR performed present value calculations and interpreted the results from economic studies. TA and MXRR wrote the results, discussion and conclusions. All review authors critically edited and approved the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-03-27 00:54:30 +1000" MODIFIED_BY="Tea Andabaka">
<P>In the protocol, we prespecified that we would analyse the number of children with secondary complications as one of the main outcomes. However, since different studies assessed different secondary complications (e.g. otitis media in <LINK REF="STD-IMpact_x002d_RSV-1998" TYPE="STUDY">IMpact-RSV 1998</LINK>, cardiac surgery/interventional catheterisation earlier than planned in <LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>), the data were not comparable and we discarded this outcome. Due to this, the main outcomes included in the final 'Summary of findings' tables differ to some extent from those prespecified by the protocol. Also, two RCTs assessed RSV-specific outpatient medically attended lower respiratory tract infections (<LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>; <LINK REF="STD-Feltes-2011" TYPE="STUDY">Feltes 2011</LINK>) and we decided to add this outcome in the review, even though we did not prespecify it in the protocol.</P>
<P>In the protocol, we prespecified including not only full, but also partial economic evaluations. However, we included in the review only full economic evaluations assessing cost-effectiveness or cost-utility of palivizumab prophylaxis compared to no intervention taken, due to the fact that a large number of these high-quality studies was available. With the intention of being concise, we did not report specific costs (resources) identified and considered in the obtained total cost per patient in each of the 34 included economic evaluations.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2010-12-22 12:28:48 +1000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Maria X Rojas">
<STUDIES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Maria X Rojas">
<INCLUDED_STUDIES MODIFIED="2012-10-15 12:50:51 +1000" MODIFIED_BY="Maria X Rojas">
<STUDY DATA_SOURCE="PUB" ID="STD-Abarca-2009" MODIFIED="2012-04-06 21:51:02 +1000" MODIFIED_BY="Tea Andabaka" NAME="Abarca 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-04-06 21:51:00 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abarca K, Jung E, Fernandez P, Zhao L, Harris B, Connor EM, et al; Motavizumab Study Group</AU>
<TI>Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>4</NO>
<PG>267-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bentley-2011" MODIFIED="2012-09-26 11:57:41 +1000" MODIFIED_BY="Tea Andabaka" NAME="Bentley 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-09-26 11:57:41 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bentley A, Filipovic I, Gooch K, Buesch K</AU>
<TI>A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the UK</TI>
<SO>Thorax</SO>
<YR>2011</YR>
<VL>66</VL>
<NO>Suppl 4</NO>
<PG>A136-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carbonell_x002d_Estrany-2010" MODIFIED="2012-04-06 21:51:40 +1000" MODIFIED_BY="Tea Andabaka" NAME="Carbonell-Estrany 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-04-06 21:51:40 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, et al; Motavizumab Study Group</AU>
<TI>Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a non-inferiority trial</TI>
<SO>Pediatrics</SO>
<YR>2010</YR>
<VL>125</VL>
<NO>1</NO>
<PG>e35-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chirico-2009" MODIFIED="2012-08-02 00:09:11 +1000" MODIFIED_BY="Tea Andabaka" NAME="Chirico 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-02 00:09:11 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chirico G, Ravasio R, Sbarigia U</AU>
<TI>Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants</TI>
<SO>Italian Journal of Pediatrics</SO>
<YR>2009</YR>
<VL>35</VL>
<PG>4</PG>
<IDENTIFIERS MODIFIED="2012-01-22 05:47:59 +1000" MODIFIED_BY="Tea Andabaka">
<IDENTIFIER MODIFIED="2012-01-22 05:47:59 +1000" MODIFIED_BY="Tea Andabaka" TYPE="DOI" VALUE="10.1186/1824-7288-35-4"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiroli-2005" MODIFIED="2012-01-22 05:55:20 +1000" MODIFIED_BY="Tea Andabaka" NAME="Chiroli 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-22 05:54:26 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiroli S, Macagno F, Lucioni C</AU>
<TI>Cost-efficacy analysis of palivizumab in the prevention of respiratory syncytial virus infections in young children with hemodynamically significant congenital heart disease</TI>
<SO>Italian Journal of Pediatrics</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>188-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ElHassan-2006" MODIFIED="2012-01-22 05:33:59 +1000" MODIFIED_BY="Maria X Rojas" NAME="ElHassan 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-12-30 06:47:48 +1000" MODIFIED_BY="Maria X Rojas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>ElHassan NO, Sorbero MES, Hall CB, Stevens TP, Dick AW</AU>
<TI>Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>2006</YR>
<VL>160</VL>
<PG>1070-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Embleton-2007" MODIFIED="2012-01-22 06:01:52 +1000" MODIFIED_BY="Tea Andabaka" NAME="Embleton 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-22 06:01:49 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Embleton ND, Dharmaraj ST, Deshpande S</AU>
<TI>Cost-effectiveness of palivizumab in infancy</TI>
<SO>Expert Review of Pharmacoeconomics and Outcomes Research</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>5</NO>
<PG>445-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feltes-2003" MODIFIED="2012-04-06 21:53:21 +1000" MODIFIED_BY="Tea Andabaka" NAME="Feltes 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-04-06 21:53:21 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al; Cardiac Synagis Study Group</AU>
<TI>Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>143</VL>
<NO>4</NO>
<PG>532&#8211;40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feltes-2011" MODIFIED="2012-04-06 21:59:43 +1000" MODIFIED_BY="Tea Andabaka" NAME="Feltes 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-04-06 21:59:43 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feltes TF, Sondheimer HM, Tulloh RMR, Harris BS, Jensen KM, Losonsky GA, et al; Motavizumab Cardiac Study Group</AU>
<TI>A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease</TI>
<SO>Pediatric Research</SO>
<YR>2011</YR>
<VL>70</VL>
<NO>2</NO>
<PG>186-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-2010" MODIFIED="2012-04-06 22:05:01 +1000" MODIFIED_BY="Tea Andabaka" NAME="Fernandez 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-04-06 22:04:58 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, et al; Motavizumab Study Group</AU>
<TI>A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season</TI>
<SO>BMC Pediatrics</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>38-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Altes-2010" MODIFIED="2012-01-22 18:35:49 +1000" MODIFIED_BY="Tea Andabaka" NAME="Garcia-Altes 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-01-22 18:35:49 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Altes A, Paladio N, Tebe C, Pons JMV</AU>
<TI>Cost-effectiveness analysis of the administration of palivizumab as prophylaxis of severe bronchiolitis due to respiratory syncytial virus</TI>
<TO>Anàlisi cost-efectivitat de l&#8217;administració del palivizumab en la profilaxi de les bronquiolitis greus per virus respiratori sincicial</TO>
<SO>Pediatria Catalana</SO>
<YR>2010</YR>
<VL>70</VL>
<PG>57-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hampp-2011" MODIFIED="2012-09-28 06:18:35 +1000" MODIFIED_BY="Tea Andabaka" NAME="Hampp 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-09-26 11:58:57 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hampp C, Kauf TL, Saidi A, Winterstein AG</AU>
<TI>Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab from the perspective of a Southern US medicaid agency</TI>
<SO>Value in Health</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>7</NO>
<PG>A301-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-28 06:18:35 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hampp C, Kauf TL, Saidi AS, Winterstein AG</AU>
<TI>Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>2011</YR>
<VL>165</VL>
<NO>6</NO>
<PG>498-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-2011" MODIFIED="2012-09-28 06:19:59 +1000" MODIFIED_BY="Tea Andabaka" NAME="Harris 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-09-28 06:19:59 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harris KC, Anis AH, Crosby MC, Cender LM, Potts JE, Human DG</AU>
<TI>Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>2011</YR>
<VL>27</VL>
<PG>523.e11-.e15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-26 12:00:47 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Human DG, Harris KC, Anis AH, Crosby MC, Cender LM, Potts JE</AU>
<TI>Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective</TI>
<SO>Cardiology in the Young</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>Suppl 1</NO>
<PG>30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hascoet-2008" MODIFIED="2012-01-22 18:34:13 +1000" MODIFIED_BY="Tea Andabaka" NAME="Hascoet 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-22 18:34:13 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hascoet JM, Fagnani F, Charlemagne A, Vieux R, Roze JC</AU>
<TI>Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting</TI>
<TO>Aspects methodologiques de l&#8217;evaluation economique du medicament en pediatrie: exemple de la prophylaxie de l&#8217;infection a VRS en France</TO>
<SO>Archives de Pediatrie</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>1739-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IMpact_x002d_RSV-1998" MODIFIED="2012-04-06 21:28:05 +1000" MODIFIED_BY="Tea Andabaka" NAME="IMpact-RSV 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-04-06 21:28:05 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The IMpact-RSV Study Group</AU>
<TI>Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>102</VL>
<NO>3 Pt 1</NO>
<PG>531&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joffe-1999" MODIFIED="2012-01-22 06:53:09 +1000" MODIFIED_BY="Tea Andabaka" NAME="Joffe 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-01-22 06:53:06 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA</AU>
<TI>Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>104</VL>
<NO>3</NO>
<PG>419-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kang-2009" MODIFIED="2012-01-22 06:59:05 +1000" MODIFIED_BY="Tea Andabaka" NAME="Kang 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-01-22 06:58:59 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kang HY, Kim HS, Choi JY, Kim YH</AU>
<TI>Cost-effectiveness analysis of palivizumab in the prevention of respiratory syncytial virus infection in Korean children with congenital heart disease</TI>
<SO>Value in Health</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>7</NO>
<PG>A424</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanctot-2008" MODIFIED="2012-01-22 07:07:32 +1000" MODIFIED_BY="Tea Andabaka" NAME="Lanctot 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-22 07:07:13 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanctot KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, et al</AU>
<TI>The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>11</NO>
<PG>3223-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lazaro-y-de-Mercado-2006" MODIFIED="2012-09-28 06:22:17 +1000" MODIFIED_BY="Tea Andabaka" NAME="Lazaro y de Mercado 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-09-26 12:01:58 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carbonell-Estrany X, Lázaro y de Mercado P</AU>
<TI>Health economics and RSV</TI>
<SO>Paediatric Respiratory Reviews</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>Suppl 1</NO>
<PG>12-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-28 06:22:17 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lazaro y de Mercado P, Figueras Aloy J, Domenech Martinez E, Echaniz Urcelay I, Closa Monasterolo R, Wood MA</AU>
<TI>The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain</TI>
<TO>La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infección por virus respiratorio sincitial en prematuros de 32-35 semanas en España</TO>
<SO>Anales de Pediatria</SO>
<YR>2006</YR>
<VL>65</VL>
<NO>4</NO>
<PG>316-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lazaro-y-de-Mercado-2007" MODIFIED="2012-09-28 06:23:10 +1000" MODIFIED_BY="Tea Andabaka" NAME="Lazaro y de Mercado 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-09-28 06:23:10 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lazaro y de Mercado P, Figueras J, Domenech E, Closa R, Echaniz I, Wood MA, et al</AU>
<TI>Cost-effectiveness of palivizumab in preventing respiratory syncytial virus in premature infants and children with chronic lung disease in Spain</TI>
<TO>Coste-efectividad de palivizumab para prevenir el virus respiratorio sincitial en niños prematuros y niños con enfermedad pulmonar crónica en España</TO>
<SO>Pharmacoeconomics - Spanish Research Articles</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>2</NO>
<PG>57-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lofland-2000" MODIFIED="2012-01-22 18:02:46 +1000" MODIFIED_BY="Tea Andabaka" NAME="Lofland 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-22 18:02:46 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lofland JH, Touch SM, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, et al</AU>
<TI>Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis</TI>
<SO>Clinical Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>11</NO>
<PG>1357-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayen_x002d_Herrera-2011" MODIFIED="2012-09-26 12:04:32 +1000" MODIFIED_BY="Tea Andabaka" NAME="Mayen-Herrera 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-09-26 12:04:32 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mayen-Herrera E, Buesch K, Cortina D</AU>
<TI>Economic evaluation of the use of palivizumab as prophylactic treatment for the reduction of complications associated with respiratory syncytial virus in pre-term patients</TI>
<SO>Value in Health</SO>
<YR>2011</YR>
<VL>14</VL>
<NO>7</NO>
<PG>A565-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neovius-2011" MODIFIED="2012-10-15 12:50:51 +1000" MODIFIED_BY="Tea Andabaka" NAME="Neovius 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-02-08 19:10:27 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neovius K, Buesch K, Neovius M</AU>
<TI>Burden of respiratory syncytial virus (RSV) and potential impact of prophylaxis in infants in Sweden: a cost-effectiveness analysis</TI>
<SO>Acta Paediatrica</SO>
<YR>2010</YR>
<VL>99</VL>
<PG>96-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-15 12:50:51 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Neovius K, Buesch K, Sandstrom K, Neovius M</AU>
<TI>Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden</TI>
<SO>Acta Paediatrica</SO>
<YR>2011</YR>
<VL>100</VL>
<NO>10</NO>
<PG>1306-14</PG>
<IDENTIFIERS MODIFIED="2012-10-15 12:49:41 +1000" MODIFIED_BY="Tea Andabaka">
<IDENTIFIER MODIFIED="2012-10-15 12:49:41 +1000" MODIFIED_BY="Tea Andabaka" TYPE="DOI" VALUE="10.1111/j.1651-2227.2011.02309.x"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nuijten-2007" MODIFIED="2012-01-22 18:54:26 +1000" MODIFIED_BY="Tea Andabaka" NAME="Nuijten 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-22 18:54:06 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nuijten MJC, Wittenberg W, Lebmeier M</AU>
<TI>Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis</TI>
<SO>Pharmacoeconomics</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>1</NO>
<PG>55-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nuijten-2009a" MODIFIED="2012-01-22 18:46:17 +1000" MODIFIED_BY="Tea Andabaka" NAME="Nuijten 2009a" YEAR="2009">
<REFERENCE MODIFIED="2012-01-22 18:22:49 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nuijten M, Lebmeier M, Wittenberg W</AU>
<TI>Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands</TI>
<SO>Journal of Medical Economics</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>4</NO>
<PG>291-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nuijten-2009b" MODIFIED="2012-01-22 18:46:05 +1000" MODIFIED_BY="Tea Andabaka" NAME="Nuijten 2009b" YEAR="2009">
<REFERENCE MODIFIED="2012-01-22 18:45:45 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nuijten M, Lebmeier M, Wittenberg W</AU>
<TI>Cost effectiveness of palivizumab in children with congenital heart disease in Germany</TI>
<SO>Journal of Medical Economics</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>4</NO>
<PG>301-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nuijten-2010" MODIFIED="2012-01-22 18:50:14 +1000" MODIFIED_BY="Tea Andabaka" NAME="Nuijten 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-01-22 18:49:17 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nuijten MJ, Wittenberg W</AU>
<TI>Cost effectiveness of palivizumab in Spain: an analysis using observational data</TI>
<SO>European Journal of Health Economics</SO>
<YR>2010</YR>
<VL>11</VL>
<PG>105-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravasio-2006" MODIFIED="2012-01-22 19:15:08 +1000" MODIFIED_BY="Tea Andabaka" NAME="Ravasio 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-22 19:14:46 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravasio R, Lucioni C, Chirico G</AU>
<TI>Cost-effectiveness analysis of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infections among premature infants, with different gestational ages</TI>
<TO>Costo-efficacia di palivizumab versus non profilassi nella prevenzione delle infezioni da VRS nei bambini pretermine, a diversa età gestazionale</TO>
<SO>PharmacoEconomics - Italian Research Articles</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>2</NO>
<PG>105-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raya-Ortega-2006" MODIFIED="2012-04-11 03:33:19 +1000" MODIFIED_BY="Tea Andabaka" NAME="Raya Ortega 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-04-11 03:33:19 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raya Ortega L, Marquez Calderon S, Navarro Caballero JA, Villegas Portero R</AU>
<TI>Cost-effectiveness of palivizumab in the prevention of hospital admissions for syncytial respiratory virus in pre-term babies born at 32 to 35 weeks</TI>
<SO>Sevilla: Andalusian Agency for Health Technology Assessment (AETSA)</SO>
<YR>2006</YR>
<VL>Informe 14</VL>
<PG>1-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Resch-2008" MODIFIED="2012-01-22 19:38:18 +1000" MODIFIED_BY="Tea Andabaka" NAME="Resch 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-22 19:38:16 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Resch B, Gusenleitner W, Nuijten MJC, Lebmeier M, Wittenberg W</AU>
<TI>Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria</TI>
<SO>Clinical Therapeutics</SO>
<YR>2008</YR>
<VL>30</VL>
<NO>4</NO>
<PG>749-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Resch-2012" MODIFIED="2012-09-26 12:27:05 +1000" MODIFIED_BY="Tea Andabaka" NAME="Resch 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-09-26 12:27:05 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Resch B, Sommer C, Nuijten MJC, Seidinger S, Walter E, Schoellbauer V, et al</AU>
<TI>Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>1</NO>
<PG>e1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rietveld-2010" MODIFIED="2012-01-22 19:41:45 +1000" MODIFIED_BY="Tea Andabaka" NAME="Rietveld 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-01-22 19:41:45 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rietveld E, Steyerberg EW, Polder JJ, Veeze HJ, Vergouwe Y, Huysman MWA, et al</AU>
<TI>Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2010</YR>
<VL>95</VL>
<PG>493-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roeckl_x002d_Wiedmann-2003" MODIFIED="2012-09-29 03:22:14 +1000" MODIFIED_BY="Tea Andabaka" NAME="Roeckl-Wiedmann 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-09-29 03:22:14 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH</AU>
<TI>Economic evaluation of possible prevention of RSV-related hospitalisations in premature infants in Germany</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>162</VL>
<PG>237-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salinas_x002d_Escudero-2012" MODIFIED="2012-09-13 19:21:05 +1000" MODIFIED_BY="Tea Andabaka" NAME="Salinas-Escudero 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-09-13 19:21:00 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salinas-Escudero G, Martinez-Valverde S, Reyes-Lopez A, Garduno-Espinosa J, Munoz-Hernandez O, Granados-Garcia V, et al</AU>
<TI>Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico</TI>
<SO>Salud Publica de Mexico</SO>
<YR>2012</YR>
<VL>54</VL>
<NO>1</NO>
<PG>47-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smart-2010" MODIFIED="2012-01-22 19:54:28 +1000" MODIFIED_BY="Tea Andabaka" NAME="Smart 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-01-22 19:54:25 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smart KA, Paes BA, Lanctot KL</AU>
<TI>Changing costs and the impact on RSV prophylaxis</TI>
<SO>Journal of Medical Economics</SO>
<YR>2010</YR>
<VL>13</VL>
<NO>4</NO>
<PG>705-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subramanian-1998" MODIFIED="2012-04-06 23:04:45 +1000" MODIFIED_BY="Tea Andabaka" NAME="Subramanian 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-04-06 23:04:11 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subramanian SKN, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, et al; MEDI-493 Study Group</AU>
<TI>Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>2</NO>
<PG>110-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tam-2009" MODIFIED="2012-01-22 19:57:08 +1000" MODIFIED_BY="Tea Andabaka" NAME="Tam 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-01-22 19:57:01 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanctot KL</AU>
<TI>The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic</TI>
<SO>Journal of Medical Economics</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>4</NO>
<PG>361-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vogel-2002" MODIFIED="2012-01-22 20:02:37 +1000" MODIFIED_BY="Tea Andabaka" NAME="Vogel 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-22 20:02:35 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vogel AM, McKinlay MJ, Ashton T, Lennon DR, Harding JE, Pinnock R, et al</AU>
<TI>Cost-effectiveness of palivizumab in New Zealand</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2002</YR>
<VL>38</VL>
<PG>352-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2011" MODIFIED="2012-08-02 00:14:12 +1000" MODIFIED_BY="Tea Andabaka" NAME="Wang 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-02 00:14:12 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang D, Bayliss S, Meads C</AU>
<TI>Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses</TI>
<SO>Health Technology Assessment</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>5</NO>
<PG>1-124</PG>
<IDENTIFIERS MODIFIED="2012-01-22 20:06:16 +1000" MODIFIED_BY="Tea Andabaka">
<IDENTIFIER MODIFIED="2012-01-22 20:06:16 +1000" MODIFIED_BY="Tea Andabaka" TYPE="DOI" VALUE="10.3310/hta15050"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiner-2012" MODIFIED="2012-09-16 02:33:08 +1000" MODIFIED_BY="Tea Andabaka" NAME="Weiner 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-09-13 19:30:24 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ</AU>
<TI>Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by medicaid in the United States</TI>
<SO>Journal of Medical Economics</SO>
<YR>2012</YR>
<VL>15</VL>
<NO>5</NO>
<PG>997-1018</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yount-2004" MODIFIED="2012-01-22 20:21:20 +1000" MODIFIED_BY="Tea Andabaka" NAME="Yount 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-22 20:21:15 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yount LE, Mahle WT</AU>
<TI>Economic analysis of palivizumab in infants with congenital heart disease</TI>
<SO>Pediatrics</SO>
<YR>2004</YR>
<VL>114</VL>
<NO>6</NO>
<PG>1606-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<STUDY DATA_SOURCE="PUB" ID="STD-Banerji-2009" MODIFIED="2012-04-08 04:35:30 +1000" MODIFIED_BY="Tea Andabaka" NAME="Banerji 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-04-08 04:35:19 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Banerji A, Lanctot KL, Paes BA, Masoud ST, Tam DY, Macdonald WA, et al</AU>
<TI>Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>8</NO>
<PG>702-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buckley-2010" MODIFIED="2012-04-08 05:05:05 +1000" MODIFIED_BY="Tea Andabaka" NAME="Buckley 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-04-08 05:05:05 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD</AU>
<TI>Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization</TI>
<SO>Journal of Managed Care Pharmacy</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>1</NO>
<PG>15-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2003" MODIFIED="2012-04-08 04:40:31 +1000" MODIFIED_BY="Tea Andabaka" NAME="Chan 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-04-08 04:40:31 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan PWK, Abdel-Latif MEA</AU>
<TI>Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation</TI>
<SO>Acta Paediatrica</SO>
<YR>2003</YR>
<VL>92</VL>
<NO>4</NO>
<PG>481-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-2000" MODIFIED="2012-04-08 05:08:19 +1000" MODIFIED_BY="Tea Andabaka" NAME="Clark 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-04-08 05:08:19 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark SJ, Beresford MW, Subhedar NV, Shaw NJ</AU>
<TI>Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2000</YR>
<VL>83</VL>
<NO>4</NO>
<PG>313-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Datar-2012" MODIFIED="2012-09-26 12:30:37 +1000" MODIFIED_BY="Tea Andabaka" NAME="Datar 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-09-26 12:30:37 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Datar M, Banahan BF</AU>
<TI>Palavizumab (Synagis) use and outcomes among medicaid beneficiaries</TI>
<SO>Value in Health</SO>
<YR>2012</YR>
<VL>15</VL>
<NO>4</NO>
<PG>A58-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farina-2002" MODIFIED="2012-04-08 04:51:21 +1000" MODIFIED_BY="Tea Andabaka" NAME="Farina 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-04-08 04:50:22 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farina D, Rodriguez SP, Bauer G, Novali L, Bouzas L, Gonzalez H, et al</AU>
<TI>Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>4</NO>
<PG>287-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korbal-2003" MODIFIED="2012-04-11 01:07:16 +1000" MODIFIED_BY="Tea Andabaka" NAME="Korbal 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-04-11 01:07:15 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korbal P, Mikolajczak A, Szymanski W</AU>
<TI>Effectiveness of passive immunisation against respiratory syncytium virus in a group of premature infants with birth weight below 1000 grams</TI>
<TO>Ocena skutecznosci stosowania uodpornienia biernego przeciwko wirusom syncytium nablonka oddechowego (RSV) preparatem Synagis w grupie wczesniakow z masa urodzeniowa ciala ponizej 1000 gramow</TO>
<SO>Ginekologia Polska</SO>
<YR>2003</YR>
<VL>74</VL>
<NO>10</NO>
<PG>1154-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krilov-2010" MODIFIED="2012-04-08 05:11:56 +1000" MODIFIED_BY="Tea Andabaka" NAME="Krilov 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-04-08 05:11:56 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ</AU>
<TI>Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States</TI>
<SO>Value in Health</SO>
<YR>2010</YR>
<VL>13</VL>
<NO>1</NO>
<PG>77-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapena-Lopez-2003" MODIFIED="2012-04-08 05:19:28 +1000" MODIFIED_BY="Tea Andabaka" NAME="Lapena Lopez 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-04-08 05:19:28 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapena Lopez de Armentia S, Robles Garcia MB, Martinez Badas JP, Castanon Fernandez L, Mallo Castano L, Herrero Mendoza B, et al</AU>
<TI>Potential impact and cost-efficacy of bronchiolitis prophylaxis with palivizumab in preterm infants with a gestational age of less than 33 weeks</TI>
<SO>Anales de Pediatria</SO>
<YR>2003</YR>
<VL>59</VL>
<NO>4</NO>
<PG>328-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2001" MODIFIED="2012-04-08 05:35:26 +1000" MODIFIED_BY="Tea Andabaka" NAME="Lee 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-04-08 05:35:26 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee SL, Etches P, Robinson JL</AU>
<TI>Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta</TI>
<SO>Paediatrics and Child Health</SO>
<YR>2001</YR>
<VL>6</VL>
<NO>8</NO>
<PG>525-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marchetti-1999" MODIFIED="2012-03-21 06:54:10 +1000" MODIFIED_BY="Tea Andabaka" NAME="Marchetti 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-03-21 06:54:10 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marchetti A, Lau H, Magar R, Wang L, Devercelli G</AU>
<TI>Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings</TI>
<SO>Clinical Therapeutics</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>4</NO>
<PG>752-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marques-2010" MODIFIED="2013-03-15 22:48:08 +1000" MODIFIED_BY="Tea Andabaka" NAME="Marques 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-03-15 22:48:08 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marques T, Cardoso K</AU>
<TI>Palivizumab prophylaxis: comparative study between immunized and non immunized infants admitted with respiratory syncytial virus infection</TI>
<SO>Early Human Development</SO>
<YR>2010</YR>
<VL>86</VL>
<NO>Suppl</NO>
<PG>123-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez-2002" MODIFIED="2012-09-26 12:31:43 +1000" MODIFIED_BY="Tea Andabaka" NAME="Martinez 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-09-26 12:31:43 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez JL</AU>
<TI>Palivizumab in preventing infection caused by respiratory syncitial virus (RSV)</TI>
<TO>Palivizumab en la prevención de infección por virus respiratorio sincicial</TO>
<SO>Revista Chilena de Pediatria</SO>
<YR>2002</YR>
<VL>73</VL>
<NO>1</NO>
<PG>9-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCormick-2002" MODIFIED="2012-04-08 04:54:04 +1000" MODIFIED_BY="Tea Andabaka" NAME="McCormick 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-04-08 04:54:02 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCormick J, Tubman R</AU>
<TI>Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>4</NO>
<PG>262-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meberg-2006" MODIFIED="2012-09-29 03:22:14 +1000" MODIFIED_BY="Tea Andabaka" NAME="Meberg 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-09-29 03:22:14 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meberg A, Bruu AL</AU>
<TI>Respiratory syncytial virus infections in congenital heart defects - hospitalisations and costs</TI>
<SO>Acta Paediatrica</SO>
<YR>2006</YR>
<VL>95</VL>
<NO>4</NO>
<PG>404-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meissner-1999" MODIFIED="2012-04-06 23:09:43 +1000" MODIFIED_BY="Tea Andabaka" NAME="Meissner 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-04-06 23:09:43 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meissner HC, Groothuis JR, Rodriguez WJ, Welliver RC, Hogg G, Gray PH, et al</AU>
<TI>Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1999</YR>
<VL>43</VL>
<NO>5</NO>
<PG>1183-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Numa-2000" MODIFIED="2012-04-08 04:57:08 +1000" MODIFIED_BY="Tea Andabaka" NAME="Numa 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-04-08 04:57:08 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Numa A</AU>
<TI>Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2000</YR>
<VL>36</VL>
<PG>422-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parmigiani-2001" MODIFIED="2012-09-26 12:32:10 +1000" MODIFIED_BY="Tea Andabaka" NAME="Parmigiani 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-09-26 12:32:10 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parmigiani S, Ubaldi A, Capuano C, Magini GM, Bianchi ME</AU>
<TI>Palivizumab in infants with gestational age &#8804; 28 weeks and bronchopulmonary dysplasia</TI>
<SO>Acta Bio-Medica de l Ateneo Parmense</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>5-6</NO>
<PG>109-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rackham-2005" MODIFIED="2012-04-08 05:26:46 +1000" MODIFIED_BY="Tea Andabaka" NAME="Rackham 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-04-08 05:26:46 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rackham OJ, Thorburn K, Kerr SJ</AU>
<TI>The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations</TI>
<SO>Cardiology in the Young</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>3</NO>
<PG>251-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reeve-2006" MODIFIED="2012-04-08 05:32:08 +1000" MODIFIED_BY="Tea Andabaka" NAME="Reeve 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-04-08 05:32:07 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reeve CA, Whitehall JS, Buetnner PG, Norton R, Reeve DM, Francis F</AU>
<TI>Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2006</YR>
<VL>42</VL>
<NO>5</NO>
<PG>253-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez-2008" MODIFIED="2012-02-08 19:12:00 +1000" MODIFIED_BY="Tea Andabaka" NAME="Rodriguez 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-02-08 19:12:00 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez SP, Farina D, Bauer G</AU>
<TI>Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>7</NO>
<PG>660-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shireman-2002" MODIFIED="2012-04-08 04:59:22 +1000" MODIFIED_BY="Tea Andabaka" NAME="Shireman 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-04-08 04:59:22 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shireman TI, Braman KS</AU>
<TI>Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid's high-risk children</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>2002</YR>
<VL>156</VL>
<NO>12</NO>
<PG>1251-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stevens-2000" MODIFIED="2012-04-06 21:38:57 +1000" MODIFIED_BY="Tea Andabaka" NAME="Stevens 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-04-06 21:38:57 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM</AU>
<TI>Respiratory syncytial virus and premature infants born at 32 weeks&#8217; gestation or earlier: hospitalization and economic implications of prophylaxis</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>2000</YR>
<VL>154</VL>
<NO>1</NO>
<PG>55-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strutton-2003" MODIFIED="2012-09-26 12:33:15 +1000" MODIFIED_BY="Tea Andabaka" NAME="Strutton 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-09-26 12:33:15 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strutton DR, Stang PE</AU>
<TI>Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>143</VL>
<NO>Suppl 5</NO>
<PG>157-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takeuchi-2002" MODIFIED="2012-04-06 23:09:27 +1000" MODIFIED_BY="Tea Andabaka" NAME="Takeuchi 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-04-06 23:09:27 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takeuchi Y, Cho H, Yamashita Y, Mishiku Y, Nakao A, Aso T, et al</AU>
<TI>Safety and pharmacokinetics of palivizumab, administered in infants with a history of prematurity or chronic lung disease</TI>
<SO>Japanese Journal of Chemotherapy</SO>
<YR>2002</YR>
<VL>50</VL>
<NO>4</NO>
<PG>215-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vann-2007" MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" NAME="Vann 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vann JJ, Feaganes J, Wegner S</AU>
<TI>Reliability of medicaid claims versus medical record data: in a cost analysis of palivizumab</TI>
<SO>Pharmacoeconomics</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>9</NO>
<PG>793-800</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008" MODIFIED="2012-09-28 06:28:09 +1000" MODIFIED_BY="[Empty name]" NAME="Wang 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-09-26 12:33:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang D, Cummins C, Bayliss S, Sandercock J, Burls A</AU>
<TI>Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation</TI>
<SO>Clinical Governance: an International Journal</SO>
<YR>2009</YR>
<VL>14</VL>
<NO>2</NO>
<PG>156-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-28 06:28:09 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang D, Cummins C, Bayliss S, Sandercock J, Burls A</AU>
<TI>Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation</TI>
<SO>Health Technology Assessment</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>36</NO>
<PG>1-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wegner-2004" MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" NAME="Wegner 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, et al</AU>
<TI>Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid program</TI>
<SO>Pediatrics</SO>
<YR>2004</YR>
<VL>114</VL>
<NO>6</NO>
<PG>1612-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wendel-2010" MODIFIED="2012-09-13 20:01:44 +1000" MODIFIED_BY="Tea Andabaka" NAME="Wendel 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-09-13 20:01:42 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wendel B, Jorden J</AU>
<TI>Financial impact of a clinically based palivizumab prior authorization program in a medicaid population</TI>
<SO>Journal of the American Pharmacists Association</SO>
<YR>2010</YR>
<VL>50</VL>
<NO>2</NO>
<PG>231</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-07-28 01:35:10 +1000" MODIFIED_BY="Tea Andabaka">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00233064" MODIFIED="2012-07-28 01:35:10 +1000" MODIFIED_BY="Tea Andabaka" NAME="NCT00233064" YEAR="3064">
<REFERENCE MODIFIED="2012-07-28 01:31:18 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00233064</AU>
<TI>A Phase IV, Randomized, Double-Blind Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) in Children at High Risk for the Development of Serious RSV Disease</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT00233064</SO>
<YR>(accessed 27 July 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00240929" MODIFIED="2012-07-28 01:19:31 +1000" MODIFIED_BY="Tea Andabaka" NAME="NCT00240929" YEAR="0929">
<REFERENCE MODIFIED="2012-07-28 01:14:34 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00240929</AU>
<TI>A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis), A Humanized Respiratory Syncytial Virus Monoclonal Antibody, in Children With a History of Prematurity</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT00240929</SO>
<YR>(accessed 27 July 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NTR1023" MODIFIED="2012-07-28 01:07:21 +1000" MODIFIED_BY="Tea Andabaka" NAME="NTR1023" YEAR="1023">
<REFERENCE MODIFIED="2012-07-28 01:06:57 +1000" MODIFIED_BY="Tea Andabaka" PRIMARY="NO" TYPE="OTHER">
<AU>NTR1023</AU>
<TI>Effect of palivizumab on respiratory syncytial virus-associated burden of disease: a randomized controlled trial</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=NTR1023</SO>
<YR>(accessed 27 July 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-28 01:07:21 +1000" MODIFIED_BY="Tea Andabaka"/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2012-07-22 03:37:22 +1000" MODIFIED_BY="Tea Andabaka"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-03-15 22:52:02 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-03-15 22:52:02 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AAP-2009" MODIFIED="2011-06-30 13:17:31 +1000" MODIFIED_BY="[Empty name]" NAME="AAP 2009" TYPE="JOURNAL_ARTICLE">
<AU>American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn</AU>
<TI>Policy statement-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>124</VL>
<NO>6</NO>
<PG>1694-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arms-2008" MODIFIED="2011-06-30 13:20:55 +1000" MODIFIED_BY="[Empty name]" NAME="Arms 2008" TYPE="JOURNAL_ARTICLE">
<AU>Arms JL, Ortega H, Reid S</AU>
<TI>Chronological and clinical characteristics of apnea associated with respiratory syncytial virus infection: a retrospective case series</TI>
<SO>Clinical Pediatrics</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>9</NO>
<PG>953-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atkins-2004" MODIFIED="2012-08-01 19:35:12 +1000" MODIFIED_BY="Tea Andabaka" NAME="Atkins 2004" TYPE="JOURNAL_ARTICLE">
<AU>Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7454</NO>
<PG>1490</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDC-2011" MODIFIED="2013-03-15 22:50:23 +1000" MODIFIED_BY="[Empty name]" NAME="CDC 2011" TYPE="JOURNAL_ARTICLE">
<AU>Centers for Disease Control and Prevention</AU>
<TI>Respiratory syncytial virus: United States, July 2007-June 2011</TI>
<SO>Morbidity and Mortality Weekly Report</SO>
<YR>2011</YR>
<VL>60</VL>
<NO>35</NO>
<PG>1203-6</PG>
<IDENTIFIERS MODIFIED="2013-03-15 22:50:23 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-15 22:50:23 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21900874"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Domachowske-1999" MODIFIED="2013-03-15 22:50:32 +1000" MODIFIED_BY="[Empty name]" NAME="Domachowske 1999" TYPE="JOURNAL_ARTICLE">
<AU>Domachowske JB, Rosenberg HF</AU>
<TI>Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment</TI>
<SO>Clinical Microbiology Reviews</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>2</NO>
<PG>298-309</PG>
<IDENTIFIERS MODIFIED="2013-03-15 22:50:32 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-15 22:50:32 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 0194461"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Drummond-1996" MODIFIED="2011-06-30 13:33:42 +1000" MODIFIED_BY="[Empty name]" NAME="Drummond 1996" TYPE="JOURNAL_ARTICLE">
<AU>Drummond MF, Jefferson TO; The BMJ Economic Evaluation Working Party</AU>
<TI>Guidelines for authors and peer reviewers of economic submissions to the BMJ</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<NO>7052</NO>
<PG>275-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2009" MODIFIED="2013-03-15 22:50:59 +1000" MODIFIED_BY="[Empty name]" NAME="FDA 2009" TYPE="OTHER">
<AU>United States Food and Drug Administration</AU>
<TI>Safety Alerts for Human Medical Products &gt; Synagis (palivizumab)</TI>
<SO>http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm155089.htm</SO>
<YR>2009 (accessed 5 February 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2010" MODIFIED="2013-03-15 22:51:03 +1000" MODIFIED_BY="[Empty name]" NAME="FDA 2010" TYPE="OTHER">
<AU>United States Food and Drug Administration</AU>
<TI>Background Package for BLA 125283 motavizumab</TI>
<SO>http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM213825.pdf</SO>
<YR>2010 (accessed 5 February 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleming-2005" MODIFIED="2011-06-30 13:39:22 +1000" MODIFIED_BY="[Empty name]" NAME="Fleming 2005" TYPE="JOURNAL_ARTICLE">
<AU>Fleming DM, Pannell RS, Cross KW</AU>
<TI>Mortality in children from influenza and respiratory syncytial virus</TI>
<SO>Journal of Epidemiology and Community Health</SO>
<YR>2005</YR>
<VL>59</VL>
<NO>7</NO>
<PG>586-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2009" MODIFIED="2011-05-30 15:29:53 +1000" MODIFIED_BY="[Empty name]" NAME="Glanville 2009" TYPE="JOURNAL_ARTICLE">
<AU>Glanville J, Kaunelis D, Mensinkai S</AU>
<TI>How well do search filters perform in identifying economic evaluations in MEDLINE and EMBASE</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2009</YR>
<VL>25</VL>
<NO>4</NO>
<PG>522-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Golder-2006" MODIFIED="2011-06-30 13:42:12 +1000" MODIFIED_BY="[Empty name]" NAME="Golder 2006" TYPE="JOURNAL_ARTICLE">
<AU>Golder S, McIntosh H, Duffy S, Glanville J; Centre for Reviews and Dissemination and UK Cochrane Centre Search Filters Design Group</AU>
<TI>Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE</TI>
<SO>Health Information and Libraries Journal</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>1</NO>
<PG>3-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2008" MODIFIED="2013-03-15 22:52:02 +1000" MODIFIED_BY="Tea Andabaka" NAME="GRADEpro 2008" TYPE="COMPUTER_PROGRAM">
<AU>Brozek J, Oxman A, Schünemann H</AU>
<TI>GRADEpro</TI>
<YR>2008</YR>
<EN>3.2 for Windows</EN>
<PB>-</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-1979" MODIFIED="2011-06-30 13:47:38 +1000" MODIFIED_BY="[Empty name]" NAME="Hall 1979" TYPE="JOURNAL_ARTICLE">
<AU>Hall CB, Hall WJ, Speers DM</AU>
<TI>Clinical and physiological manifestations of bronchiolitis and pneumonia. Outcome of respiratory syncytial virus</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1979</YR>
<VL>133</VL>
<NO>8</NO>
<PG>798-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-2009a" MODIFIED="2012-09-26 12:37:42 +1000" MODIFIED_BY="[Empty name]" NAME="Hall 2009a" TYPE="JOURNAL_ARTICLE">
<AU>Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al</AU>
<TI>The burden of respiratory syncytial virus infection in young children</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>6</NO>
<PG>588-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-2009b" MODIFIED="2011-06-30 14:04:07 +1000" MODIFIED_BY="[Empty name]" NAME="Hall 2009b" TYPE="BOOK_SECTION">
<AU>Hall CB, Walsh EE</AU>
<TI>Respiratory syncytial virus</TI>
<SO>Feigin and Cherry's Textbook of Pediatric Infectious Diseases</SO>
<YR>2009</YR>
<VL>2</VL>
<PG>2462-87</PG>
<EN>6th</EN>
<ED>Feigin RD et al</ED>
<PB>Saunders Elsevier</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-2010" MODIFIED="2011-06-30 14:38:37 +1000" MODIFIED_BY="[Empty name]" NAME="Hall 2010" TYPE="BOOK_SECTION">
<AU>Hall CB</AU>
<TI>Respiratory syncytial virus</TI>
<SO>Mendell, Douglas and Bennett's Principles and Practice of Infectious Diseases</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>2207-21</PG>
<EN>7th</EN>
<ED>Mendell GL, Bennett JE, Dolin R</ED>
<PB>Churchill Livingstone Elsevier</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-11-22 05:53:08 +1000" MODIFIED_BY="Tea Andabaka" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistence in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557&#8211;60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2011-07-21 15:55:49 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2011-07-21 15:54:34 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>Chapter 16: Special topics in statistics</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacobson-2001" MODIFIED="2012-09-13 18:39:25 +1000" MODIFIED_BY="Maria X Rojas" NAME="Jacobson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jacobson PD, Kanna ML</AU>
<TI>Cost-effectiveness analysis in the courts: recent trends and future prospects</TI>
<SO>Journal of Health Politics, Policy and Law</SO>
<YR>2001</YR>
<VL>26</VL>
<NO>2</NO>
<PG>291-326</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1997" MODIFIED="2011-07-01 13:13:17 +1000" MODIFIED_BY="[Empty name]" NAME="Johnson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC</AU>
<TI>Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>5</NO>
<PG>1215&#8211;24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2011-07-21 15:52:28 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mullins-2003" MODIFIED="2011-07-01 13:26:17 +1000" MODIFIED_BY="[Empty name]" NAME="Mullins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mullins JA, Lamonte AC, Bresee JS, Anderson LJ</AU>
<TI>Substantial variability in community RSV season timing</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>10</NO>
<PG>857-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nair-2010" MODIFIED="2012-09-26 12:38:46 +1000" MODIFIED_BY="[Empty name]" NAME="Nair 2010" TYPE="JOURNAL_ARTICLE">
<AU>Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al</AU>
<TI>Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>375</VL>
<NO>9725</NO>
<PG>1545-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Purcell-2004" MODIFIED="2011-07-01 13:48:09 +1000" MODIFIED_BY="[Empty name]" NAME="Purcell 2004" TYPE="JOURNAL_ARTICLE">
<AU>Purcell K, Fergie J</AU>
<TI>Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>5</NO>
<PG>418-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ralstone-2009" MODIFIED="2011-07-01 13:49:34 +1000" MODIFIED_BY="[Empty name]" NAME="Ralstone 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ralston S, Hill V</AU>
<TI>Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review</TI>
<SO>Journal of Pediatrics</SO>
<YR>2009</YR>
<VL>155</VL>
<NO>5</NO>
<PG>728-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Red-Book-2012" MODIFIED="2013-02-20 16:40:22 +1000" MODIFIED_BY="[Empty name]" NAME="Red Book 2012" TYPE="BOOK_SECTION">
<AU>American Academy of Pediatrics</AU>
<TI>Respiratory syncytial virus</TI>
<SO>Red Book: 2012 Report of the Committee on Infectious Diseases</SO>
<YR>2012</YR>
<PG>609-18</PG>
<EN>29th</EN>
<ED>Pickering LK</ED>
<PB>Churchill Livingstone</PB>
<CY>Elk Grove Village</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-02-20 12:53:54 +1000" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2012" MODIFIED="2012-09-26 12:39:19 +1000" MODIFIED_BY="Tea Andabaka" NAME="Robinson 2012" TYPE="COCHRANE_REVIEW">
<AU>Robinson KA, Odelola OA, Saldanha IJ, Mckoy NA</AU>
<TI>Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-09-26 12:39:19 +1000" MODIFIED_BY="Tea Andabaka">
<IDENTIFIER MODIFIED="2012-09-26 12:39:19 +1000" MODIFIED_BY="Tea Andabaka" TYPE="DOI" VALUE="10.1002/14651858.CD007743.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shay-2001" MODIFIED="2011-07-01 13:58:27 +1000" MODIFIED_BY="[Empty name]" NAME="Shay 2001" TYPE="JOURNAL_ARTICLE">
<AU>Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ</AU>
<TI>Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2001</YR>
<VL>183</VL>
<NO>1</NO>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simoes-2003" MODIFIED="2012-09-26 12:39:28 +1000" MODIFIED_BY="[Empty name]" NAME="Simoes 2003" TYPE="JOURNAL_ARTICLE">
<AU>Simoes EA, Carbonell-Estrany X</AU>
<TI>Impact of severe disease caused by respiratory syncytial virus in children living in developed countries</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>Suppl 2</NO>
<PG>13-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-2003" MODIFIED="2012-09-26 12:39:35 +1000" MODIFIED_BY="[Empty name]" NAME="Thompson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al</AU>
<TI>Mortality associated with influenza and respiratory syncytial virus in the United States</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>2</NO>
<PG>179&#8211;86</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-02-06 09:34:57 +1000" MODIFIED_BY="Tea Andabaka">
<REFERENCE ID="REF-Lozano-2007" MODIFIED="2011-05-02 02:06:26 +1000" MODIFIED_BY="Tea Andabaka" NAME="Lozano 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Lozano JM, Escovar C, Vásquez V</AU>
<TI>Monoclonal antibodies for preventing respiratory syncytial virus infection</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-05-02 02:06:26 +1000" MODIFIED_BY="Tea Andabaka">
<IDENTIFIER MODIFIED="2011-05-02 02:06:26 +1000" MODIFIED_BY="Tea Andabaka" TYPE="DOI" VALUE="10.1002/14651858.CD006602.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-1999" MODIFIED="2008-05-18 14:38:47 +1000" MODIFIED_BY="[Empty name]" NAME="Wang 1999" TYPE="COCHRANE_REVIEW">
<AU>Wang EEL, Tang NK</AU>
<TI>Immunoglobulin for preventing respiratory syncytial virus infection</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-05-18 14:38:47 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-05-18 14:38:47 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001725.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Maria X Rojas">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Maria X Rojas" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:38 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Abarca-2009">
<CHAR_METHODS MODIFIED="2013-06-12 08:29:38 +1000" MODIFIED_BY="Tea Andabaka">
<P>Study design: 2-year study, using different methodologies. The first year of this study was a phase I/II, multicentre, open-label, dose-escalation study. The second year (consecutive RSV season) was a randomized (1:1), double-blind study</P>
<P>Dates of study: late winter 2004 in the United States (year 1) and May to June 2005 (year 2). Dates for recruitment during year one in the Southern Hemisphere are not given</P>
<P>Locations: year 1 - USA (9 sites), Chile (4 sites) and Brazil (3 sites). Year 2 - 6 sites in South America (4 in Chile and 2 in Brazil)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-12 08:29:38 +1000" MODIFIED_BY="Tea Andabaka">
<P>Season 1:</P>
<P>217 children with:</P>
<P>1) a gestational age between 32 and 35 weeks and were &#8804; 6 months of chronological age; or</P>
<P>2) were &#8804; 24 months of age and had CLD of prematurity requiring treatment with stable or decreasing doses of diuretics, steroids, or bronchodilators within the previous 6 months</P>
<P>Children were excluded if they had any of the following: hospitalization at the time of entry (unless discharge was expected within 3 days of study entry); birth hospitalization of &gt; 6 weeks&#8217; duration (for children without CLD) or birth hospitalization &gt; 12 weeks&#8217; duration (for children with CLD); chronic oxygen therapy or mechanical ventilation at the time of study entry (including continuous positive airway pressure); congenital heart disease; evidence of infection with hepatitis A, B or C virus; known renal impairment; hepatic dysfunction; chronic seizure disorder; immunodeficiency or human immunodeficiency virus infection or mother with known infection; laboratory findings in blood obtained within 7 days before study entry for blood urea nitrogen or creatinine &gt; 1.5 times the upper limit of normal for age; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 1.5 times the upper limit of normal for age; haemoglobin &lt; 9.5 G/dL, white blood cell count &lt; 4000 cells/mm<SUP>3</SUP>, or platelet count &lt; 120,000 cells/mm<SUP>3</SUP>; acute illness or progressive clinical disorder; active infection, including acute RSV infection; previous reaction to immunoglobulin intravenous (IVIG), blood products, or other foreign proteins; treatment with palivizumab; current or previous (within 120 days) treatment with immunoglobulin products (e.g. RSV-IVIG) or any investigational agents; current participation in any investigational study; or previous participation in any investigational study using RSV vaccines or monoclonal antibodies</P>
<P>Season 2:</P>
<P>136 children (66 in motavizumab group and 70 in palivizumab group) who received &#8805; 3 doses of motavizumab (3 or 15 mg/kg) in the previous RSV season and were &#8804; 24 months of age at enrolment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-12 08:29:38 +1000" MODIFIED_BY="Tea Andabaka">
<P>During season 1, children received between 2 and 5 doses of motavizumab (3 or 15 mg/kg) at 30-day intervals, depending on when during the RSV season a child was enrolled</P>
<P>During season 2, children were randomized to receive intramuscular injections of motavizumab (15 mg/kg) or palivizumab (15 mg/kg) every 30 days for a total of 4 to 5 doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-28 05:02:21 +1000" MODIFIED_BY="Tea Andabaka">
<P>Primary outcomes: adverse events and serious adverse events (assessed for severity and potential relationship to study drug)</P>
<P>Children were followed for AEs and SAEs from the first study injection through 30 days after the final dose</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-12 08:29:38 +1000" MODIFIED_BY="Tea Andabaka">
<P>The data extracted for our analysis includes only data from the second year, when the study was randomized and double-blind</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Bentley-2011">
<CHAR_METHODS MODIFIED="2012-09-16 02:25:15 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-utility analysis, payer's perspective, decision analytic model, lifetime follow-up, GBP, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-16 02:25:15 +1000" MODIFIED_BY="Tea Andabaka">
<P>Infants with CLD, and preterm infants born at less than 29, 29 to 32, and 33 to 35 weeks gestational age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-16 02:25:15 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 16:35:09 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: QALYs, mortality benefits included, risk of sequelae included</P>
<P>Summary measures: incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is an abstract of a presentation at a conference. Authors IF, KG and KB are employed at Abbott. This study suggests that the use of palivizumab is cost-effective in the UK</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Carbonell_x002d_Estrany-2010">
<CHAR_METHODS MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Tea Andabaka">
<P>Study design: randomized (1:1), double-blind, palivizumab-controlled, phase III, non-inferiority trial</P>
<P>Dates of study: November 2004 and May 2006 during 2 RSV seasons in the northern hemisphere and 1 season in the southern hemisphere</P>
<P>Locations: 347 sites in 24 countries</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Tea Andabaka">
<P>6635 preterm children (3329 to motavizumab group and 3306 to palivizumab group) with a gestational age &#8804; 35 weeks who were either:</P>
<P>1) &#8804; 24 months of age with chronic lung disease (CLD) that required medical management within 6 months before randomization, or</P>
<P>2) &#8804; 6 months of age at enrolment</P>
<P>Exclusion criteria were: hospitalization at randomization (unless discharge was anticipated within 10 days); mechanical ventilation or other mechanical support; life expectancy &lt; 6 months; active RSV infection; known renal, hepatic, chronic seizure, unstable neurologic or haemodynamically significant congenital heart disorders; immunodeficiency; use of palivizumab or RSV intravenous immunoglobulin &lt; 3 months before randomization or anticipated use during the study; receipt of RSV vaccine; and participation in any other investigational study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-28 05:03:17 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children received motavizumab (15 mg/kg) or palivizumab (15 mg/kg) applied as intramuscular injections at 30-day intervals for the total of 5 doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Tea Andabaka">
<P>Primary outcomes: hospitalization or death due to RSV</P>
<P>Primary efficacy outcome was met when a child had a positive RSV test and was hospitalised for respiratory symptoms or had a new onset of RSV-positive lower respiratory illness with worsening respiratory status while already in the hospital or when a death caused by RSV occurred</P>
<P>Secondary outcomes: all-cause and RSV-specific outpatient medically attended lower respiratory tract infection (MALRI), frequency and incidence of medically attended otitis media (OM), frequency of prescribed antibiotics for LRI and OM, adverse events and serious adverse events (graded for severity and causality), development of anti motavizumab antibodies, motavizumab serum concentrations</P>
<P>Children were involved during only 1 season and were followed up for 150 days after randomization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-03 06:30:20 +1000" MODIFIED_BY="Tea Andabaka"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Chirico-2009">
<CHAR_METHODS MODIFIED="2012-03-22 06:17:44 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-utility and cost-effectiveness analysis, payer's perspective, decision analytic model, lifetime follow-up, 3% discount rate, 2007 EUR, Italy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 06:17:08 +1000" MODIFIED_BY="Tea Andabaka">
<P>Preterm infants of different gestational ages (GA) (less than 33 weeks, and 33 to 35 weeks), with or without bronchopulmonary dysplasia (BPD)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 06:17:08 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: hospitalization due to RSV infection (ordinary ward or ICU), mortality benefits included, risk of recurrent wheezing included, LYGs and QALYs</P>
<P>Summary measures: incremental cost per QALY, incremental cost per LYG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:03:36 +1000" MODIFIED_BY="Tea Andabaka">
<P>Author U.S. is employed at Abbott. This paper was supported by a non-binding contribution provided by Abbott. This study suggests that palivizumab prophylaxis is cost-effective</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Chiroli-2005">
<CHAR_METHODS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-effectiveness analysis, payer's perspective, decision analytic model, 1-year follow-up, no discounting, 2004 EUR, Italy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-22 12:37:38 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children with haemodynamically significant congenital heart disease (CHD)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 06:18:20 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: hospitalization due to RSV infection, ICU stay, mortality benefits included, risk of sequelae not included, LYGs</P>
<P>Summary measures: incremental cost per LYG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Author SC is employed at Abbott. This study supports the cost-effectiveness of palivizumab prophylaxis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Maria X Rojas" STUDY_ID="STD-ElHassan-2006">
<CHAR_METHODS MODIFIED="2012-03-16 06:21:30 +1000" MODIFIED_BY="Maria X Rojas">
<P>Cost-utility analysis, societal perspective, decision analytic model, 8 years follow-up, 3% discount rate, 2002 USD, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-04-10 03:15:27 +1000" MODIFIED_BY="Maria X Rojas">
<P>Preterm infants without chronic lung disease (CLD) born at 26 to 32 weeks' gestation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 06:21:30 +1000" MODIFIED_BY="Maria X Rojas">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Maria X Rojas">
<P>Effectiveness outcomes: hospitalization due to RSV infection, mortality benefits not included, risk of asthma included</P>
<P>Summary measures: incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:03:49 +1000" MODIFIED_BY="Maria X Rojas">
<P>No conflict of interest declared. This study supports implementing more restrictive guidelines for palivizumab prophylaxis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Embleton-2007">
<CHAR_METHODS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-effectiveness analysis, societal perspective, 1-year follow-up, no discounting, 2005 GBP, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 06:27:01 +1000" MODIFIED_BY="Tea Andabaka">
<P>Preterm infants with less than 32 weeks gestational age without BPD, or preterm infants with BPD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 06:27:01 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: hospitalization, mortality benefits not included, risk of wheezing or asthma not included</P>
<P>Summary measures: incremental cost per hospitalization averted</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:03:52 +1000" MODIFIED_BY="Tea Andabaka">
<P>Not funded by the industry. This study does not support the cost-effectiveness of palivizumab prophylaxis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:42 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Feltes-2003">
<CHAR_METHODS MODIFIED="2013-06-12 08:29:40 +1000" MODIFIED_BY="Tea Andabaka">
<P>Study design: randomized (1:1), double-blind, placebo-controlled, multicentre trial</P>
<P>Dates of study: 4 consecutive RSV seasons from 1998 through 2002</P>
<P>Locations: 76 &#8211; USA (47 sites), Canada (6 sites), Sweden (3 sites), Germany (4 sites), Poland (6 sites), France (4 sites) and UK (6 sites)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>1287 children (639 to palivizumab group and 648 to placebo group) with congenital heart disease (CHD) who:</P>
<P>1) were &#8804; 24 months old at the time of random assignment;</P>
<P>2) had documented haemodynamically significant CHD determined by the investigator; and</P>
<P>3) had unoperated or partially corrected CHD</P>
<P>Children were not eligible if they had unstable cardiac or respiratory status, including cardiac defects so severe that survival was not expected or for which cardiac transplantation was planned or anticipated; were hospitalised, unless discharge was anticipated within 21 days; anticipated cardiac surgery within 2 weeks of random assignment; required mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure, or other mechanical respiratory or cardiac support; had associated noncardiac anomalies or end-organ dysfunction resulting in anticipated survival of &lt; 6 months or unstable abnormalities of end-organ function</P>
<P>Additional exclusion criteria were known HIV infection; acute RSV or other acute infection or illness; previous receipt of palivizumab or other monoclonal antibody; receipt of investigational agents within the previous 3 months (other than investigational agents commonly used during cardiac surgery or the immediate postoperative period, i.e. nitric oxide); current participation in other investigational protocols of drugs or biological agents; or receipt of intravenous immune globulin (IVIG), including RSV-IVIG, within 3 months before random assignment or anticipated use of IVIG, RSV-IVIG, or open-label palivizumab during the study period. Children with uncomplicated small atrial or ventricular septal defects or patent ductus arteriosus were excluded</P>
<P>Children with the following anatomic diagnoses were included in the cyanotic stratum: pulmonary atresia with ventricular septal defect, pulmonary atresia with intact septum, tetralogy of Fallot, single ventricle including hypoplastic left or right heart, tricuspid atresia, double-outlet right ventricle with transposed great arteries, Ebstein anomaly, or D-transposition of the great arteries with/without ventricular septal defect, with/without pulmonary stenosis. The remaining children were stratified to the &#8220;other&#8221; (acyanotic) stratum</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children received palivizumab (15 mg/kg) or an equal volume of placebo by intramuscular injection every 30 days for a total of 5 doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:42 +1000" MODIFIED_BY="Tea Andabaka">
<P>Primary outcome: incidence of RSV hospitalization, including primary RSV hospitalisations and nosocomial RSV hospitalisations</P>
<P>A primary RSV hospitalization was defined as a hospitalization for an acute cardiorespiratory illness in which the RSV antigen test was positive within 48 hours before or after admission. Deaths occurring outside the hospital that could be demonstrated to be associated with RSV were also considered as primary RSV hospitalization end points. A nosocomial RSV hospitalization was one in which hospitalised patients had an objective measure of worsening cardiorespiratory status reported as a serious adverse event and the RSV antigen test was positive</P>
<P>Secondary outcomes: total RSV hospital days, RSV hospital days with increased supplemental oxygen, incidence and total days of RSV-associated intensive care, incidence and total days of RSV-associated mechanical ventilation, serum palivizumab concentration, the palivizumab through concentrations before second and fifth doses, adverse events and serious adverse events (assessed for severity and potential relation to study drug)</P>
<P>Children participated during only 1 season and were followed for 150 days after random assignment (30 days after the last scheduled study injection)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-03 06:31:33 +1000" MODIFIED_BY="Tea Andabaka"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:42 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Feltes-2011">
<CHAR_METHODS MODIFIED="2013-06-12 08:29:42 +1000" MODIFIED_BY="Tea Andabaka">
<P>Study design: randomized (1:1), multinational, double-blind, palivizumab-controlled, phase II trial</P>
<P>Dates of study: 2 RSV seasons (2005 to 2006, and 2007 to 2008)</P>
<P>Locations: 34 sites in season 1 (North America, 51; European Union, 56; and rest of the world, 27) and 100 sites in season 2 (North America, 37; European Union, 48; and rest of the world, 15)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-12 08:29:42 +1000" MODIFIED_BY="Tea Andabaka">
<P>1236 children (624 to motavizumab group and 612 to palivizumab group) aged &#8804; 24 months who had:</P>
<P>1) Documented haemodynamically significant CHD defined as uncorrected or palliated cyanotic CHD or acyanotic CHD associated with documented pulmonary hypertension (systolic pulmonary arterial pressure &#8805; 40 mm Hg) and/or a requirement for daily medication to manage congestive heart failure</P>
<P>Patients not eligible for enrolment included those with unstable cardiac or respiratory status, including severe cardiac defects with unanticipated survival or with anticipated cardiac transplantation; hospitalization, unless discharge was anticipated within 21 days; cardiac surgery anticipated within 2 weeks of randomization; any requirement for mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure, or other mechanical respiratory or cardiac support; any associated noncardiac anomalies or end organ dysfunction resulting in anticipated survival of &lt; 6 months or unstable abnormalities of end organ function; acute respiratory illness, or other acute infection or illness (patients with respiratory symptoms were tested for RSV before randomization and were excluded if they were positive); chronic seizure or neurologic disorder; immunodeficiency; mother with human immunodeficiency virus (HIV) infection (unless the child was negative for HIV infection); known allergy to any immunoglobulin products; receipt of any polyclonal antibody or palivizumab within 3 months before randomization; use of any investigational agents other than those commonly used during cardiac surgery or the immediate postoperative period; or current participation in any other investigational protocols</P>
<P>Children with cyanotic CHD included those with the most commonly encountered cyanotic cardiac lesions. Children who did not have one of the designated diagnoses to be included in the cyanotic stratum were classified as 'other' anticipating that this group would largely comprise children with acyanotic CHD lesions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-28 05:04:32 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children received motavizumab (15 mg/kg) or palivizumab (15 mg/kg) applied as intramuscular injections at 30-day intervals for a total of 5 doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:42 +1000" MODIFIED_BY="Tea Andabaka">
<P>Primary outcomes: adverse events and serious adverse events (assessed for severity and relationship to study drug)</P>
<P>Secondary outcomes: incidence of RSV hospitalization, RSV outpatient medically attended lower respiratory tract infection (for patients in season 2 only)</P>
<P>RSV hospitalization was defined as hospitalization for cardiac/respiratory symptoms accompanied by a positive RSV test or a new onset of RSV-positive lower respiratory illness with worsening respiratory status while already in the hospital or death caused by RSV. RSV outpatient MALRI was an outpatient medically attended event diagnosed as a lower respiratory illness accompanied by a positive RSV test. Each patient participated during a single RSV season and was followed for 150 days after random assignment (30 days after the last dose of study drug)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:04:39 +1000" MODIFIED_BY="Tea Andabaka">
<P>Inclusion and exclusion criteria for patients in this study are consistent with criteria in <LINK REF="STD-Feltes-2003" TYPE="STUDY">Feltes 2003</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Fernandez-2010">
<CHAR_METHODS MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka">
<P>Study design: phase II, randomized (1:1:1), double-blind, cross-over study</P>
<P>Dates of study: 1 RSV season (April 2006 through February 2007)</P>
<P>Locations: 18 &#8211; Chile (7 sites), New Zealand (5 sites) and Australia (6 sites)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka">
<P>260 children (83 to M/P treatment group, 84 to P/M treatment group, and 93 to motavizumab only group) born preterm who:</P>
<P>1) had gestational age &#8804; 35 weeks <I>and </I>the chronological age was &#8804; 6 months at the time of entry into the study; or</P>
<P>2) if they were &#8804; 24 months of age at the time of entry into the study and had a diagnosis of CLD of prematurity requiring medical management within 6 months before randomization</P>
<P>Eligible children had to be in good health at the time of study entry. They could not be hospitalised (unless discharge was expected within 10 days); be receiving chronic oxygen therapy or any ventilatory support; have significant congenital heart disease; have evidence of infection with hepatitis A, B, or C virus or HIV; have any acute illness, including acute RSV infection; known renal impairment, hepatic dysfunction, chronic seizure disorder or immunodeficiency; have suspected serious allergic or immune-mediated events in association with prior receipt of immunoglobulins, blood products or other foreign proteins; have received within the past 120 days or currently be receiving immunoglobulin products, palivizumab or any investigational agent</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-27 04:25:11 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children received motavizumab (15 mg/kg) or palivizumab (15 mg/kg) applied as intramuscular injections at 30-day intervals for a total of 5 doses in the following way:</P>
<P>1) 2 doses of motavizumab followed by 3 doses of palivizumab &#8211; M/P treatment group</P>
<P>2) 2 doses of palivizumab followed by 3 doses of motavizumab &#8211; P/M treatment group</P>
<P>3) 5 doses of motavizumab only &#8211; control</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka">
<P>Primary outcomes: adverse events, serious adverse events and laboratory evaluations</P>
<P>AEs were assessed for severity, relationship to study treatment, and whether the event met criteria as an SAE</P>
<P>Secondary outcomes: anti drug antibodies and serum trough concentrations of motavizumab and palivizumab</P>
<P>Children were monitored for AEs and SAEs from the time of randomization through study day 150 (30 days after the final planned dose)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a cross-over study whereby participants received either motavizumab/palivizumab, palivizumab/motavizumab or motavizumab only, with cross-over occurring after dose 2, out of a total of 5 doses. The data extracted for our analysis include only data after the first 2 doses, before the cross-over occurred</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia_x002d_Altes-2010">
<CHAR_METHODS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness analysis, payer's perspective, decision analytic model, 1-year and an alternative lifetime follow-up, 3% discount rate, 2008 EUR, Spain</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm children less than 2 years old with and without chronic lung disease, children less than 2 years old with chronic lung disease and children less than 5 years old with congenital heart disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 07:55:52 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: hospitalization rate, mortality benefits included, risk of sequelae not included, ICU stay</P>
<P>Summary measures: incremental cost per hospitalization averted, incremental cost per LYG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-29 03:22:14 +1000" MODIFIED_BY="[Empty name]">
<P>Not funded by the industry. Administration of palivizumab is not cost-effective in these populations, neither for hospitalisations averted nor for LYGs. Paper is written in Spanish</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Hampp-2011">
<CHAR_METHODS MODIFIED="2012-03-16 06:26:45 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-effectiveness analysis, payer's perspective, decision analytic model, no discounting, 2010 USD, Florida, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children up to 2 years of age with: CLD only, CHD only, CLD and prematurity (&#8804; 32 weeks gestation), CHD and prematurity, CHD and CLD, any of these indications, none of these indications and premature infants up to 6 months of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 06:26:45 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: incidence rate of hospitalization due to RSV infection, absolute risk reduction, mortality benefits not included, risk of wheezing or asthma not included</P>
<P>Summary measures: incremental cost per RSV hospitalization avoided</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-29 03:22:14 +1000" MODIFIED_BY="Tea Andabaka">
<P>No conflict if interest reported. This study suggests that recommendations for the use of palivizumab should be reconsidered, because the cost of prophylaxis far exceeded the economic benefit of prevented hospitalisations in any risk group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Harris-2011">
<CHAR_METHODS MODIFIED="2012-03-16 06:26:19 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-effectiveness analysis, societal perspective, decision analytic model, no discounting, 2007 CAD, Canada</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children less than 2 years old with haemodynamically significant CHD, born at 36 weeks gestation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:01:36 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: risk of admission to hospital, days in hospital, mortality benefits included, risk of sequelae not included</P>
<P>Summary measures: incremental cost to prevent one day of hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Author DGH received an honorarium of less than CAD 1000 from Abbott Laboratories. This study suggests that palivizumab is not cost-effective</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hascoet-2008">
<CHAR_METHODS MODIFIED="2012-03-24 03:24:43 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness analysis, societal and payer's perspective, decision analytic model, lifetime follow-up, 3% discount rate, 2006 EUR, France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-07 17:47:02 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm infants born at 32 weeks of gestational age or less, with BPD or CHD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:01:40 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: mortality benefits included, risk of sequelae included, hospitalization due to RSV infection</P>
<P>Summary measures: incremental cost per LYG, cost per hospitalization averted</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Author HB is employed at Abbott. This study suggests that palivizumab prophylaxis is cost-effective. Paper is written in French</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-IMpact_x002d_RSV-1998">
<CHAR_METHODS MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka">
<P>Study design: multicentre, randomized, double-blind, placebo-controlled, phase III trial</P>
<P>Dates of study: 1996 to 1997 RSV season</P>
<P>Locations: 139 - USA (119 sites), UK (11 sites) and Canada (9 sites)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka">
<P>1502 children (1002 in palivizumab group and 500 in placebo group) who were either:</P>
<P>1) 35 weeks gestation or less and 6 months of age or younger; or</P>
<P>2) 24 months old or younger and had a clinical diagnosis of BPD requiring ongoing medical treatment (i.e. supplemental oxygen, steroids, bronchodilators or diuretics within the past 6 months)</P>
<P>Children were excluded if they had any of the following: hospitalization at the time of entry that was anticipated to last more than 30 days; mechanical ventilation at the time of entry; life expectancy less than 6 months; active or recent RSV infection; known hepatic or renal dysfunction, seizure disorder, immunodeficiency, allergy to IgG products; receipt of RSV immune globulin within the past 3 months; or previous receipt of palivizumab, other monoclonal antibodies, RSV vaccines or other investigational agents. Children with congenital heart disease were excluded, except for those with a patent ductus arteriosus or a septal defect that was uncomplicated and haemodynamically insignificant</P>
<P>Attrition: 16 participants due to death (n = 7), withdrawal of consent (n = 4) or loss to follow-up (n = 5)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-28 05:06:05 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children received palivizumab (15 mg/kg) or an equivalent volume of placebo applied as intramuscular injections every 30 days for a total of 5 doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka">
<P>Primary outcome: hospitalization with confirmed RSV infection</P>
<P>Children were considered to have reached the primary outcome if:</P>
<P>1) they were hospitalised for a respiratory illness and the RSV antigen test of respiratory secretions was positive; or</P>
<P>2) if children already hospitalised for reasons other than RSV illness had a positive RSV test, and had a minimum LRI score of 3 and at least 1 point higher compared with their last health visit</P>
<P>Secondary outcomes: total RSV hospital days, RSV hospital days with increased supplemental oxygen, RSV hospital days with moderate/severe lower respiratory tract illness, incidence and total days of intensive care and mechanical ventilation, incidence of non-RSV hospitalization, incidence of otitis media, adverse events (assessed for severity and potential relationship to study drug)</P>
<P>Children were followed for 150 days from randomization (30 days after the last scheduled injection)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Joffe-1999">
<CHAR_METHODS MODIFIED="2012-03-22 06:22:49 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-effectiveness analysis, societal perspective, decision analytic model, 3% discount rate, 1995 USD, California, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Preterm infants discharged from the neonatal intensive care unit within 12 months prior to RSV season (8 risk groups)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-24 00:43:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to RSV-IVIG prophylaxis and no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: number needed to treat to prevent 1 RSV hospitalization, mortality benefits included, risk of sequelae not included</P>
<P>Summary measures: incremental cost per hospitalization averted, incremental cost per LYG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:06:28 +1000" MODIFIED_BY="Tea Andabaka">
<P>No conflict of interest declared. This study suggests more restrictive recommendations for the use of palivizumab</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Kang-2009">
<CHAR_METHODS MODIFIED="2012-03-22 06:23:18 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-effectiveness analysis, payer's and societal perspective, decision analytic model, lifetime follow-up, 5% discount rate, KW, Korea</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 06:26:03 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children with congenital heart disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 06:26:03 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: number of RSV hospitalisations and deaths avoided</P>
<P>Summary measures: incremental cost per LYG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:06:31 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is an abstract of a presentation at a conference. This study suggests that the use of palivizumab is cost-effective</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Lanctot-2008">
<CHAR_METHODS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" NOTES="&lt;p&gt;compare&lt;/p&gt;" NOTES_MODIFIED="2013-03-15 23:28:26 +1000" NOTES_MODIFIED_BY="Tea Andabaka">
<P>Cost-effectiveness and cost-utility analysis, payer's and societal perspective, decision analytic model, lifetime follow-up, 5% discount rate, 2007 CAD, Canada</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-22 05:14:44 +1000" MODIFIED_BY="Tea Andabaka">
<P>Preterm infants born at 32 to 35 weeks of gestational age without chronic lung disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:03:48 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: hospitalization due to RSV infection (general ward or ICU), risk of asthma and recurrent wheezing included, mortality benefits included, LYGs, QALYs</P>
<P>Summary measures: incremental cost per LYG, incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Abbott provided financial support for this analysis. This study suggests that palivizumab prophylaxis is cost-effective from both perspectives, in patients with 2 or more risk factors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lazaro-y-de-Mercado-2006">
<CHAR_METHODS MODIFIED="2012-03-22 06:25:25 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness and cost-utility analysis, payer's and societal perspective, decision analytic model, lifetime follow-up, 3% discount rate, 2006 EUR, Spain</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-24 00:33:18 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm infants born at 32 to 35 weeks' gestational age with 2 or more risk factors described by the Spanish Neonatology Society</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:03:52 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: life expectancy, mortality benefits included, hospitalization rate, risk of recurrent wheezing included, number needed to treat</P>
<P>Summary measures: incremental cost per LYG, incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Funded by the industry. This study suggests that palivizumab is a cost-effective alternative for the prophylaxis of RSV in preterm children with 2 or more risk factors. Paper is written in Spanish</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lazaro-y-de-Mercado-2007">
<CHAR_METHODS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness and cost-utility analysis, payer's and societal perspective, decision analytic model, lifetime follow-up, 3.5% discount rate, 2006 EUR, Spain</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-24 00:33:39 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm infants born at 35 weeks of gestational age or less and 6 months of age or younger, or 24 months old or younger and with a clinical diagnosis of BPD requiring ongoing medical treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:05:29 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: life expectancy, mortality benefits included, hospitalization rate, risk of recurrent wheezing included, number needed to treat</P>
<P>Summary measures: incremental cost per LYG, incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>No conflict of interest declared. However, for the economic evaluation performed on the same topic by the same authors in 2006, the authors received a grant from Abbott. This study suggests that palivizumab is a cost-effective alternative for the prophylaxis of RSV in preterm children with 2 or more risk factors. Paper is written in Spanish</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Lofland-2000">
<CHAR_METHODS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-effectiveness analysis, payer&#8217;s perspective, decision analytic model, 1-year follow-up, no discounting, 1999 USD, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 06:24:07 +1000" MODIFIED_BY="Tea Andabaka">
<P>Preterm infants (&#8804; 35 weeks of gestational age) and children with BPD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 06:24:07 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: hospitalization due to RSV infection, mortality benefits not included, risk of sequelae not included</P>
<P>Summary measures: incremental cost per RSV hospitalization avoided</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:06:48 +1000" MODIFIED_BY="Tea Andabaka">
<P>Paper was supported by a grant from MedImmune, Inc., Gaithersburg. This study gives ICER ranges for different palivizumab prophylaxis costs, and leaves the conclusions about the cost-effectiveness up to the readers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Mayen_x002d_Herrera-2011">
<CHAR_METHODS MODIFIED="2012-09-16 02:26:38 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-utility analysis, payer's perspective, decision analytic model, 3% discount rate, MXN, Mexico</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-16 02:26:38 +1000" MODIFIED_BY="Tea Andabaka">
<P>Preterm infants born at less than 29 weeks of gestational age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-16 02:26:39 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-16 02:26:39 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: QALYs</P>
<P>Summary measures: incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is an abstract of a presentation at a conference. Author EMH is employed at Abbott. This study suggests that palivizumab prophylaxis is cost-effective</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Neovius-2011">
<CHAR_METHODS MODIFIED="2012-07-22 03:28:42 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-utility and cost-effectiveness analysis, societal perspective, decision analytic Markov model, lifetime follow-up, 3% discount rate, 2009 SEK, Sweden</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-16 06:25:23 +1000" MODIFIED_BY="Tea Andabaka">
<P>Preterm infants born at less than 29 weeks of gestation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 06:25:23 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: hospitalization due to RSV infection, risk of asthma included, mortality benefits included</P>
<P>Summary measures: incremental cost per QALY, incremental cost per LYG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Authors KB and KS are employed at Abbott. Study was funded by Abbott Scandinavia. Palivizumab was found to be cost-effective, based on a willingness-to-pay of SEK 500,000 per QALY</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nuijten-2007">
<CHAR_METHODS MODIFIED="2012-03-23 08:36:20 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness and cost-utility analysis, payer's and societal perspective, decision analytic model, lifetime follow-up, 3.5% discount rate, 2003 GBP, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-23 08:37:30 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm infants born at 35 weeks of gestation or less, children with BPD (&#8804; 2 years) and children with CHD (&#8804; 2 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-22 23:46:17 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: mortality benefits included, risk of sequelae included, hospitalization rate, life expectancy, utilities</P>
<P>Summary measures: incremental cost per LYG, incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:06:57 +1000" MODIFIED_BY="[Empty name]">
<P>Funded by the industry. This study suggests that palivizumab prophylaxis may be a cost-effective option against severe RSV infections in the UK versus no prophylaxis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Nuijten-2009a">
<CHAR_METHODS MODIFIED="2012-03-22 06:26:19 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-utility and cost-effectiveness analysis, societal perspective, decision analytic model, lifetime follow-up, no discounting, 2006 EUR, Netherlands</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Preterm infants and infants with BPD (as one subgroup) and children with CHD (as another subgroup)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 06:23:24 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: hospitalization due to RSV infection, risk of asthma and recurrent wheezing included, mortality benefits included, life expectancy, utilities</P>
<P>Summary measures: incremental cost per QALY, incremental cost per LYG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Author WW is employed at Abbott. Author MN was paid by Abbott to conduct this analysis. This study suggests that palivizumab prophylaxis is cost-effective</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Nuijten-2009b">
<CHAR_METHODS MODIFIED="2012-03-22 06:26:31 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-utility and cost-effectiveness analysis, societal and payer&#8217;s perspective, decision analytic model, lifetime follow-up, 5% discount rate, 2006 EUR, Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-22 12:38:28 +1000" MODIFIED_BY="Tea Andabaka">
<P>Infants with haemodynamically significant congenital heart disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-16 06:22:02 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: hospitalization due to RSV infection, risk of asthma and recurrent wheezing included, mortality benefits included, utilities</P>
<P>Summary measures: incremental cost per QALY, incremental cost per LYG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Author WW is employed at Abbott. Author MN was paid by Abbott to conduct this analysis. This study suggests that palivizumab prophylaxis is cost-effective</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nuijten-2010">
<CHAR_METHODS MODIFIED="2012-03-22 06:26:58 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness and cost-utility analysis, payer's and societal perspective, decision analytic model, lifetime follow-up, 3% discount rate, 2006 EUR, Spain</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 08:18:39 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm children born at or before 32 weeks of gestational age who were less than 6 months old at the onset of RSV season</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:18:53 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: mortality benefits included, risk of sequelae included, hospitalization rate, life expectancy, utilities</P>
<P>Summary measures: incremental cost per LYG, incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:07:09 +1000" MODIFIED_BY="[Empty name]">
<P>Funded by the industry. This study suggests that palivizumab may be a cost-effective prophylactic option against severe RSV infections in Spain compared to no prophylaxis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ravasio-2006">
<CHAR_METHODS MODIFIED="2012-03-22 06:27:22 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness and cost-utility analysis, payer's perspective, decision analytic model, 14 years follow-up, 3% discount rate, EUR, Italy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-19 22:16:02 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm infants of less than 33 weeks, or 33 to 35 weeks of gestation, with and without BPD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:20:28 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: mortality benefits included, hospitalization rate, risk of asthma included</P>
<P>Summary measures: incremental cost per LYG, incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:07:12 +1000" MODIFIED_BY="[Empty name]">
<P>Funded by the industry. This study suggests that palivizumab is cost-effective in prevention of RSV infection in preterm infants. Paper is written in Italian</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Raya-Ortega-2006">
<CHAR_METHODS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-effectiveness analysis, payer's perspective, decision analytic model, 1-year follow-up, no discounting, 2006 EUR, Spain</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-04-11 03:35:25 +1000" MODIFIED_BY="Tea Andabaka">
<P>Preterm infants born at 32 to 35 weeks of gestation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-11 03:35:35 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: hospitalization rate</P>
<P>Summary measures: incremental cost per hospitalization avoided</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:07:16 +1000" MODIFIED_BY="Tea Andabaka">
<P>Not funded by the industry. This study suggests that palivizumab prophylaxis is not cost-effective. Paper is written in Spanish</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Resch-2008">
<CHAR_METHODS MODIFIED="2012-08-08 06:22:20 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness and cost-utility analysis, payer's and societal perspective, decision analytic model, lifetime follow-up, 5% discount rate, 2006 EUR, Austria</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 08:33:24 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm infants born at 35 weeks of gestation or less, children with BPD and children with CHD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:21:38 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: hospitalization, mortality benefits included, life expectancy, risk of asthma included</P>
<P>Summary measures: incremental cost per LYG, incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Author WW is employed at Abbott. Palivizumab was cost-effective compared to no prophylaxis in high-risk infants in Austria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Resch-2012">
<CHAR_METHODS MODIFIED="2012-09-16 02:27:06 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-effectiveness and cost-utility analysis, payer's and societal perspective, decision analytic model, lifetime follow-up, 5% discount rate, 2010 EUR, Austria</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-16 02:27:06 +1000" MODIFIED_BY="Tea Andabaka">
<P>Preterm infants born at 36 weeks of gestation or less, children with BPD and children with CHD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-16 02:27:06 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 16:34:50 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: LYG, QALY, mortality benefits included, risk of sequelae included</P>
<P>Summary measures: incremental cost per LYG, incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Conflicts of interest are not clearly stated. Author SS is employed at Abbott. Study suggests that palivizumab is cost-effective in prevention of RSV disease in high-risk infants. This study incorporated changes in medication costs and new country-specific epidemiologic data, as compared to <LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rietveld-2010">
<CHAR_METHODS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness analysis, societal perspective, decision analytic model, 1-year follow-up, no discounting, 2000 EUR, Netherlands</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm infants born at 28 weeks of gestation or less, with birth weight &#8804; 2500 g, having BPD and aged 0 months at the beginning of the season (October)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:23:10 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: hospitalization rate, mortality benefits not included, risk of sequelae not included</P>
<P>Summary measures: cost per hospitalization averted</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-19 16:34:49 +1000" MODIFIED_BY="[Empty name]">
<P>Not funded by the industry. This study recommends a restrictive immunisation policy, immunizing only the children with BPD in high-risk months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roeckl_x002d_Wiedmann-2003">
<CHAR_METHODS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness analysis, societal perspective, decision analytic model, 1-year follow-up, no discounting, EUR, Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-19 22:24:06 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm infants of male gender born at &#8804; 35 weeks of gestational age, with siblings in daycare, discharge between October and December, and with or without CLD. Economic evaluation is nested in the Munich RSV study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:42:08 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:44 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: hospitalization rate, mortality benefits included, risk of sequelae not included</P>
<P>Summary measures: cost per hospitalization averted</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:07:34 +1000" MODIFIED_BY="[Empty name]">
<P>Funded by the industry. This study suggests restrictive use of palivizumab prophylaxis in preterm infants with CLD in their risk combination</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Salinas_x002d_Escudero-2012">
<CHAR_METHODS MODIFIED="2012-09-16 02:27:32 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-effectiveness and cost-utility analysis, payer's perspective, decision analytic model, 18 years follow-up, 3% discount rate, 2009 USD, Mexico</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Preterm infants without CLD or CHD, born at less than 29, or at 29 to 32 weeks of gestational age, and up to 6 months old at the start of the RSV season, or born during the season</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-16 02:27:32 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 16:34:48 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: LYG, QALY, risk of asthma included, mortality benefits included</P>
<P>Summary measures: incremental cost per LYG, incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>The authors received support of Abbott Laboratories in Mexico. This study suggests that palivizumab is a cost-effective alternative for preterm infants &#8804; 32 weeks of gestational age (wGA) in Mexico</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smart-2010">
<CHAR_METHODS MODIFIED="2012-03-22 06:28:37 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness and cost-utility analysis, payer's and societal perspective, decision analytic model, lifetime follow-up, 5% discount rate, 2010 CAD, Canada</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-24 00:36:18 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm infants born at 32 to 35 weeks' gestational age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:43:53 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:45 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: hospitalization rate, mortality benefits included, with and without risk of sequelae included, life expectancy</P>
<P>Summary measures: incremental cost per LYG, incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:07:59 +1000" MODIFIED_BY="[Empty name]">
<P>Not funded by the industry. Palivizumab was cost-effective compared to no prophylaxis in high-risk infants in Canada. Methodology was based on <LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK> study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:45 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Subramanian-1998">
<CHAR_METHODS MODIFIED="2013-06-12 08:29:45 +1000" MODIFIED_BY="Tea Andabaka">
<P>Study design: randomized (2:1), double-blind, placebo-controlled, phase I/II, multicentre, dose-escalation trial</P>
<P>Dates of study: 1995 to 1996 RSV season</P>
<P>Locations: 10 sites (locations not specified)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>62 patients (42 to palivizumab group and 20 to placebo group) who:</P>
<P>1) were born at &#8804; 35 weeks of gestation and were &#8804; 6 months of age; or</P>
<P>2) had bronchopulmonary dysplasia and were &#8804; 24 months of age</P>
<P>Infants were excluded if they had any of the following: mechanical ventilation at the time of enrolment; life expectancy &lt; 1 year; known renal impairment, hepatic dysfunction, persistent seizure disorder or immunodeficiency; blood urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase or bilirubin &gt; 1.5 times the upper limit of normal for age; haemoglobin &lt; 9.0 g/dl; white blood cell count &lt; 2000 cells/mm<SUP>3</SUP>; platelet count &lt; 110,000 cells/mm<SUP>3</SUP>; abnormal serum IgG, IgM and IgA values, positive hepatitis B surface antigen, hepatitis C antibody or HIV antibody (unless provided to be not infected with HIV); supplemental oxygen requirement of &gt; 30% FiO<SUB>2</SUB> or &gt; 1.5 litres/min; any acute illness or progressive clinical disorder, including acute RSV infection; previous reaction to intravenous immunoglobulin, blood products or other foreign proteins; treatment with intravenous immunoglobulin or other immunoglobulin products within the past 2 months; treatment with other investigational agents or participation in any investigational study of RSV agents; or expectation that the patient would not be able to be followed for the duration of the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-28 05:08:46 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children received 3, 10 or 15 mg/kg of palivizumab intravenously, or an equal volume of placebo applied as intravenous infusion every 30 days (- 3 to + 7 days) for up to 5 doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-15 13:32:53 +1000" MODIFIED_BY="Tea Andabaka">
<P>Primary outcomes: adverse events (assessed for severity, seriousness and relationship to study drug)</P>
<P>Secondary outcomes: frequency and severity of RSV infection</P>
<P>Infants who were assessed by the family or the patient&#8217;s physician as having a respiratory infection or who had 2 or more of the following new respiratory symptoms (coryza, fever, cough, wheezing, intercostal retractions or nasal flaring) or who had exacerbation of existing respiratory conditions were evaluated for evidence of RSV infection (RSV antigen). When a child was hospitalised for RSV illness, the child was evaluated daily until discharge</P>
<P>Patients were followed for 150 days (30 days after the last infusion)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:08:52 +1000" MODIFIED_BY="Tea Andabaka">
<P>The data extracted for our analysis includes only data for 15 mg/kg dosing regimen</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tam-2009">
<CHAR_METHODS MODIFIED="2012-03-22 06:28:54 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness and cost-utility analysis, payer's and societal perspective, decision analytic model, lifetime follow-up, 5% discount rate, 2007 CAD, Canada</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 08:45:56 +1000" MODIFIED_BY="[Empty name]">
<P>Infants less than 1 year of age on Baffin Island</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:46:06 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: hospitalization rate, mortality benefits included, risk of sequelae not included, life expectancy, utilities</P>
<P>Summary measures: incremental cost per LYG, incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:09:04 +1000" MODIFIED_BY="[Empty name]">
<P>Funded by the industry. Palivizumab was cost-effective in infants less than 1 year of age residing in the Eastern Canadian Arctic. However, palivizumab was not cost-effective for infants of all ages residing in Iqaluit</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vogel-2002">
<CHAR_METHODS MODIFIED="2012-03-24 03:44:26 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness analysis, societal perspective, decision analytic model, no discounting, 2000 NZD, New Zealand</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-24 00:36:30 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm infants &lt; 32 weeks' gestational age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:48:22 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: hospitalization rate, mortality benefits not included, risk of sequelae not included, number needed to treat</P>
<P>Summary measures: cost per hospitalization averted</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:09:09 +1000" MODIFIED_BY="[Empty name]">
<P>Funded by the industry. This study does not indicate cost savings associated with the use of palivizumab for any subgroup</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2011">
<CHAR_METHODS MODIFIED="2012-03-21 08:52:03 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-utility analysis, payer's perspective, decision analytic model, lifetime follow-up, 3.5% discount rate, 2006 GBP, UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm infants &#8804; 35 weeks gestational age. Subgroup analyses in four categories: CLD, CLD/CHD, acyanotic CHD and cyanotic CHD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:52:35 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 16:34:44 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: odds ratios for age, gestational age, gender, CHD, CLD, sibling at school, multiple births, smoking exposure, overcrowding, parental education of high school or less, mortality benefits included, with and without risk of sequelae included</P>
<P>Summary measures: incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:09:13 +1000" MODIFIED_BY="[Empty name]">
<P>Not funded by the industry. This study suggests that palivizumab is not cost-effective</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Weiner-2012">
<CHAR_METHODS MODIFIED="2012-09-16 02:28:08 +1000" MODIFIED_BY="Tea Andabaka">
<P>Cost-utility analysis, societal perspective, decision analytic model, lifetime follow-up, 3% discount rate, 2010 USD, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Preterm infants without CLD or CHD divided in 4 subgroups; data presented for infants born at less than 32 weeks of gestation and with 6 months of chronological age or less</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-16 02:28:08 +1000" MODIFIED_BY="Tea Andabaka">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-19 16:34:44 +1000" MODIFIED_BY="Tea Andabaka">
<P>Effectiveness outcomes: QALYs, utilities, mortality benefits included, risk of sequelae not included</P>
<P>Summary measures: incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-28 05:09:22 +1000" MODIFIED_BY="Tea Andabaka">
<P>Funded by the industry. This study suggests that palivizumab prophylaxis is highly cost-effective</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yount-2004">
<CHAR_METHODS MODIFIED="2012-07-22 03:39:16 +1000" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness and cost-utility analysis,  payer's perspective, decision analytic model, lifetime follow-up, 3% discount rate, 2002 USD, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-24 00:42:18 +1000" MODIFIED_BY="[Empty name]">
<P>Children with congenital hearth disease &#8804; 2 years old</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 08:53:07 +1000" MODIFIED_BY="[Empty name]">
<P>Palivizumab prophylaxis compared to no prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="[Empty name]">
<P>Effectiveness outcomes: hospitalization rate, life expectancy, mortality benefits included, risk of sequelae included</P>
<P>Summary measures: incremental cost per LYG, incremental cost per QALY</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-22 12:38:43 +1000" MODIFIED_BY="[Empty name]">
<P>Not funded by the industry. Routine use of palivizumab in young children with haemodynamically significant CHD needs to be evaluated further</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AEs = adverse events<BR/>BPD = bronchopulmonary dysplasia<BR/>CAD = Canadian dollar<BR/>CHD = congenital heart disease<BR/>CLD = chronic lung disease<BR/>EUR = Euro<BR/>GA = gestational age<BR/>GBP = Great British pound<BR/>HIV = human immunodeficiency virus<BR/>ICER = incremental cost-effectiveness ratio<BR/>ICU = intensive care unit<BR/>IVIG = intravenous immunoglobulin<BR/>ITT = intention-to-treat<BR/>KW = Korean won<BR/>LRI = lower respiratory tract infection<BR/>LYGs = life-years gained<BR/>MALRI = medically attended lower respiratory tract infection<BR/>MXN = Mexican peso<BR/>NZD = New Zealand dollar<BR/>RSV = respiratory syncytial virus<BR/>QALYs = quality-adjusted life-years<BR/>SAEs = serious adverse events<BR/>SEK = Swedish krona<BR/>UK = United Kingdom<BR/>USA = United States of America<BR/>USD = United States dollar<BR/>wGA = weeks of gestational age</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:39 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Banerji-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:39 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:40 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Buckley-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:40 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:41 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Chan-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:41 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:41 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Clark-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:41 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:42 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Datar-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:42 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:43 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Farina-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:43 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Korbal-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a retrospective analysis, not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:47 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Krilov-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:47 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:48 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Lapena-Lopez-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:48 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:49 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Lee-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:49 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:50 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Marchetti-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:50 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:53 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Marques-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:53 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Martinez-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a trial with a historical control, not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:55 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-McCormick-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:55 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:55 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Meberg-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:55 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:14:02 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Meissner-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:14:02 +1000" MODIFIED_BY="Tea Andabaka">
<P>Product SB 209763 is not palivizumab. It is another kind of intramuscular monoclonal antibody against respiratory syncytial virus (RSV) that failed to prove efficacy in preventing severe RSV disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:09:57 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Numa-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:09:57 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is neither a cost-effectiveness nor a cost-utility analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Parmigiani-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:10:02 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Rackham-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:10:02 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:10:02 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Reeve-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:10:02 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:10:03 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Rodriguez-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:10:03 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:10:04 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Shireman-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:10:04 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is neither a cost-effectiveness nor a cost-utility analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Stevens-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>This economic evaluation analyses RSV-IVIG and palivizumab together. Results of these analyses represent combined effect of both prophylaxis. There is no comparison of palivizumab prophylaxis alone with placebo, no prophylaxis or other prophylaxis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Strutton-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a systematic review of economic evaluations and not a primary analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Takeuchi-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:10:09 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Vann-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:10:09 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:10:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:10:10 +1000" MODIFIED_BY="Tea Andabaka">
<P>The technology assessment performed in <LINK REF="STD-Wang-2008" TYPE="STUDY">Wang 2008</LINK> was later updated and reported in <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:10:11 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Wegner-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:10:11 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-28 05:10:12 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-Wendel-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-28 05:10:12 +1000" MODIFIED_BY="Tea Andabaka">
<P>This is a partial economic evaluation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-NCT00233064">
<CHAR_METHODS MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka">
<P>Study design: phase IV, randomized, double-blind, dose comparison trial</P>
<P>Date of first enrolment: October 2005</P>
<P>Target sample size: 417</P>
<P>Recruitment status: completed in November 2007</P>
<P>Locations: sites in USA</P>
<P>Sponsor: MedImmune LLC</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka">
<P>Inclusion criteria:</P>
<OL>
<LI>Medically stable child with chronic lung disease of prematurity who is &#8804; 24 months of age at randomization or child with premature birth (gestational age &#8804; 35 weeks or less) and who is 6 months of age or younger at randomization</LI>
<LI>Written informed consent obtained from the patient's parent(s) or legal guardian(s)</LI>
<LI>The child must be able to complete the follow-up visit 4 to 6 months after the last dose of study drug</LI>
</OL>
<P>Exclusion criteria:</P>
<OL>
<LI>Hospitalisation at the time of randomization (unless discharge is anticipated within 3 weeks)</LI>
<LI>Be receiving mechanical ventilation at the time of study entry (including CPAP)</LI>
<LI>Congenital heart disease (children with uncomplicated CHD (e.g. PDA, small septal defect) and children with complicated CHD who are currently anatomically and haemodynamically normal can be enrolled)</LI>
<LI>Mother with HIV infection (unless the child has been proven to be not infected)</LI>
<LI>Life expectancy &lt; 6 months</LI>
<LI>Known allergy to Ig products</LI>
<LI>Acute respiratory or other acute infection or illness</LI>
<LI>Previous reaction to IVIG, blood products, or other foreign proteins</LI>
<LI>Receipt of lyophilised palivizumab, RSV-IVIG, or other RSV-specific monoclonal antibody, or any other polyclonal antibody (for example, hepatitis B IG, IVIG, VZIG) within 3 months prior to randomization</LI>
<LI>Any previous receipt of MEDI-524</LI>
<LI>Participation in other investigational drug product studies</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-15 22:20:10 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children received 15 mg/kg of liquid palivizumab, or 15 mg/kg of lyophilised palivizumab administered intramuscularly every 30 days for a total of 5 injections</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-28 05:10:30 +1000" MODIFIED_BY="Tea Andabaka">
<P>Primary outcome: number and percentage of participants with immune reactivity</P>
<P>Children were followed for 240 to 300 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-NCT00240929">
<CHAR_METHODS MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka">
<P>Study design: phase II, randomized, double-blind, dose comparison, cross-over trial</P>
<P>Date of first enrolment: September 2002</P>
<P>Target sample size: 150</P>
<P>Recruitment status: completed in April 2003</P>
<P>Locations: 20 sites in the USA</P>
<P>Sponsor: MedImmune LLC</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka">
<P>Inclusion criteria:</P>
<OL>
<LI>The child must have been born at less than or equal to 35 weeks gestation and be less than or equal to 6 months of age at the time of randomization (child must be randomized on or before their 6-month birthday)</LI>
<LI>The child's parent or legal guardian must provide written informed consent</LI>
<LI>The child must be able to complete the follow-up visits on study days 30 and 60 within the protocol specified windows (± 2 days)</LI>
<LI>Parent/legal guardian of patient has available telephone access</LI>
</OL>
<P>Exclusion criteria:</P>
<OL>
<LI>Hospitalised</LI>
<LI>Birth hospitalization &gt; 6 weeks duration</LI>
<LI>Receiving mechanical ventilation at the time of study entry (including CPAP)</LI>
<LI>Bronchopulmonary dysplasia (BPD), defined as history of prematurity and associated chronic lung disease with oxygen requirement for &gt; 28 days</LI>
<LI>Congenital heart disease (CHD) (children with medically or surgically corrected (closed) patent ductus arteriosus and no other CHD may be enrolled)</LI>
<LI>Known renal impairment, hepatic dysfunction, chronic seizure disorder or immunodeficiency</LI>
<LI>Any of the following laboratory findings in blood obtained within 7 days prior to study entry: BUN or creatinine &gt; 1.5 the upper limit of normal for age, AST (SGOT) or ALT (SGPT) &gt; 1.5 the upper limit of normal for age, haemoglobin &lt; 9.0 gm/dL, white blood cell count &lt; 4000 cells/mm3, platelet count &lt; 110,000 cells/mm3</LI>
<LI>Acute illness or progressive clinical disorder</LI>
<LI>History of recent difficult venous access</LI>
<LI>Active infection, including acute RSV infection</LI>
<LI>Previous reaction to IVIG, blood products or other foreign proteins</LI>
<LI>Received within the past 120 days or currently receiving IVIG, other immunoglobulin products or any investigational agents</LI>
<LI>Have ever received palivizumab</LI>
<LI>Currently participating in any investigational study</LI>
<LI>Previously participated in any investigational study of RSV vaccines or monoclonal antibodies</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-15 22:21:45 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children received sequence A (single dose of the liquid formulation on study day 0 and a single dose of the lyophilised formulation on study day 30), or sequence B (single dose of the lyophilised formulation on study day 0 and single dose of the liquid formulation on study day 30)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-28 05:10:47 +1000" MODIFIED_BY="Tea Andabaka">
<P>Primary outcomes: adverse events and palivizumab concentrations in serum</P>
<P>Secondary outcomes: adverse events and serious adverse events</P>
<P>Children were followed for 30 days after each injection</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka" STUDY_ID="STD-NTR1023">
<CHAR_METHODS MODIFIED="2013-06-12 08:29:46 +1000" MODIFIED_BY="Tea Andabaka">
<P>Study design: randomized, double-blind, placebo-controlled trial</P>
<P>Date of first enrolment: 1 October 2007</P>
<P>Target sample size: 452</P>
<P>Recruitment status: completed</P>
<P>Locations: sites in Netherlands</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka">
<P>Inclusion criteria:</P>
<OL>
<LI>Gestational age 32 to 35 weeks</LI>
</OL>
<P>Exclusion criteria:</P>
<OL>
<LI>Severe congenital anomaly</LI>
<LI>Congenital heart disease</LI>
<LI>Down syndrome</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-28 05:10:56 +1000" MODIFIED_BY="Tea Andabaka">
<P>Children received monthly injection of placebo or palivizumab 15 mg/kg during the winter season</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-28 05:10:59 +1000" MODIFIED_BY="Tea Andabaka">
<P>Primary outcome: number of wheezing days during the first year of life</P>
<P>Secondary outcomes: health-related quality of life at age 1, 3 and 6 years, and asthmatic symptoms at age 3 and 6 years measured by questionnaires<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES>
<P>ALT = alanine aminotransferase<BR/>AST = aspartate aminotransferase<BR/>BPD = bronchopulmonary dysplasia<BR/>BUN = blood urea nitrogen<BR/>CHD = congenital heart disease<BR/>CPAP = continuous positive airway pressure<BR/>HIV = human immunodeficiency virus<BR/>IG = immunoglobulin<BR/>IVIG = intravenous immunoglobulin<BR/>PDA = persistent ductus arteriosus<BR/>RSV = respiratory syncytial virus<BR/>SGOT = serum glutamic oxaloacetic transaminase<BR/>SGPT = serum glutamic pyruvic transaminase<BR/>USA = United States of America<BR/>VZIG = varicella zoster immunoglobulin</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-07-22 03:37:22 +1000" MODIFIED_BY="Tea Andabaka" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-06-12 08:29:45 +1000" MODIFIED_BY="Maria X Rojas">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Maria X Rojas" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-12 08:29:38 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Abarca-2009">
<DESCRIPTION>
<P>Study has 2 phases: first phase was open-label, with motavizumab and no comparison group. In the second consecutive RSV season children were randomly assigned 1:1 to receive motavizumab or palivizumab. The randomization schedule was stratified by site with a block size of 4 (p. 268)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:09 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Bentley-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-08 01:47:19 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Carbonell_x002d_Estrany-2010">
<DESCRIPTION>
<P>Children were randomly assigned 1:1 by using an interactive voice-response system to receive motavizumab or palivizumab. Randomisation was stratified by site and diagnosis of protocol-defined CLD (p. e36)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:08 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chirico-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:08 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chiroli-2005">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:07 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-ElHassan-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:06 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Embleton-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-08 01:47:30 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Feltes-2003">
<DESCRIPTION>
<P>Random assignment was based on a computer-generated sequence, and was stratified by site to reduce the effect of practice discrepancies and anatomic cardiac lesion. Randomisation was performed centrally with the use of an interactive voice response system (p. 533)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-15 13:49:50 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Feltes-2011">
<DESCRIPTION>
<P>Patients were randomly assigned 1:1 using an interactive voice-response system. Randomisation was stratified by site and the presence or absence of cyanotic CHD (p. 187)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Fernandez-2010">
<DESCRIPTION>
<P>Children were randomly assigned 1:1:1 (stratified by site) using an automated randomization system (p. 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:05 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Altes-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:04 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hampp-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:04 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:03 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hascoet-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-IMpact_x002d_RSV-1998">
<DESCRIPTION>
<P>Randomisation (2 treatment to 1 control) was performed centrally using an interactive voice randomization system (p. 532)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:02 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Joffe-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Kang-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lanctot-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:00 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:59 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:58 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lofland-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:58 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Mayen_x002d_Herrera-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:57 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Neovius-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:56 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:55 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009a">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:54 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009b">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:54 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:53 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Ravasio-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:52 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Raya-Ortega-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:51 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:50 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:49 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Rietveld-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:48 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Roeckl_x002d_Wiedmann-2003">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:48 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Salinas_x002d_Escudero-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:46 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Smart-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-08 01:48:13 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Subramanian-1998">
<DESCRIPTION>
<P>Randomisation (1 placebo: 2 MEDI-493 within each dosage) was done centrally. Insufficient information about sequence generation process is given (p. 111)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:46 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Tam-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:45 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Vogel-2002">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:44 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Weiner-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Yount-2004">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Maria X Rojas" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-08 01:47:09 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Abarca-2009">
<DESCRIPTION>
<P>During the second RSV season, treatment assignments were double-blind. Only the independent monitor and the study pharmacist had access to information that identified a patient's treatment allocation. Method of allocation concealment remains unclear (p. 268)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:09 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Bentley-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-08 01:47:19 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Carbonell_x002d_Estrany-2010">
<DESCRIPTION>
<P>All personnel at all sites were blind to study treatment. Motavizumab and palivizumab were provided in identical vials in coded kits (p. e36)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:08 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chirico-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:07 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chiroli-2005">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:07 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-ElHassan-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:06 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Embleton-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-08 01:47:30 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Feltes-2003">
<DESCRIPTION>
<P>Children were randomly assigned 1:1 to receive palivizumab or an equal volume of identically appearing placebo. Palivizumab and placebo were supplied in coded vials and dispensed in a syringe that did not identify the contents. Randomisation was performed centrally using an interactive voice response system (p. 533)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-15 13:49:55 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Feltes-2011">
<DESCRIPTION>
<P>Motavizumab and palivizumab were provided in identical vials in coded kits. Randomisation was performed centrally. All study personnel were blinded to treatment assignments (p. 187)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Fernandez-2010">
<DESCRIPTION>
<P>This was a randomized, double-blind study (p. 2). Method of allocation concealment remains unclear; no information is provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:05 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Altes-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:04 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hampp-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:03 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:03 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hascoet-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-IMpact_x002d_RSV-1998">
<DESCRIPTION>
<P>Participants were centrally randomized to receive palivizumab or an equal volume of identically appearing placebo. Palivizumab and placebo were supplied as powder in coded vials and dispensed in a syringe that did not identify the contents (p. 532)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:02 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Joffe-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Kang-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lanctot-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:00 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:59 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:58 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lofland-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:58 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Mayen_x002d_Herrera-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:57 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Neovius-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:56 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:55 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009a">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:54 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009b">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:53 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:53 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Ravasio-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:52 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Raya-Ortega-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:51 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:50 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:49 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Rietveld-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:48 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Roeckl_x002d_Wiedmann-2003">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:47 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Salinas_x002d_Escudero-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:46 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Smart-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-28 05:08:56 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Subramanian-1998">
<DESCRIPTION>
<P>The study drug (palivizumab or placebo) was dispensed from the pharmacy in a syringe enclosed in a plastic bag that did not contain the drug assignment on the label (p. 111, 112)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:46 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Tam-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:45 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Vogel-2002">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:44 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Weiner-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Yount-2004">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-03-14 04:49:33 +1000" MODIFIED_BY="Tea Andabaka" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-06-12 08:29:45 +1000" MODIFIED_BY="Maria X Rojas" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-08 01:47:09 +1000" MODIFIED_BY="Tea Andabaka" RESULT="NO" STUDY_ID="STD-Abarca-2009">
<DESCRIPTION>
<P>In season 1, 217 children were enrolled. Of these 217, 136 children participated in the next season. Of the 136 children, 131 (96.3%) completed the second season of the study. Reasons for attrition are given within season 2, though for attrition between season 1 and season 2 are not. Despite only 131/136 participants completing the study, data on all 136 participants are reported in Table 2</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:09 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Bentley-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-08 01:47:19 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Carbonell_x002d_Estrany-2010">
<DESCRIPTION>
<P>Attrition rates in both groups were same (1.8%) and reasons for attrition were provided. The ITT population included all randomly assigned patients. The safety population included all patients who received any study medication and had any safety follow-up (p. e37)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:08 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chirico-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:07 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chiroli-2005">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:07 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-ElHassan-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:06 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Embleton-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-08 01:47:30 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Feltes-2003">
<DESCRIPTION>
<P>95.6% of participants in the palivizumab group and 95.5% in the placebo group completed the study, and 93% of participants in the palivizumab group and 91.8% in the placebo group received all 5 injections. All randomly assigned patients were included in the safety and efficacy analyses, and patients who received at least 1 dose of study drug were included in the analyses of serum palivizumab concentrations (p. 534)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-12 08:29:42 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Feltes-2011">
<DESCRIPTION>
<P>Comparable attrition rates in both groups. Reasons for attrition given in supplemental material. The ITT population included all randomized patients. The safety population included all patients who received any study medication and had any safety follow-up (p. 187)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Fernandez-2010">
<DESCRIPTION>
<P>94.6% of subjects received all 5 doses of study drug and 92.7% subjects completed the study. Reasons for attrition are given (p. 5). The safety population included all randomized subjects who received study drug and had any safety follow-up (p. 4)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:05 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Altes-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:04 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hampp-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:03 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:02 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hascoet-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-IMpact_x002d_RSV-1998">
<DESCRIPTION>
<P>99% of children completed the protocol follow-up, 94% of placebo group and 92% of palivizumab group received all 5 injections. All randomized patients were included in the safety and efficacy analyses (p. 532, 533)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:02 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Joffe-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Kang-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:00 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lanctot-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:35:00 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:59 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:58 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lofland-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:58 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Mayen_x002d_Herrera-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:56 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Neovius-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:56 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:55 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009a">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:54 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009b">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:53 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:53 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Ravasio-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:52 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Raya-Ortega-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:51 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:50 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:49 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Rietveld-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:48 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Roeckl_x002d_Wiedmann-2003">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:47 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Salinas_x002d_Escudero-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:46 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Smart-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-12 08:29:45 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Subramanian-1998">
<DESCRIPTION>
<P>All randomized patients who received study drug were included in analyses. Overall 91.9% patients completed the study. Reasons for attrition are given (p. 112)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:45 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Tam-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:45 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Vogel-2002">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:44 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Weiner-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-19 16:34:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Yount-2004">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Maria X Rojas" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Abarca-2009">
<DESCRIPTION>
<P>All outcomes reported in the methods are also reported in the results section. Adverse events were described on an as-reported basis, with clear criteria for defining adverse events, severe adverse events, etc.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:09 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Bentley-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-08 01:47:19 +1000" MODIFIED_BY="Tea Andabaka" RESULT="NO" STUDY_ID="STD-Carbonell_x002d_Estrany-2010">
<DESCRIPTION>
<P>6635 participants from 347 sites in 24 countries. RSV-specific outpatient MALRI was assessed only in children from 133 sites (p. e38). This likely represents the sample size calculation on page e37, though it is unclear how these sites were selected, possibly introducing bias toward sites with better outcomes data. Standard deviations for continuous data (days) are not reported (p. e46)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:08 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chirico-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:07 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chiroli-2005">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:06 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-ElHassan-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:06 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Embleton-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" RESULT="NO" STUDY_ID="STD-Feltes-2003">
<DESCRIPTION>
<P>All primary and secondary outcomes and safety/adverse events data were included in report of results. Adverse events were categorised, and graded by a blinded investigator for potential relation to study drug (p. 534). Standard deviations for continuous data (days) are not reported (p. 536)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="NO" STUDY_ID="STD-Feltes-2011">
<DESCRIPTION>
<P>Adverse events were determined on an as-encountered basis, and assessed for severity and relationship to study drug by the blinded site investigators (p. 187). Secondary outcomes reported in the methods are also reported in the results section. RSV outpatient MALRIs were assessed for patients in season 2 only, with no explanations provided, and without reporting the total number of randomized patients in the subset</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Fernandez-2010">
<DESCRIPTION>
<P>All outcomes reported in the methods are also reported in the results section. Adverse events were determined on an as-encountered basis and assessed by the investigator for severity, relationship to study drug and whether it met criteria as an SAE (p. 3)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:05 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Altes-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:04 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hampp-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:03 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:02 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hascoet-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-28 05:06:19 +1000" MODIFIED_BY="Tea Andabaka" RESULT="NO" STUDY_ID="STD-IMpact_x002d_RSV-1998">
<DESCRIPTION>
<P>Primary and secondary endpoints listed in the methods on page 532 are reported in results section on pages 533 to 534. Adverse events were defined as they happened, in both groups, and reported on page 534. Standard deviations for continuous data (days) are not reported (p. 533, 534)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:02 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Joffe-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Kang-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:00 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lanctot-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:59 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:59 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:58 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lofland-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:57 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Mayen_x002d_Herrera-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:56 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Neovius-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:56 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:55 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009a">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:54 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009b">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:53 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:52 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Ravasio-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:52 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Raya-Ortega-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:51 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:50 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:49 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Rietveld-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:48 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Roeckl_x002d_Wiedmann-2003">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:47 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Salinas_x002d_Escudero-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:46 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Smart-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-08 01:48:13 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Subramanian-1998">
<DESCRIPTION>
<P>All outcomes reported in the methods are also reported in the results section. LRI score was used; adverse events were reported on as-encountered basis and assessed by the blinded investigator for relationship to study drug (p. 111)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:45 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Tam-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:45 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Vogel-2002">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:44 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Weiner-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:42 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Yount-2004">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-06-08 01:47:09 +1000" MODIFIED_BY="Maria X Rojas" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-08 01:47:09 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Abarca-2009">
<DESCRIPTION>
<P>This study was sponsored by MedImmune. One of MedImmune employees assisted with data analysis and several study authors received research grants or were employees/consultants of MedImmune (p. 267, 272)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:09 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Bentley-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:09 +1000" MODIFIED_BY="Tea Andabaka" RESULT="NO" STUDY_ID="STD-Carbonell_x002d_Estrany-2010">
<DESCRIPTION>
<P>This study was sponsored by MedImmune. All authors were compensated by or employees of MedImmune (p. e35).</P>
<P>Differences in laboratory methods used to test for the presence of RSV in this study were cited by the FDA as a significant methodological concern which may have favoured motavizumab over palivizumab in this study. This was cited as one of the reasons for rejecting the licensing approval for motavizumab</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:08 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chirico-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:07 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chiroli-2005">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:06 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-ElHassan-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:06 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Embleton-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-28 05:04:18 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Feltes-2003">
<DESCRIPTION>
<P>This study was supported by MedImmune, several MedImmune employees contributed to this study (p. 532, 538)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-28 05:04:46 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Feltes-2011">
<DESCRIPTION>
<P>This study was sponsored by MedImmune (p. 186). MedImmune was involved in study design; collection, analysis and interpretation of data; and writing of the manuscript. Several authors are employees/consultants/speakers of MedImmune</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-28 05:05:27 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Fernandez-2010">
<DESCRIPTION>
<P>This study was sponsored by MedImmune (p. 12). All authors received research grants/funding or were employees of MedImmune. MedImmune was involved in study design, and analysis and interpretation of data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:05 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Altes-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:04 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hampp-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:03 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:02 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hascoet-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-28 05:06:20 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-IMpact_x002d_RSV-1998">
<DESCRIPTION>
<P>Employees of MedImmune contributed to the study and assisted in preparation of the manuscript (p. 537)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Joffe-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Kang-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:35:00 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lanctot-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:59 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:59 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:58 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lofland-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:57 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Mayen_x002d_Herrera-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:56 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Neovius-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:56 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:55 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009a">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:54 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009b">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:53 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:52 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Ravasio-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:51 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Raya-Ortega-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:51 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:50 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:49 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Rietveld-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:48 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Roeckl_x002d_Wiedmann-2003">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:47 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Salinas_x002d_Escudero-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:46 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Smart-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-28 05:08:59 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Subramanian-1998">
<DESCRIPTION>
<P>Several authors of this study are MedImmune employees (p. 110)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:45 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Tam-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:45 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Vogel-2002">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:44 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Weiner-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-19 16:34:42 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Yount-2004">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Maria X Rojas" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-08 01:47:09 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Abarca-2009">
<DESCRIPTION>
<P>Treatment assignments were double-blind. Does not state how the treatments were delivered. Only the independent monitor and the study pharmacist had access to information that identified a patient's treatment allocation (p. 268)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:35:09 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Bentley-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-09-28 05:03:30 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Carbonell_x002d_Estrany-2010">
<DESCRIPTION>
<P>Injections were provided in identical vials in coded kits. All personnel at all sites were blind to study treatment (p. e36)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:35:08 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chirico-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:35:07 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chiroli-2005">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:35:06 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-ElHassan-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:35:05 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Embleton-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-09-28 05:04:20 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Feltes-2003">
<DESCRIPTION>
<P>Palivizumab and placebo were identically appearing, supplied in coded vials and dispensed in a syringe that did not identify the contents (p. 533)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-09-28 05:04:48 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Feltes-2011">
<DESCRIPTION>
<P>Motavizumab and palivizumab were delivered in identical vials in coded kits. All study personnel were blinded to treatment assignments (p. 187)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-09-28 05:05:28 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Fernandez-2010">
<DESCRIPTION>
<P>Details on blinding of participants and personnel are not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:35:05 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Altes-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:35:04 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hampp-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:35:03 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:35:02 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hascoet-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-12 08:29:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-IMpact_x002d_RSV-1998">
<DESCRIPTION>
<P>Participants were centrally randomized to receive palivizumab or an equal volume of identically appearing placebo (p. 532)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Joffe-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Kang-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:35:00 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lanctot-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:59 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:59 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:58 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lofland-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:57 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Mayen_x002d_Herrera-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:56 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Neovius-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:56 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:55 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009a">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:54 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009b">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:53 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:52 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Ravasio-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:51 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Raya-Ortega-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:51 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:50 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:49 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Rietveld-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:48 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Roeckl_x002d_Wiedmann-2003">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:47 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Salinas_x002d_Escudero-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:46 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Smart-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-08 01:48:13 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Subramanian-1998">
<DESCRIPTION>
<P>Study drug assignment and the investigators were blinded. Study drugs were dispensed from the pharmacy in a syringe enclosed in a plastic bag that did not contain the drug assignment on the label. The safety monitoring committee had the power to unblind the study group assignment if needed, but didn't do it during their review (p. 111, 112)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:45 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Tam-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:45 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Vogel-2002">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:44 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Weiner-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-19 16:34:42 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Yount-2004">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-06-12 08:29:42 +1000" MODIFIED_BY="Maria X Rojas" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-09-28 05:02:55 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Abarca-2009">
<DESCRIPTION>
<P>This is an adverse events study, where the first phase was open-label. Details of monitoring regime are reported for season 1 and season 2, though it is unclear whether assessors had knowledge of which intervention participants received</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:35:09 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Bentley-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-09-28 05:03:31 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Carbonell_x002d_Estrany-2010">
<DESCRIPTION>
<P>All personnel at all sites were blind to study treatment (p. e36)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:35:08 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chirico-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:35:07 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Chiroli-2005">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:35:06 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-ElHassan-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:35:05 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Embleton-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-12 08:29:42 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Feltes-2003">
<DESCRIPTION>
<P>This was a double-blind study with good randomization protocols. Adverse events were categorised, and graded by a blinded investigator for potential relation to study drug (p. 534)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-09-28 05:04:50 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Feltes-2011">
<DESCRIPTION>
<P>Study was not powered as a stand-alone efficacy study, though it reports efficacy data (p. 189). The authors note that despite this, their results were consistent with previous studies, thus the actual impact of the study being underpowered may be minimal</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-09-28 05:05:29 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Fernandez-2010">
<DESCRIPTION>
<P>Details on blinding of participants and personnel are not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:35:05 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Altes-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:35:04 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hampp-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:35:03 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:35:02 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Hascoet-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-08 01:47:52 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-IMpact_x002d_RSV-1998">
<DESCRIPTION>
<P>Adverse events were judged by the blinded investigator to be related or not to the study drug (p. 534)</P>
<P>LRI score was completed on all patients, regardless and all patients were followed for 150 days (30 days after the last immunisation), regardless of the amount of study drug they received (p. 532)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Joffe-1999">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:35:01 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Kang-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:35:00 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lanctot-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:59 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:59 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lazaro-y-de-Mercado-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:58 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Lofland-2000">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:57 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Mayen_x002d_Herrera-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:56 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Neovius-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:55 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2007">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:55 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009a">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:54 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2009b">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:53 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Nuijten-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:52 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Ravasio-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:51 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Raya-Ortega-2006">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:50 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2008">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:50 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Resch-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:49 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Rietveld-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:48 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Roeckl_x002d_Wiedmann-2003">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:47 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Salinas_x002d_Escudero-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:46 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Smart-2010">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-08 01:48:13 +1000" MODIFIED_BY="Tea Andabaka" RESULT="YES" STUDY_ID="STD-Subramanian-1998">
<DESCRIPTION>
<P>Outcomes were assessed by the blinded investigator. The treatment assignment was unblinded by the medical monitor for 1 child who died who was assigned to the placebo group (p. 111, 112)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:45 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Tam-2009">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:44 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Vogel-2002">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:44 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:43 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Weiner-2012">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-19 16:34:42 +1000" MODIFIED_BY="Tea Andabaka" RESULT="UNKNOWN" STUDY_ID="STD-Yount-2004">
<DESCRIPTION>
<P>See <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> for assessment of risk of bias in economic evaluations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-03-27 00:23:30 +1000" MODIFIED_BY="Maria X Rojas">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-09-03 02:49:47 +1000" MODIFIED_BY="Grade Profiler">Palivizumab compared to placebo for high risk of severe respiratory syncytial virus infection</TITLE>
<TABLE COLS="7" ROWS="32">
<TR>
<TH COLSPAN="7">
<P>
<B>Palivizumab compared to placebo for </B>high risk<B> of severe respiratory syncytial virus infection</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients at high risk of severe respiratory syncytial virus infection<BR/>
<B>Settings: </B>hospital<BR/>
<B>Intervention:</B> palivizumab<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Palivizumab</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Hospitalisation for RSV infection</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.49 </B>
<BR/>(0.37 to 0.64)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2831<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>101 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
<BR/>(37 to 65)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>49 per 1000</B>
<BR/>(37 to 64)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.69 </B>
<BR/>(0.42 to 1.15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2831<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>28 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>19 per 1000</B>
<BR/>(12 to 32)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>42 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>29 per 1000</B>
<BR/>(18 to 48)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Total RSV hospital days per 100 children</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2789<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Data on standard deviations missing; meta-analysis not possible.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Admission to ICU</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.5 </B>
<BR/>(0.3 to 0.81)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2789<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 1000</B>
<BR/>(10 to 28)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 1000</B>
<BR/>(10 to 28)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mechanical ventilation for RSV infection</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.1 </B>
<BR/>(0.2 to 6.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2789<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>13 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>14 per 1000</B>
<BR/>(3 to 80)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>12 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>13 per 1000</B>
<BR/>(2 to 73)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Supplemental oxygen therapy for RSV infection</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Numbers not reported in any of the three studies</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Number of children reporting any SAE</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.88 </B>
<BR/>(0.8 to 0.96)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1287<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>631 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>555 per 1000</B>
<BR/>(505 to 606)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>631 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>555 per 1000</B>
<BR/>(505 to 606)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>ICU:</B> intensive care unit; <B>RR:</B> risk ratio; <B>RSV:</B> respiratory syncytial virus; <B>SAE:</B> serious adverse event</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>No statistical significance in results and very wide 95% CIs around estimates of effect.<BR/>
<SUP>2</SUP>Data on standard deviations missing in both studies.<BR/>
<SUP>3</SUP>Substantial heterogeneity across the two studies; point estimates of effect on opposite sides.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-03-15 23:28:26 +1000" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2012-09-03 02:50:55 +1000" MODIFIED_BY="Grade Profiler">Palivizumab compared to motavizumab for high risk of severe respiratory syncytial virus infection</TITLE>
<TABLE COLS="7" ROWS="32">
<TR>
<TH COLSPAN="7">
<P>
<B>Palivizumab compared to motavizumab for </B>high risk<B> of severe respiratory syncytial virus infection</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients at high risk of severe respiratory syncytial virus infection<BR/>
<B>Settings: </B>hospital<BR/>
<B>Intervention:</B> palivizumab<BR/>
<B>Comparison: </B>motavizumab</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Motavizumab</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Palivizumab</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Hospitalisation for RSV infection</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.36 </B>
<BR/>(0.97 to 1.9)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>7870<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 1000</B>
<BR/>(14 to 28)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>23 per 1000</B>
<BR/>(16 to 32)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.74 </B>
<BR/>(0.38 to 1.43)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>8265<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>5 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 1000</B>
<BR/>(2 to 7)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>11 per 1000</B>
<BR/>(6 to 21)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Total RSV hospital days per 100 children</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean total RSV hospital days per 100 children in the intervention groups was<BR/>
<B>24.95 higher</B>
<BR/>(21.59 lower to 71.49 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>7870<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Admission to ICU</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.68 </B>
<BR/>(0.89 to 3.19)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>7870<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>6 per 1000</B>
<BR/>(3 to 12)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>6 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
<BR/>(5 to 19)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mechanical ventilation for RSV infection</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 3.79 </B>
<BR/>(1.26 to 11.42)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>7870<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 1000</B>
<BR/>(1 to 12)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>2 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>8 per 1000</B>
<BR/>(3 to 23)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Supplemental oxygen therapy for RSV infection</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.49 </B>
<BR/>(0.98 to 2.26)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>7870<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>9 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>14 per 1000</B>
<BR/>(9 to 21)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>12 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 1000</B>
<BR/>(12 to 27)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Number of children reporting any SAE</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.04 </B>
<BR/>(0.96 to 1.13)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>8238<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>191 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>199 per 1000</B>
<BR/>(183 to 216)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>119 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>124 per 1000</B>
<BR/>(114 to 134)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval;<B> ICU:</B> intensive care unit; <B>RR:</B> risk ratio; <B>RSV</B>
<B>: </B>respiratory syncytial virus; <B>SAE</B>
<B>:</B> serious adverse event</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>No statistical significance in results and very wide 95% CI around pooled estimate of effect.<BR/>
<SUP>2</SUP>The 95% CI includes no effect and confidence limits are very wide.<BR/>
<SUP>3</SUP>Data on standard deviations missing in <LINK REF="STD-Carbonell_x002d_Estrany-2010" TYPE="STUDY">Carbonell-Estrany 2010</LINK>.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-06-12 08:29:48 +1000" MODIFIED_BY="Maria X Rojas">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-06-12 08:29:47 +1000" MODIFIED_BY="Tea Andabaka" NO="1">
<TITLE MODIFIED="2013-03-27 00:22:15 +1000" MODIFIED_BY="Tea Andabaka">Characteristics of included economic evaluations</TITLE>
<TABLE COLS="9" ROWS="35">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Study ID</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Country</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Study design</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Population</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Economic outcomes</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Intervention<SUP>1</SUP> (doses)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Perspective</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Price year</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Time horizon</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Bentley-2011" TYPE="STUDY">Bentley 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UK</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Infants with CLD, preterm infants &lt; 29 wGA, 29 to 32 wGA, and 33 to 35 wGA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chirico-2009" TYPE="STUDY">Chirico 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Italy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CUA</P>
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at &lt; 33 wGA, and 33 to 35 wGA, with and without BPD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per QALY and LYG)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2007 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chiroli-2005" TYPE="STUDY">Chiroli 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Italy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Children with haemodynamically significant CHD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2004 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 year</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-ElHassan-2006" TYPE="STUDY">ElHassan 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at 26 to 32 wGA without CLD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2002 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 years</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UK</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at &lt; 32 wGA without BPD and with BPD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per hospitalization averted)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2005 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 year</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Garcia_x002d_Altes-2010" TYPE="STUDY">Garcia-Altes 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Spain</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm children &lt; 2 years old with and without CLD, children &lt; 2 years old with CLD, and children &lt; 5 years old with CHD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per hospitalization avoided and LYG)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (3 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2008 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 year</P>
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Children &lt; 2 years old with different combinations of risk factors (8 subgroups)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per hospitalization avoided)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (6 doses, 50 to 200 mg vials used)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2010 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Harris-2011" TYPE="STUDY">Harris 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Canada</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Children &lt; 2 years old, born at 36 wGA, with haemodynamically significant CHD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per 1 day of hospitalization prevented)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (4.5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2007 CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hascoet-2008" TYPE="STUDY">Hascoet 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>France</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at &#8804; 32 wGA with BPD or CHD (2 subgroups)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and hospitalization averted)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (4.87 and 4.93 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Joffe-1999" TYPE="STUDY">Joffe 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants discharged within 12 months prior to RSV season (8 risk groups)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per hospitalization averted and LYG)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (4 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1995 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Kang-2009" TYPE="STUDY">Kang 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Korea</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Children with CHD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5 doses)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>KW</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Canada</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at 32 to 35 wGA without CLD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5.39 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2007 CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lazaro-y-de-Mercado-2006" TYPE="STUDY">Lazaro y de Mercado 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Spain</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at 32 to 35 wGA with 2 or more risk factors</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (3.88 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lazaro-y-de-Mercado-2007" TYPE="STUDY">Lazaro y de Mercado 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Spain</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at &#8804; 35 wGA and 6 months of age or younger, or &#8804; 24 months old and with BPD requiring treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (4.1 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lofland-2000" TYPE="STUDY">Lofland 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at &#8804; 35 wGA and children with BPD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per hospitalization avoided)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1999 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 year</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Mayen_x002d_Herrera-2011" TYPE="STUDY">Mayen-Herrera 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mexico</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants &lt; 29 wGA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MXN</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Neovius-2011" TYPE="STUDY">Neovius 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sweden</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CUA</P>
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at &lt; 29 wGA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per QALY and LYG)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2009 SEK</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UK</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at &#8804; 35 wGA, children with BPD (&#8804; 2 years) and children with CHD (&#8804; 2 years)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (4.87 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2003 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2009a" TYPE="STUDY">Nuijten 2009a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Netherlands</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CUA</P>
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants, preterm children, children with BPD and children with CHD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per QALY and LYG)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (4.87 and 4.93 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2009b" TYPE="STUDY">Nuijten 2009b</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Germany</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CUA</P>
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Children with haemodynamically significant CHD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per QALY and LYG)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (4.93 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2010" TYPE="STUDY">Nuijten 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Spain</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Children born at &#8804; 32 wGA who were &lt; 6 months old at the onset of RSV season</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (4.1 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ravasio-2006" TYPE="STUDY">Ravasio 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Italy</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants &lt; 33 wGA, and 33 to 35 wGA, with and without BPD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2005 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 years</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Raya-Ortega-2006" TYPE="STUDY">Raya Ortega 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Spain</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at 32 to 35 wGA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per hospitalization avoided)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (3.8 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 year</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Austria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at &#8804; 35 wGA, children with BPD and children with CHD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (4.87 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Austria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants &#8804; 36 wGA, children with BPD and children with CHD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (3.98 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2010 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rietveld-2010" TYPE="STUDY">Rietveld 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Netherlands</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants &#8804; 28 wGA, birth weight &#8804; 2500 g, having BPD, aged 0 months at the beginning of season (October)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cost per hospitalization averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2000 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 year</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Germany</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants of male gender born at &#8804; 35 wGA, with siblings in day care, discharge between October and December, and with or without CLD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cost per hospitalization averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (4 to 5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 year</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Salinas_x002d_Escudero-2012" TYPE="STUDY">Salinas-Escudero 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mexico</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants &lt; 29 wGA or 29 to 32 wGA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (4.1 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2009 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18 years</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Smart-2010" TYPE="STUDY">Smart 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Canada</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at 32 to 35 wGA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5.39 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2010 CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tam-2009" TYPE="STUDY">Tam 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Canada</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Infants &lt; 1 year of age from Baffin Island</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2007 CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>New Zealand</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at &lt; 32 wGA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cost per hospitalization averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (3 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2000 NZD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>UK</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants born at &#8804; 35 wGA or children with CLD and CHD; 4 subgroup analyses: CLD, CLD/CHD, acyanotic CHD, and cyanotic CHD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2006 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Weiner-2012" TYPE="STUDY">Weiner 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CUA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterm infants &lt; 32 wGA and &#8804; 6 months of age, without CLD or CHD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (&#8804; 5 doses at 15 mg/kg, depending on month of birth)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2010 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Yount-2004" TYPE="STUDY">Yount 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CUA</P>
<P>CEA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Children with CHD &#8804; 2 years old</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ICER</P>
<P>(per LYG and QALY)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Palivizumab (5 doses at 15 mg/kg)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal</P>
<P>Payer's</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2002 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lifetime</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>BPD = bronchopulmonary dysplasia<BR/>CAD = Canadian dollar<BR/>CEA = cost-effectiveness analysis<BR/>CHD = congenital heart disease<BR/>CLD = chronic lung disease<BR/>CUA = cost-utility analysis<BR/>EUR = Euro<BR/>GBP = Great British pound<BR/>ICER = incremental cost-effectiveness ratio<BR/>KW = Korean won<BR/>LYG = life-year gained<BR/>MXN = Mexican peso<BR/>NZD = New Zealand dollar<BR/>QALY = quality-adjusted life-year<BR/>RSV = respiratory syncytial virus<BR/>SEK = Swedish krona<BR/>UK = United Kingdom<BR/>USA = United States of America<BR/>USD = United States dollar<BR/>wGA = weeks of gestational age<BR/>
</P>
<P>
<SUP>1</SUP>Palivizumab prophylaxis was compared to no prophylaxis in all included economic evaluations.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-06-12 08:29:48 +1000" MODIFIED_BY="Tea Andabaka" NO="2">
<TITLE MODIFIED="2013-03-27 00:23:20 +1000" MODIFIED_BY="Tea Andabaka">Economic impact of immunoprophylaxis given at neonatal period or within the first 6 months of life</TITLE>
<TABLE COLS="7" ROWS="42">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Study ID</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Funded by industry</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Incremental effectiveness</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Incremental cost</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Discount rate (%)</B>
</P>
<P>
<B>Price year</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>ICER reported</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>ICER present value at 2011 EUR</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Infants born at </I>
</B>&#8804; <B>
<I>35 weeks of gestation without other comorbidity</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Payer's perspective</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chirico-2009" TYPE="STUDY">Chirico 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.088 LYG</P>
<P>0.159 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 1376.50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2007 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 33 wGA:</P>
<P>EUR 17,885.86/LYG</P>
<P>EUR 9380.00/QALY</P>
<P>Preterms 33 to 35 wGA:</P>
<P>EUR 28,417.08/LYG</P>
<P>EUR 14,937.32/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 33 wGA:</P>
<P>EUR 19,433.61/LYG         </P>
<P>EUR 10,191.70/QALY</P>
<P>Preterms 33 to 35 wGA:</P>
<P>EUR 30,876.15/LYG         </P>
<P>EUR 16,229.92/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.29% absolute risk reduction</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Any studied indication:</P>
<P>USD 4805</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2010 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USD 302,103/hosp. averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 252,885.00/hosp. averted</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.137 LYG</P>
<P>0.198 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs including asthma:</P>
<P>CAD 4140</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2007 CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs including asthma:</P>
<P>CAD 30,230/LYG</P>
<P>CAD 20,924/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs including asthma:</P>
<P>EUR 22,738.62/LYG      </P>
<P>EUR 15,738.76/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.14 LYG</P>
<P>0.19 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GBP 2858</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.5%</P>
<P>2003 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GBP 20,344/LYG</P>
<P>GBP 14,883/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 35,724.66/LYG</P>
<P>EUR 26,134.98/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2010" TYPE="STUDY">Nuijten 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.33 LYL</P>
<P>0.49 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs:</P>
<P>EUR 6321</P>
<P>Direct costs with sequelae:</P>
<P>EUR 3205</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs:</P>
<P>EUR 18,872/LYL</P>
<P>EUR 12,814/QALY</P>
<P>Direct costs with sequelae:</P>
<P>EUR 9570/LYL</P>
<P>EUR 6498/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs:</P>
<P>EUR 21,147.66/LYL</P>
<P>EUR 14,359.16/QALY</P>
<P>Direct costs with sequelae:</P>
<P>EUR 10,723.99/LYL</P>
<P>EUR 7281.55/QALY </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ravasio-2006" TYPE="STUDY">Ravasio 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 33 wGA:</P>
<P>0.080 LYG</P>
<P>0.150 QALY</P>
<P>Preterms 33 to 35 wGA:</P>
<P>0.080 LYG</P>
<P>0.151 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 33 wGA:</P>
<P>EUR 1873.80</P>
<P>Preterms 33 to 35 wGA:</P>
<P>EUR 2834.99</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2005 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 33 wGA:</P>
<P>EUR 23,413.52/LYG<BR/>
</P>
<P>EUR 12,452.72/QALY</P>
<P>Preterms 33 to 35 wGA:</P>
<P>EUR 35,255.90/LYG</P>
<P>EUR 18,790.96/QALY<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 33 wGA:</P>
<P>EUR 26,439.11/LYG</P>
<P>EUR 14,061.91/QALY</P>
<P>Preterms 33 to 35 wGA:</P>
<P>EUR 39,811.81/LYG</P>
<P>EUR 21,219.20/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Raya-Ortega-2006" TYPE="STUDY">Raya Ortega 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Hospitalisation avoided:</P>
<P>42 cases</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 2,860,367</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 68,104/hosp. avoided</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 76,316.25/hosp. avoided</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.10 LYG</P>
<P>0.14 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without asthma:</P>
<P>EUR 2955</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without asthma:</P>
<P>EUR 29,558/LYG</P>
<P>EUR 20,704/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without asthma:</P>
<P>EUR 32,938.16/LYG</P>
<P>EUR 23,071.65/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &#8804; 36 wGA:</P>
<P>0.09 LYG</P>
<P>0.13 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without wheezing:</P>
<P>EUR  3146</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2010 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without wheezing:</P>
<P>EUR 34,956/LYG</P>
<P>EUR 26,212/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without wheezing:</P>
<P>EUR 36,097.98/LYG</P>
<P>EUR 27,068.32/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Salinas_x002d_Escudero-2012" TYPE="STUDY">Salinas-Escudero 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 29 wGA and 29 to 32 wGA:</P>
<P>0.12 LYG</P>
<P>0.16 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 29 wGA:</P>
<P>USD 2871</P>
<P>Preterms 29 to 32 wGA:</P>
<P>USD 3400</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2009 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 29 wGA:</P>
<P>USD 25,029/LYG</P>
<P>USD 17,532/QALY</P>
<P>Preterms 29 to 32 wGA:</P>
<P>USD 29,637/LYG</P>
<P>USD 20,760/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 29 wGA:</P>
<P>EUR 19,425.36/LYG</P>
<P>EUR 13,606.84/QALY</P>
<P>Preterms 29 to 32 wGA:</P>
<P>EUR 23,001.70/LYG</P>
<P>EUR 16,112.13/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Smart-2010" TYPE="STUDY">Smart 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.137 LYG</P>
<P>0.198 QALY</P>
<P>(from <LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK>) </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2010 CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs including asthma:</P>
<P>CAD 20,814/QALY</P>
<P>Direct costs without asthma:</P>
<P>CAD 31,360/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs including asthma:    </P>
<P>EUR 16,981.12/QALY</P>
<P>Direct costs without asthma:</P>
<P>EUR 25,585.08/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.0072 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GBP 3315</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.5%</P>
<P>2006 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>GBP 78,000/QALY to</P>
<P>GBP 965,000/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>EUR 133,477.60/QALY to</P>
<P>EUR 1,651,357.46/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Societal perspective</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-ElHassan-2006" TYPE="STUDY">ElHassan 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range (min to max):</P>
<P>0.0018 QALY (32 wGA) to</P>
<P>0.0060 QALY (26 wGA)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms 29 to 30 wGA:</P>
<P>USD 2449</P>
<P>Preterms 32 wGA:</P>
<P>USD 6330</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2002 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms 29 to 30 wGA:</P>
<P>USD 675,780/QALY</P>
<P>Preterms 32 wGA:</P>
<P>USD 1,855,000/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms 29 to 30 wGA:</P>
<P>EUR 894,362.54/QALY</P>
<P>Preterms 32 wGA:</P>
<P>EUR 2,455,003.86/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 32 wGA:</P>
<P>GBP 2550</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2005 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 32 wGA:</P>
<P>GBP 40,400/hosp. averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 32 wGA:      </P>
<P>EUR 72,780.17/hosp. averted</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.137 LYG</P>
<P>0.198 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct and indirect including asthma:</P>
<P>CAD 2578</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2007 CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct and indirect including asthma:</P>
<P>CAD 18,825/LYG</P>
<P>CAD 13,029/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct and indirect including asthma:</P>
<P>EUR 14,159.92/LYG     </P>
<P>EUR 9800.25/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Neovius-2011" TYPE="STUDY">Neovius 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.102 QALY</P>
<P>0.073 LYG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SEK 20,020</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2009 SEK</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SEK 275,907/LYG</P>
<P>SEK 195,420/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 26,448.33/LYG</P>
<P>EUR 18,732.88/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2010" TYPE="STUDY">Nuijten 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.33 LYL</P>
<P>0.49 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Indirect costs:</P>
<P>- EUR 3601</P>
<P>Total costs:</P>
<P>- EUR 396</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Total costs:</P>
<P>Dominant</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Total (direct and indirect) costs:</P>
<P>Dominant</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Hospitalisation averted:</P>
<P>125 cases</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 3,161,000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2002 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 25,288/hosp. averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 29,199.27/hosp. averted</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Hospitalisation averted:</P>
<P>29 infants</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NZD 1,090,000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2000 NZD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NZD 37,000/hosp. averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 24,617.27/hosp. averted</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Weiner-2012" TYPE="STUDY">Weiner 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Preterms &lt; 32 wGA:</P>
<P>0.046 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Total costs:</P>
<P> - USD 2339</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2010 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dominant</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dominant</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Infants with bronchopulmonary dysplasia (BPD) or chronic lung disease (CLD)</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Payer's perspective</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chirico-2009" TYPE="STUDY">Chirico 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.088 LYG</P>
<P>0.159 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 1376.50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2007 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 4332.29/LYG</P>
<P>EUR 2731.81/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 4707.18/LYG</P>
<P>EUR 2968.21/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lofland-2000" TYPE="STUDY">Lofland 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5% lower incidence of hospitalization</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>1999 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USD 79,706/hosp. averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 104,456.40/hosp. averted</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ravasio-2006" TYPE="STUDY">Ravasio 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.122 LYG<BR/>
</P>
<P>0.231 QALY<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 677.36</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2005 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 5537.03/LYG</P>
<P>EUR 2937.84/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 6252.55/LYG</P>
<P>EUR 3317.48/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.052 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GBP 3315</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.5%</P>
<P>2006 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>GBP 10,000/QALY to</P>
<P>GBP 66,000/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>EUR 17,112.51/QALY to</P>
<P>EUR 112,942.58/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Societal perspective</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GBP 2663</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2005 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GBP 54,800/hosp. averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 98,721.62/hosp. averted</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hascoet-2008" TYPE="STUDY">Hascoet 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.18 LYG</P>
<P>Hospitalisations: not clear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 4905</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 27,255/LYG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 29,511.31/LYG</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2009a" TYPE="STUDY">Nuijten 2009a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.42 QALY</P>
<P>0.37 LYG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs including asthma:</P>
<P>EUR 5369</P>
<P>Direct and indirect including asthma:</P>
<P>EUR 3007</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs including asthma:</P>
<P>EUR 12,728/QALY</P>
<P>EUR 14,701/LYG</P>
<P>Direct and indirect including asthma:</P>
<P>EUR 7130/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs including asthma:</P>
<P>EUR 13,901.85/QALY</P>
<P>EUR 16,056.81/LYG</P>
<P>Direct and indirect including asthma:</P>
<P>EUR 7787.57/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rietveld-2010" TYPE="STUDY">Rietveld 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Hospitalisation risk difference:</P>
<P>0.1 to 4.2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>EUR 550 to EUR 955</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2000 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>EUR 13,190/hosp. averted to</P>
<P>EUR 833,695/hosp. averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>EUR 16,481.18/hosp. averted to</P>
<P>EUR 1,041,719.41/hosp. averted</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Hospitalisation averted:</P>
<P>296 cases</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 1,965,000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2002 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 6639/hosp. averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 7665.85/hosp. averted</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Infants with congenital heart disease (CHD)</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Payer's perspective</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyanotic CHD:</P>
<P>0.0670 QALY</P>
<P>Cyanotic CHD:</P>
<P>0.0226 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyanotic CHD:</P>
<P>GBP 3285</P>
<P>Cyanotic CHD:</P>
<P>3609</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.5%</P>
<P>2006 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyanotic CHD (range):</P>
<P>GBP 100,000/QALY to</P>
<P>GBP 266,000/QALY</P>
<P>Cyanotic CHD (range):</P>
<P>GBP 230,000/QALY to</P>
<P>GBP 596,000/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyanotic CHD (range):</P>
<P>EUR 171,125.13/QALY to</P>
<P>EUR 455,192.83/QALY</P>
<P>Cyanotic CHD (range):</P>
<P>EUR 393,587.79/QALY to</P>
<P>EUR 1,019,905.75/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Societal perspective</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hascoet-2008" TYPE="STUDY">Hascoet 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.26 LYG</P>
<P>Hospitalisations: not clear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 5405</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 20,788/LYG</P>
<P>Hospitalisations: not clear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 22,508.93/LYG</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2009a" TYPE="STUDY">Nuijten 2009a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.39 QALY</P>
<P>1.36 LYG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs including asthma:</P>
<P>EUR 5926</P>
<P>Direct and indirect including asthma:</P>
<P>EUR 2670</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs including asthma:</P>
<P>EUR 4256/QALY</P>
<P>EUR 4353/LYG</P>
<P>Direct and indirect including asthma:</P>
<P>Dominant</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs including asthma:</P>
<P>EUR 4648.51/QALY</P>
<P>EUR 4754.46/LYG</P>
<P>Direct and indirect including asthma:</P>
<P>Dominant</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CAD = Canadian dollar<BR/>EUR = Euro<BR/>ICER = incremental cost-effectiveness ratio<BR/>GBP = Great British pound<BR/>hosp. = hospitalization<BR/>LYL = life-year lost<BR/>LYG = life-year gained<BR/>NA = not applied<BR/>NZD = New Zealand dollar<BR/>QALY = quality-adjusted life-year<BR/>SEK = Swedish krona<BR/>wGA = weeks of gestational age<BR/>USD = United States dollar</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2013-06-12 08:29:48 +1000" MODIFIED_BY="Tea Andabaka" NO="3">
<TITLE MODIFIED="2013-03-27 00:23:26 +1000" MODIFIED_BY="Tea Andabaka">Economic impact of immunoprophylaxis given to children aged 6 months and older</TITLE>
<TABLE COLS="7" ROWS="27">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Study ID</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Funded by industry</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Incremental effectiveness</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Incremental cost</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Discount rate (%)</B>
</P>
<P>
<B>Price year</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>ICER reported</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>ICER present value at 2011 EUR</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Children born at </I>
</B>&#8804; <B>
<I>35 weeks of gestation without other comorbidity</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Payer's perspective</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tam-2009" TYPE="STUDY">Tam 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Children living in rural and urban areas (all areas):</P>
<P>0.13 QALY</P>
<P>Children living in high-risk areas:</P>
<P>0.36 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs:</P>
<P>All areas: CAD 5057</P>
<P>High-risk areas: CAD 119</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2007 CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs:</P>
<P>All areas:</P>
<P>CAD 39,435/QALY</P>
<P>High-risk areas:</P>
<P>CAD 334/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs:</P>
<P>All areas:</P>
<P>EUR 29,662.50/QALY</P>
<P>High-risk areas:</P>
<P>EUR 251.23/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.0072 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GBP 3263</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.5%</P>
<P>2006 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>GBP 383,000/QALY to</P>
<P>GBP 54,436,000/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>EUR 655,409.23/QALY to</P>
<P>EUR 93,153,673.29/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Societal perspective</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tam-2009" TYPE="STUDY">Tam 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Children living in rural and urban areas (all areas):</P>
<P>0.13 QALY</P>
<P>Children living in high-risk areas:</P>
<P>0.36 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct and indirect costs:</P>
<P>All areas: CAD 4753</P>
<P>High-risk areas: - CAD 730</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2007 CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct and indirect costs:</P>
<P>All areas:</P>
<P>CAD 37,070/QALY</P>
<P>High-risk areas:</P>
<P>Dominant</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct and indirect costs:</P>
<P>All areas:</P>
<P>EUR 27,883.58/QALY</P>
<P>High-risk areas:</P>
<P>Dominant</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Children with congenital heart disease (CHD)</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Payer's perspective</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chiroli-2005" TYPE="STUDY">Chiroli 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.5 LYG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 3394.16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2004 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 7186/LYG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 8276.82/LYG</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.65% absolute risk reduction</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Any studied indication:</P>
<P>USD 4805</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2010 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USD 823,868/hosp. averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 689,645.11/hosp. averted</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cyanotic CHD:</P>
<P>0.25 LYG</P>
<P>0.26 QALY</P>
<P>Acyanotic CHD:</P>
<P>0.74 LYG</P>
<P>0.78 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cyanotic CHD:</P>
<P>GBP 3904</P>
<P>Acyanotic CHD:</P>
<P>GBP 2733</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.5%</P>
<P>2003 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cyanotic CHD:</P>
<P>GBP 15,575/LYG</P>
<P>GBP 14,816/QALY</P>
<P>Acyanotic CHD:</P>
<P>GBP 3688/LYG</P>
<P>GBP 3512/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cyanotic CHD:</P>
<P>EUR 27,350.15/LYG</P>
<P>EUR 26,017.33/QALY</P>
<P>Acyanotic CHD:</P>
<P>EUR 6476.24/LYG</P>
<P>EUR 6167.17/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2009b" TYPE="STUDY">Nuijten 2009b</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.38 QALY</P>
<P>0.36 LYG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's perspective:</P>
<P>EUR 6364</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's perspective:</P>
<P>EUR 16,673/QALY</P>
<P>EUR 17,700/LYG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Payer's perspective:</P>
<P>EUR 18,166.72/QALY</P>
<P>EUR 19,285.73/LYG</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.36 LYG</P>
<P>0.38 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without asthma:</P>
<P>EUR 4349</P>
<P>Direct costs including asthma:</P>
<P>EUR 3724</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without asthma:</P>
<P>EUR 12,091/LYG</P>
<P>EUR 11,390/QALY</P>
<P>Direct costs including asthma:</P>
<P>EUR 10,355/LYG</P>
<P>EUR 9754/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without asthma:</P>
<P>EUR 13,473.69/LYG</P>
<P>EUR 12,692.53/QALY</P>
<P>Direct costs including asthma:</P>
<P>EUR 11,539.17/LYG</P>
<P>EUR 10,869.44/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.36 LYG</P>
<P>0.38 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without wheezing:</P>
<P>EUR 3224</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2010 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without wheezing:</P>
<P>EUR 8956/LYG</P>
<P>EUR 8484/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without wheezing:</P>
<P>EUR 9248.58/LYG</P>
<P>EUR 8761.16/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyanotic CHD:</P>
<P>0.0670 QALY</P>
<P>Cyanotic CHD:</P>
<P>0.0226 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyanotic CHD:</P>
<P>GBP 3285</P>
<P>Cyanotic CHD:</P>
<P>GBP 3609</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.5%</P>
<P>2006 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyanotic CHD (range):</P>
<P>GBP 523,000/QALY to</P>
<P>GBP 14,545,000/QALY</P>
<P>Cyanotic CHD (range):</P>
<P>GBP 1,127,000/QALY to</P>
<P>GBP 30,203,000/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyanotic CHD (range):</P>
<P>EUR 894,984.41/QALY to</P>
<P>EUR 24,890,149.50/QALY</P>
<P>Cyanotic CHD (range):</P>
<P>EUR 1,928,580.16/QALY to</P>
<P>EUR 51,684,921.64/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Yount-2004" TYPE="STUDY">Yount 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>203.33 LYG</P>
<P>QALY: not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USD 20,415,753</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2002 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USD 100,338/LYG</P>
<P>USD 114,337/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 132,792.55/LYG   </P>
<P>EUR 151,319.56/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Societal perspective</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Harris-2011" TYPE="STUDY">Harris 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 day of hospitalization averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CAD 8292</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2007 CAD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CAD 15,514/day of hosp. averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 11,669.43/day of hosp. averted</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2009b" TYPE="STUDY">Nuijten 2009b</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.38 QALY</P>
<P>0.36 LYG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal perspective:</P>
<P>EUR 3637</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal perspective:</P>
<P>EUR 9529/QALY</P>
<P>EUR 10,116/LYG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Societal perspective:</P>
<P>EUR 10,382.69/QALY</P>
<P>EUR 11,022.28/LYG</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Children with bronchopulmonary dysplasia (BPD) or chronic lung disease (CLD)</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>
<I>Payer's perspective</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.03% absolute risk reduction</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Any studied indication:</P>
<P>USD 4805</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA</P>
<P>2010 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USD 1,322,422/hosp. averted</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 1,106,975.71/hosp. averted</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.11 LYG</P>
<P>0.15 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GBP 3122</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.5%</P>
<P>2003 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GBP 28,569/LYG</P>
<P>GBP 20,953/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 50,168.00/LYG</P>
<P>EUR 36,794.08/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.08 LYG</P>
<P>0.11 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without asthma:</P>
<P>EUR 3527</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without asthma:</P>
<P>EUR 45,369/LYG</P>
<P>EUR 31,867/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without asthma:</P>
<P>EUR 50,557.26/LYG</P>
<P>EUR 35,511.21/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.09 LYG</P>
<P>0.13 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without wheezing:</P>
<P>EUR 3205</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5%</P>
<P>2010 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without wheezing:</P>
<P>EUR 35,611/LYG</P>
<P>EUR 24,654/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct costs without wheezing:</P>
<P>EUR 36,774.38/LYG</P>
<P>EUR 25,459.42/QALY</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.052 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>GBP 3315</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.5%</P>
<P>2006 GBP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>GBP 29,000/QALY to</P>
<P>GBP 3,456,000/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>EUR 49,626.29/QALY to</P>
<P>EUR 5,914,084.34/QALY</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CAD = Canadian dollar<BR/>CHD = congenital heart disease<BR/>EUR = Euro<BR/>GBP = Great British pound<BR/>hosp. = hospitalization<BR/>ICER = incremental cost-effectiveness ratio<BR/>hosp. = hospitalization<BR/>LYG = life-year gained<BR/>NA = not applied<BR/>QALY = quality-adjusted life-year<BR/>USD = United States dollar</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2013-06-12 08:29:48 +1000" MODIFIED_BY="Tea Andabaka" NO="4">
<TITLE MODIFIED="2013-03-27 15:43:56 +1000" MODIFIED_BY="Tea Andabaka">Economic impact of immunoprophylaxis given to high-risk infants and children up to five years of age (born preterm, with or without bronchopulmonary dysplasia, or with congenital heart disease)</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Study ID</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Funded by industry</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Incremental effectiveness</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Incremental cost</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Discount rate (%)</B>
</P>
<P>
<B>Price year</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>ICER reported</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>ICER present value at 2011 EUR</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<I>
<B>Payer's perspective</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Garcia_x002d_Altes-2010" TYPE="STUDY">Garcia-Altes 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Hospitalisation averted:</P>
<P>0.058</P>
<P>LYG: not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3%</P>
<P>2008 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>EUR 17,337/hosp. averted to</P>
<P>EUR 68,380/hosp. averted</P>
<P>EUR 166,721/LYG to</P>
<P>EUR 147,656,881/LYG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>EUR 18,160.68/hosp. averted to</P>
<P>EUR 71,628.73/hosp. averted</P>
<P>EUR 174,641.91/LYG to</P>
<P>EUR 154,672,059.42/LYG</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<I>
<B>Societal perspective</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Joffe-1999" TYPE="STUDY">Joffe 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number needed to treat:</P>
<P>7.4 to 152</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>USD 1618.14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NA for hosp. averted</P>
<P>3% for LYG</P>
<P>1995 USD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Range:</P>
<P>USD 12,000/hosp. averted to</P>
<P>USD 420,000/hosp. averted</P>
<P>USD 33,000/LYG to</P>
<P>USD 1,200,000/LYG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Exchange rate to Euros not available for 1995</I>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lazaro-y-de-Mercado-2007" TYPE="STUDY">Lazaro y de Mercado 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not clear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.13 LYG</P>
<P>0.18 QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Direct and indirect costs:</P>
<P>EUR 726</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3.5%</P>
<P>2006 EUR</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 5583/LYG</P>
<P>EUR 4095/QALY</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EUR 6256.22/LYG</P>
<P>EUR 4588.79/QALY</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>EUR = Euro<BR/>hosp. = hospitalization<BR/>ICER = incremental cost-effectiveness ratio<BR/>LYG = life-year gained<BR/>NA = not applied<BR/>QALY = quality-adjusted life-year<BR/>USD = United States dollar</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-10-15 13:36:36 +1000" MODIFIED_BY="Maria X Rojas">
<COMPARISON ID="CMP-001" MODIFIED="2012-10-15 13:36:21 +1000" MODIFIED_BY="Tea Andabaka" NO="1">
<NAME>Palivizumab versus placebo</NAME>
<DICH_OUTCOME CHI2="0.8901686596293431" CI_END="0.6448550968209257" CI_START="0.37331537431151546" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4906468402490659" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="118" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.1905378632267759" LOG_CI_START="-0.42792412408076014" LOG_EFFECT_SIZE="-0.30923099365376805" METHOD="MH" MODIFIED="2012-10-15 13:36:21 +1000" MODIFIED_BY="Tea Andabaka" NO="1" P_CHI2="0.6407702634598086" P_Q="1.0" P_Z="3.2854439425325725E-7" Q="0.0" RANDOM="NO" SCALE="170.91491498981878" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1663" TOTAL_2="1168" WEIGHT="100.00000000000001" Z="5.106290551816889">
<NAME>Hospitalisation for RSV infection</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8185087719122958" CI_START="0.3659330980760309" EFFECT_SIZE="0.5472837022132797" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="63" LOG_CI_END="-0.0869766619176572" LOG_CI_START="-0.4365983074806097" LOG_EFFECT_SIZE="-0.2617874846991334" MODIFIED="2012-06-26 22:57:28 +1000" MODIFIED_BY="Tea Andabaka" ORDER="1" O_E="0.0" SE="0.20536948525873544" STUDY_ID="STD-Feltes-2003" TOTAL_1="639" TOTAL_2="648" VAR="0.042176625475437955" WEIGHT="46.037911155779284"/>
<DICH_DATA CI_END="0.6578723541281329" CI_START="0.3104514301221745" EFFECT_SIZE="0.4519263360072308" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="53" LOG_CI_END="-0.181858363643657" LOG_CI_START="-0.5080063351971628" LOG_EFFECT_SIZE="-0.34493234942040996" MODIFIED="2012-06-26 23:09:21 +1000" MODIFIED_BY="Tea Andabaka" ORDER="2" O_E="0.0" SE="0.19158093294902614" STUDY_ID="STD-IMpact_x002d_RSV-1998" TOTAL_1="1002" TOTAL_2="500" VAR="0.03670325386961925" WEIGHT="52.03869634539751"/>
<DICH_DATA CI_END="3.5886283604643068" CI_START="0.009292111742513761" EFFECT_SIZE="0.1826086956521739" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5549284849822533" LOG_CI_START="-2.031885576221638" LOG_EFFECT_SIZE="-0.7384785456196924" MODIFIED="2012-07-08 02:49:09 +1000" MODIFIED_BY="Tea Andabaka" ORDER="3" O_E="0.0" SE="1.5195073844872842" STUDY_ID="STD-Subramanian-1998" TOTAL_1="22" TOTAL_2="20" VAR="2.308902691511387" WEIGHT="1.923392498823218"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1488056413674685" CI_END="1.1460572187281053" CI_START="0.41895005641728145" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6929218833631771" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.05920630101490956" LOG_CI_START="-0.3778377467596942" LOG_EFFECT_SIZE="-0.15931572287239235" METHOD="MH" MODIFIED="2012-07-29 05:00:34 +1000" MODIFIED_BY="Tea Andabaka" NO="2" P_CHI2="0.5630411815564418" P_Q="1.0" P_Z="0.1530238231704506" Q="0.0" RANDOM="NO" SCALE="128.68" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1663" TOTAL_2="1168" WEIGHT="99.99999999999999" Z="1.4289318460728293">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3803966036502766" CI_START="0.45066670569717154" EFFECT_SIZE="0.7887323943661971" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" LOG_CI_END="0.1400038820757242" LOG_CI_START="-0.34614452550147395" LOG_EFFECT_SIZE="-0.1030703217128749" MODIFIED="2012-06-26 23:12:02 +1000" MODIFIED_BY="Tea Andabaka" ORDER="4" O_E="0.0" SE="0.2855659810842748" STUDY_ID="STD-Feltes-2003" TOTAL_1="639" TOTAL_2="648" VAR="0.08154792955262438" WEIGHT="76.49308085574908"/>
<DICH_DATA CI_END="1.480097642846662" CI_START="0.10766986601388652" EFFECT_SIZE="0.3992015968063872" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.17029036698327268" LOG_CI_START="-0.9679058273898017" LOG_EFFECT_SIZE="-0.39880773020326454" MODIFIED="2012-06-26 23:14:01 +1000" MODIFIED_BY="Tea Andabaka" ORDER="5" O_E="0.0" SE="0.6685820787367727" STUDY_ID="STD-IMpact_x002d_RSV-1998" TOTAL_1="1002" TOTAL_2="500" VAR="0.447001996007984" WEIGHT="19.032852012821134"/>
<DICH_DATA CI_END="7.070137371487788" CI_START="0.013101244626080647" EFFECT_SIZE="0.30434782608695654" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8494278521419525" LOG_CI_START="-1.8826874441486245" LOG_EFFECT_SIZE="-0.516629796003336" MODIFIED="2012-07-08 02:54:03 +1000" MODIFIED_BY="Tea Andabaka" ORDER="6" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Subramanian-1998" TOTAL_1="22" TOTAL_2="20" VAR="2.5755693581780537" WEIGHT="4.474067131429769"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2012-07-29 05:00:34 +1000" MODIFIED_BY="Tea Andabaka" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1641" TOTAL_2="1148" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Total RSV hospital days per 100 children</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="57.4" MEAN_2="129.0" MODIFIED="2012-06-26 23:18:24 +1000" MODIFIED_BY="Tea Andabaka" ORDER="7" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Feltes-2003" TOTAL_1="639" TOTAL_2="648" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="36.4" MEAN_2="62.6" MODIFIED="2012-06-26 23:18:25 +1000" MODIFIED_BY="Tea Andabaka" ORDER="8" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-IMpact_x002d_RSV-1998" TOTAL_1="1002" TOTAL_2="500" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.2238192405731443" CI_END="0.8121968848647068" CI_START="0.30286503922286556" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4959697988700911" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.0903386805547515" LOG_CI_START="-0.5187508559140512" LOG_EFFECT_SIZE="-0.30454476823440135" METHOD="MH" MODIFIED="2012-07-29 05:00:34 +1000" MODIFIED_BY="Tea Andabaka" NO="4" P_CHI2="0.6361451497833372" P_Q="1.0" P_Z="0.005327178224718628" Q="0.0" RANDOM="NO" SCALE="6.403916863411801" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1641" TOTAL_2="1148" WEIGHT="99.99999999999999" Z="2.7865537524414226">
<NAME>Admission to ICU</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0692186401694022" CI_START="0.2821928431758528" EFFECT_SIZE="0.5492957746478874" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" LOG_CI_END="0.029066521401510455" LOG_CI_START="-0.5494540047866625" LOG_EFFECT_SIZE="-0.26019374169257603" MODIFIED="2012-06-26 23:19:56 +1000" MODIFIED_BY="Tea Andabaka" ORDER="9" O_E="0.0" SE="0.33982582080572293" STUDY_ID="STD-Feltes-2003" TOTAL_1="639" TOTAL_2="648" VAR="0.11548158848628332" WEIGHT="54.35489810559096"/>
<DICH_DATA CI_END="0.9018144796637219" CI_START="0.2073917842568226" EFFECT_SIZE="0.4324683965402528" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="-0.04488279587845031" LOG_CI_START="-0.683208452009655" LOG_EFFECT_SIZE="-0.3640456239440526" MODIFIED="2012-06-26 23:20:28 +1000" MODIFIED_BY="Tea Andabaka" ORDER="10" O_E="0.0" SE="0.37495565017442745" STUDY_ID="STD-IMpact_x002d_RSV-1998" TOTAL_1="1002" TOTAL_2="500" VAR="0.1405917395977276" WEIGHT="45.645101894409024"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2012-07-29 05:00:34 +1000" MODIFIED_BY="Tea Andabaka" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="104.94755032396263" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1641" TOTAL_2="1148" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days in the ICU per 100 children</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="15.9" MEAN_2="71.2" MODIFIED="2012-06-26 23:22:39 +1000" MODIFIED_BY="Tea Andabaka" ORDER="11" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Feltes-2003" TOTAL_1="639" TOTAL_2="648" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="13.3" MEAN_2="12.7" MODIFIED="2012-06-26 23:23:44 +1000" MODIFIED_BY="Tea Andabaka" ORDER="12" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-IMpact_x002d_RSV-1998" TOTAL_1="1002" TOTAL_2="500" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.486432702764885" CI_END="6.086281351754665" CI_START="0.19911922256353096" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1008613041906348" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="59.7817387581811" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.7843520247047381" LOG_CI_START="-0.7008868120454438" LOG_EFFECT_SIZE="0.04173260632964716" METHOD="MH" MODIFIED="2012-07-29 05:00:34 +1000" MODIFIED_BY="Tea Andabaka" NO="6" P_CHI2="0.11483200518790115" P_Q="1.0" P_Z="0.9122958866659332" Q="0.0" RANDOM="YES" SCALE="138.43491274800346" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.9908408447461565" TOTALS="YES" TOTAL_1="1641" TOTAL_2="1148" WEIGHT="100.00000000000001" Z="0.11014310070974077">
<NAME>Mechanical ventilation for RSV infection</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3718108901125878" CI_START="0.2447811393306563" EFFECT_SIZE="0.579476861167002" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.1372942461803129" LOG_CI_START="-0.6112220481285153" LOG_EFFECT_SIZE="-0.23696390097410125" MODIFIED="2012-06-26 23:27:08 +1000" MODIFIED_BY="Tea Andabaka" ORDER="13" O_E="0.0" SE="0.43968217649241953" STUDY_ID="STD-Feltes-2003" TOTAL_1="639" TOTAL_2="648" VAR="0.19332041632511116" WEIGHT="64.27719974792885"/>
<DICH_DATA CI_END="28.312532684290588" CI_START="0.4309450781048474" EFFECT_SIZE="3.493013972055888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.4519787207113921" LOG_CI_START="-0.3655780750732946" LOG_EFFECT_SIZE="0.5432003228190487" MODIFIED="2012-06-26 23:28:13 +1000" MODIFIED_BY="Tea Andabaka" ORDER="14" O_E="0.0" SE="1.0676418588951666" STUDY_ID="STD-IMpact_x002d_RSV-1998" TOTAL_1="1002" TOTAL_2="500" VAR="1.139859138865127" WEIGHT="35.72280025207117"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2012-07-29 05:00:34 +1000" MODIFIED_BY="Tea Andabaka" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1641" TOTAL_2="1148" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days of mechanical ventilation per 100 children</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="6.5" MEAN_2="54.7" MODIFIED="2012-06-26 23:30:15 +1000" MODIFIED_BY="Tea Andabaka" ORDER="15" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Feltes-2003" TOTAL_1="639" TOTAL_2="648" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="8.4" MEAN_2="1.7" MODIFIED="2012-06-26 23:29:51 +1000" MODIFIED_BY="Tea Andabaka" ORDER="16" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-IMpact_x002d_RSV-1998" TOTAL_1="1002" TOTAL_2="500" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2012-07-29 05:00:34 +1000" MODIFIED_BY="Tea Andabaka" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1641" TOTAL_2="1148" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days of supplemental oxygen therapy per 100 children</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="27.9" MEAN_2="101.5" MODIFIED="2012-06-26 23:32:18 +1000" MODIFIED_BY="Tea Andabaka" ORDER="17" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Feltes-2003" TOTAL_1="639" TOTAL_2="648" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="30.3" MEAN_2="50.6" MODIFIED="2012-06-26 23:31:36 +1000" MODIFIED_BY="Tea Andabaka" ORDER="18" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-IMpact_x002d_RSV-1998" TOTAL_1="1002" TOTAL_2="500" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="9.893807484418973E-29" CI_END="1.0136420225587863" CI_START="0.9695854159695608" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9913690140845072" ESTIMABLE="YES" EVENTS_1="611" EVENTS_2="625" I2="100.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.0058846067955630665" LOG_CI_START="-0.013413925574218567" LOG_EFFECT_SIZE="-0.0037646593893277546" METHOD="MH" MODIFIED="2012-07-29 05:16:25 +1000" MODIFIED_BY="Tea Andabaka" NO="9" P_CHI2="0.0" P_Q="1.0" P_Z="0.44446237471234673" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="639" TOTAL_2="648" WEIGHT="100.0" Z="0.7646795803702284">
<NAME>Number of children reporting any AE</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0136420225587863" CI_START="0.9695854159695607" EFFECT_SIZE="0.9913690140845071" ESTIMABLE="YES" EVENTS_1="611" EVENTS_2="625" LOG_CI_END="0.0058846067955630665" LOG_CI_START="-0.013413925574218616" LOG_EFFECT_SIZE="-0.003764659389327803" MODIFIED="2012-07-08 03:08:39 +1000" MODIFIED_BY="Tea Andabaka" ORDER="62" O_E="0.0" SE="0.01133605344328566" STUDY_ID="STD-Feltes-2003" TOTAL_1="639" TOTAL_2="648" VAR="1.2850610766902866E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3108129048034101" CI_END="1.3837218920466816" CI_START="0.851372486945483" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.085385990545618" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.14104881202372127" LOG_CI_START="-0.0698803886442287" LOG_EFFECT_SIZE="0.03558421168974628" METHOD="MH" MODIFIED="2012-07-29 05:16:42 +1000" MODIFIED_BY="Tea Andabaka" NO="10" P_CHI2="0.8560671733379235" P_Q="1.0" P_Z="0.5084197442549857" Q="0.0" RANDOM="NO" SCALE="6.4" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1663" TOTAL_2="1168" WEIGHT="100.0" Z="0.6613003141271492">
<NAME>Number of children reporting related AE</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5405145415113048" CI_START="0.6975464440177281" EFFECT_SIZE="1.036619718309859" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="45" LOG_CI_END="0.1876658021455345" LOG_CI_START="-0.15642687090868743" LOG_EFFECT_SIZE="0.01561946561842355" MODIFIED="2012-06-26 23:39:55 +1000" MODIFIED_BY="Tea Andabaka" ORDER="21" O_E="0.0" SE="0.20212173943825182" STUDY_ID="STD-Feltes-2003" TOTAL_1="639" TOTAL_2="648" VAR="0.040853197553544565" WEIGHT="39.01311115863967"/>
<DICH_DATA CI_END="1.5066836981327918" CI_START="0.799885525323013" EFFECT_SIZE="1.0978043912175648" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="50" LOG_CI_END="0.1780220893593862" LOG_CI_START="-0.09697216210538999" LOG_EFFECT_SIZE="0.040524963626998096" MODIFIED="2012-06-26 23:39:17 +1000" MODIFIED_BY="Tea Andabaka" ORDER="22" O_E="0.0" SE="0.16153298455390813" STUDY_ID="STD-IMpact_x002d_RSV-1998" TOTAL_1="1002" TOTAL_2="500" VAR="0.026092905098893122" WEIGHT="58.24297541178108"/>
<DICH_DATA CI_END="5.542639618045832" CI_START="0.4141860687445021" EFFECT_SIZE="1.5151515151515151" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7437166417203419" LOG_CI_START="-0.38280451280407934" LOG_EFFECT_SIZE="0.1804560644581313" MODIFIED="2012-07-08 03:01:29 +1000" MODIFIED_BY="Tea Andabaka" ORDER="61" O_E="0.0" SE="0.6617241025372945" STUDY_ID="STD-Subramanian-1998" TOTAL_1="22" TOTAL_2="20" VAR="0.43787878787878787" WEIGHT="2.743913429579262"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9614569889470261" CI_START="0.8012690035653282" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8777161747994077" ESTIMABLE="YES" EVENTS_1="354" EVENTS_2="409" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-0.01707013927862325" LOG_CI_START="-0.09622165726009839" LOG_EFFECT_SIZE="-0.05664589826936082" METHOD="MH" MODIFIED="2012-07-29 05:16:51 +1000" MODIFIED_BY="Tea Andabaka" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.0050261713284736895" Q="0.0" RANDOM="NO" SCALE="2.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="639" TOTAL_2="648" WEIGHT="100.0" Z="2.8053516422982927">
<NAME>Number of children reporting any SAE</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9614569889470261" CI_START="0.8012690035653282" EFFECT_SIZE="0.8777161747994077" ESTIMABLE="YES" EVENTS_1="354" EVENTS_2="409" LOG_CI_END="-0.01707013927862325" LOG_CI_START="-0.09622165726009839" LOG_EFFECT_SIZE="-0.05664589826936082" MODIFIED="2012-06-26 23:41:32 +1000" MODIFIED_BY="Tea Andabaka" ORDER="23" O_E="0.0" SE="0.04649399346865145" STUDY_ID="STD-Feltes-2003" TOTAL_1="639" TOTAL_2="648" VAR="0.002161691428663004" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.79890747954812" CI_START="0.007497989413546518" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14486607142857144" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.44698854270131094" LOG_CI_START="-2.12505517709686" LOG_EFFECT_SIZE="-0.8390333171977747" METHOD="MH" MODIFIED="2012-07-29 05:17:00 +1000" MODIFIED_BY="Tea Andabaka" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.20099208119642564" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="639" TOTAL_2="648" WEIGHT="100.0" Z="1.2787302726454837">
<NAME>Number of children reporting related SAE</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.798907479548119" CI_START="0.007497989413546518" EFFECT_SIZE="0.14486607142857144" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4469885427013107" LOG_CI_START="-2.12505517709686" LOG_EFFECT_SIZE="-0.8390333171977747" MODIFIED="2012-06-26 23:42:22 +1000" MODIFIED_BY="Tea Andabaka" ORDER="24" O_E="0.0" SE="1.5108312128311947" STUDY_ID="STD-Feltes-2003" TOTAL_1="639" TOTAL_2="648" VAR="2.282610953664979" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-10-15 13:36:36 +1000" MODIFIED_BY="Tea Andabaka" NO="2">
<NAME>Palivizumab versus motavizumab</NAME>
<DICH_OUTCOME CHI2="2.7525426137172175E-8" CI_END="1.9009032330616487" CI_START="0.9690410797353118" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3572226499135671" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.2789600093341413" LOG_CI_START="-0.013657811881942863" LOG_EFFECT_SIZE="0.13265109872609923" METHOD="MH" MODIFIED="2012-10-15 13:36:36 +1000" MODIFIED_BY="Tea Andabaka" NO="1" P_CHI2="0.9998676246622689" P_Q="1.0" P_Z="0.07556774293867291" Q="0.0" RANDOM="NO" SCALE="3.357774020101104" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3918" TOTAL_2="3952" WEIGHT="100.0" Z="1.7770030200643894">
<NAME>Hospitalisation for RSV infection</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9813565009877594" CI_START="0.9296660752894843" EFFECT_SIZE="1.3572029774586392" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="46" LOG_CI_END="0.2969626241918326" LOG_CI_START="-0.03167301671599556" LOG_EFFECT_SIZE="0.1326448037379185" MODIFIED="2012-07-29 03:47:27 +1000" MODIFIED_BY="Tea Andabaka" ORDER="25" O_E="0.0" SE="0.193042202241917" STUDY_ID="STD-Carbonell_x002d_Estrany-2010" TOTAL_1="3306" TOTAL_2="3329" VAR="0.037265291846409185" WEIGHT="79.40002866307069"/>
<DICH_DATA CI_END="2.8451364275668083" CI_START="0.6475117088374535" EFFECT_SIZE="1.3572984749455337" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4541030961507297" LOG_CI_START="-0.18875237390691296" LOG_EFFECT_SIZE="0.13267536112190834" MODIFIED="2012-07-29 03:47:51 +1000" MODIFIED_BY="Tea Andabaka" ORDER="26" O_E="0.0" SE="0.3776164852977577" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="623" VAR="0.14259420996863165" WEIGHT="20.599971336929322"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.003797610693611013" CI_END="3.1300582103369146" CI_START="1.2495242315772992" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9776459693442225" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.4955524142854381" LOG_CI_START="0.0967446826619627" LOG_EFFECT_SIZE="0.2961485484737004" METHOD="MH" MODIFIED="2012-07-29 03:50:15 +1000" MODIFIED_BY="Tea Andabaka" NO="2" P_CHI2="0.9508617082649962" P_Q="1.0" P_Z="0.003604137729532366" Q="0.0" RANDOM="NO" SCALE="12.814240390055806" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1499" TOTAL_2="1527" WEIGHT="100.0" Z="2.9108788173157887">
<NAME>RSV-specific outpatient MALRI</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.235328757699256" CI_START="1.2215026066685484" EFFECT_SIZE="1.9879543533389687" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="24" LOG_CI_END="0.5099184180496199" LOG_CI_START="0.08689439808846397" LOG_EFFECT_SIZE="0.29840640806904195" MODIFIED="2012-07-29 03:49:52 +1000" MODIFIED_BY="Tea Andabaka" ORDER="27" O_E="0.0" SE="0.2484864033278535" STUDY_ID="STD-Carbonell_x002d_Estrany-2010" TOTAL_1="1183" TOTAL_2="1227" VAR="0.061745492638812675" WEIGHT="88.4461290678862"/>
<DICH_DATA CI_END="7.5236874116670105" CI_START="0.47917879604280994" EFFECT_SIZE="1.8987341772151898" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8764307435226507" LOG_CI_START="-0.3195024079921712" LOG_EFFECT_SIZE="0.2784641677652398" MODIFIED="2012-07-29 03:50:15 +1000" MODIFIED_BY="Tea Andabaka" ORDER="28" O_E="0.0" SE="0.7024970531643825" STUDY_ID="STD-Feltes-2011" TOTAL_1="316" TOTAL_2="300" VAR="0.4935021097046413" WEIGHT="11.553870932113801"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8979782984535813" CI_END="1.4318750861025153" CI_START="0.38029746701700246" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7379284981145117" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.15590513264877343" LOG_CI_START="-0.41987656721056343" LOG_EFFECT_SIZE="-0.131985717280895" METHOD="MH" MODIFIED="2012-07-29 03:51:42 +1000" MODIFIED_BY="Tea Andabaka" NO="3" P_CHI2="0.5938494655945918" P_Q="1.0" P_Z="0.3688869897545387" Q="0.0" RANDOM="NO" SCALE="101.64" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4071" TOTAL_2="4194" WEIGHT="100.0" Z="0.8985601744808396">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.587873622928624" CI_START="0.013039781357177392" EFFECT_SIZE="0.3145539906103286" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.880120089042957" LOG_CI_START="-1.8847296905187794" LOG_EFFECT_SIZE="-0.5023048007379113" MODIFIED="2012-07-29 03:50:43 +1000" MODIFIED_BY="Tea Andabaka" ORDER="29" O_E="0.0" SE="1.6240864467417013" STUDY_ID="STD-Abarca-2009" TOTAL_1="70" TOTAL_2="66" VAR="2.637656786490085" WEIGHT="7.4605765654471226"/>
<DICH_DATA CI_END="1.6703756363674591" CI_START="0.15175665790702242" EFFECT_SIZE="0.5034785238959467" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.22281414687033807" LOG_CI_START="-0.8188522463558232" LOG_EFFECT_SIZE="-0.2980190497427425" MODIFIED="2012-07-29 03:51:03 +1000" MODIFIED_BY="Tea Andabaka" ORDER="30" O_E="0.0" SE="0.6118799957128539" STUDY_ID="STD-Carbonell_x002d_Estrany-2010" TOTAL_1="3306" TOTAL_2="3329" VAR="0.37439712915356205" WEIGHT="38.534859459059376"/>
<DICH_DATA CI_END="2.7642815131481084" CI_START="0.4628134384726939" EFFECT_SIZE="1.1310820624546114" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.44158226930316097" LOG_CI_START="-0.334594039154594" LOG_EFFECT_SIZE="0.05349411507428352" MODIFIED="2012-07-29 03:51:23 +1000" MODIFIED_BY="Tea Andabaka" ORDER="31" O_E="0.0" SE="0.4559298057227773" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="623" VAR="0.20787198774640944" WEIGHT="43.11504506436007"/>
<DICH_DATA CI_END="5.7615648164466435" CI_START="0.015727200685501132" EFFECT_SIZE="0.3010204081632653" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.7605404519740078" LOG_CI_START="-1.8033485714026714" LOG_EFFECT_SIZE="-0.5214040597143319" MODIFIED="2012-07-29 03:51:42 +1000" MODIFIED_BY="Tea Andabaka" ORDER="32" O_E="0.0" SE="1.5060411037868122" STUDY_ID="STD-Fernandez-2010" TOTAL_1="83" TOTAL_2="176" VAR="2.2681598062953996" WEIGHT="10.88951891113344"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="71.49327002905676" CI_START="-21.593270029056768" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="24.949999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2012-09-02 23:30:41 +1000" MODIFIED_BY="Tea Andabaka" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.2934152890136493" Q="0.0" RANDOM="NO" SCALE="170.65370021399843" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3918" TOTAL_2="3952" UNITS="" WEIGHT="100.0" Z="1.0506589112399194">
<NAME>Total RSV hospital days per 100 children</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="18.1" MEAN_2="9.1" MODIFIED="2012-07-29 03:52:23 +1000" MODIFIED_BY="Tea Andabaka" ORDER="33" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Carbonell_x002d_Estrany-2010" TOTAL_1="3306" TOTAL_2="3329" WEIGHT="0.0"/>
<CONT_DATA CI_END="71.49327002905676" CI_START="-21.593270029056768" EFFECT_SIZE="24.949999999999996" ESTIMABLE="YES" MEAN_1="49.41" MEAN_2="24.46" MODIFIED="2012-09-02 23:26:51 +1000" MODIFIED_BY="Tea Andabaka" ORDER="34" SD_1="527.36" SD_2="261.18" SE="23.747002698102687" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="623" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.3906862283342743" CI_END="3.188230532865847" CI_START="0.8889579534478828" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.683509099950599" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.5035497165922574" LOG_CI_START="-0.05111878010673986" LOG_EFFECT_SIZE="0.2262154682427588" METHOD="MH" MODIFIED="2012-07-29 03:54:26 +1000" MODIFIED_BY="Tea Andabaka" NO="5" P_CHI2="0.5319392817304527" P_Q="1.0" P_Z="0.10988735163464838" Q="0.0" RANDOM="NO" SCALE="7.867007026058967" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3918" TOTAL_2="3952" WEIGHT="100.00000000000001" Z="1.5986996670635798">
<NAME>Admission to ICU</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.108235583382167" CI_START="0.890991895820018" EFFECT_SIZE="1.9132183908045977" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.613655339898301" LOG_CI_START="-0.05012624615016568" LOG_EFFECT_SIZE="0.28176454687406766" MODIFIED="2012-07-29 03:54:06 +1000" MODIFIED_BY="Tea Andabaka" ORDER="35" O_E="0.0" SE="0.3899085894167125" STUDY_ID="STD-Carbonell_x002d_Estrany-2010" TOTAL_1="3306" TOTAL_2="3329" VAR="0.1520287081009305" WEIGHT="66.78820654254224"/>
<DICH_DATA CI_END="3.9816612814869536" CI_START="0.37477570443038744" EFFECT_SIZE="1.2215686274509805" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6000643119852175" LOG_CI_START="-0.426228570862751" LOG_EFFECT_SIZE="0.08691787056123329" MODIFIED="2012-07-29 03:54:26 +1000" MODIFIED_BY="Tea Andabaka" ORDER="36" O_E="0.0" SE="0.6028495196165997" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="623" VAR="0.36342754330196503" WEIGHT="33.21179345745777"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="56.372586890507634" CI_START="-13.692586890507638" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="21.34" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2012-09-02 23:30:29 +1000" MODIFIED_BY="Tea Andabaka" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.23251458593001118" Q="0.0" RANDOM="NO" SCALE="136.716962323523" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3918" TOTAL_2="3952" UNITS="" WEIGHT="100.0" Z="1.1939064494668463">
<NAME>Days in the ICU per 100 children</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="6.3" MEAN_2="2.0" MODIFIED="2012-07-29 03:54:53 +1000" MODIFIED_BY="Tea Andabaka" ORDER="37" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Carbonell_x002d_Estrany-2010" TOTAL_1="3306" TOTAL_2="3329" WEIGHT="0.0"/>
<CONT_DATA CI_END="56.372586890507634" CI_START="-13.692586890507638" EFFECT_SIZE="21.34" ESTIMABLE="YES" MEAN_1="26.96" MEAN_2="5.62" MODIFIED="2012-09-02 23:29:24 +1000" MODIFIED_BY="Tea Andabaka" ORDER="38" SD_1="436.42" SD_2="71.78" SE="17.874097262419212" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="623" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.7610198572360372" CI_END="11.419941467304035" CI_START="1.259069265492589" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.791898906248273" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" I2="0.0" I2_Q="100.0" ID="CMP-002.07" LOG_CI_END="1.0576638779473062" LOG_CI_START="0.10004962271609029" LOG_EFFECT_SIZE="0.5788567503316981" METHOD="MH" MODIFIED="2012-07-29 04:35:04 +1000" MODIFIED_BY="Tea Andabaka" NO="7" P_CHI2="0.3830095856042316" P_Q="0.0" P_Z="0.017811662762356798" Q="1.558203021097552E-31" RANDOM="NO" SCALE="50.39284854774434" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3918" TOTAL_2="3952" WEIGHT="100.0" Z="2.3695102211779178">
<NAME>Mechanical ventilation for RSV infection</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="24.966841073788828" CI_START="1.22852408185345" EFFECT_SIZE="5.538263762855414" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.397363596776314" LOG_CI_START="0.0893836740546511" LOG_EFFECT_SIZE="0.7433736354154825" MODIFIED="2012-07-29 03:55:58 +1000" MODIFIED_BY="Tea Andabaka" ORDER="39" O_E="0.0" SE="0.7683138812117434" STUDY_ID="STD-Carbonell_x002d_Estrany-2010" TOTAL_1="3306" TOTAL_2="3329" VAR="0.590306220062653" WEIGHT="50.136857112333345"/>
<DICH_DATA CI_END="11.074782823110379" CI_START="0.3742812074880178" EFFECT_SIZE="2.0359477124183005" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.044335218448195" LOG_CI_START="-0.426801978093016" LOG_EFFECT_SIZE="0.3087666201775896" MODIFIED="2012-07-29 03:56:15 +1000" MODIFIED_BY="Tea Andabaka" ORDER="40" O_E="0.0" SE="0.8641532714948769" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="623" VAR="0.7467608766352983" WEIGHT="49.86314288766665"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="48.72458782774572" CI_START="-16.60458782774572" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="16.06" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2012-09-02 23:31:47 +1000" MODIFIED_BY="Tea Andabaka" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.3352246428851392" Q="0.0" RANDOM="NO" SCALE="123.83657624227824" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3918" TOTAL_2="3952" UNITS="" WEIGHT="100.0" Z="0.963643617905268">
<NAME>Days of mechanical ventilation per 100 children</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="3.8" MEAN_2="0.5" MODIFIED="2012-07-29 04:01:37 +1000" MODIFIED_BY="Tea Andabaka" ORDER="41" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Carbonell_x002d_Estrany-2010" TOTAL_1="3306" TOTAL_2="3329" WEIGHT="0.0"/>
<CONT_DATA CI_END="48.72458782774572" CI_START="-16.60458782774572" EFFECT_SIZE="16.06" ESTIMABLE="YES" MEAN_1="18.63" MEAN_2="2.57" MODIFIED="2012-09-02 23:31:32 +1000" MODIFIED_BY="Tea Andabaka" ORDER="42" SD_1="409.69" SD_2="46.66" SE="16.665912274613117" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="623" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.10493051603489992" CI_END="2.264591203826354" CI_START="0.9760033859897531" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.48669051346174" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.354989816085831" LOG_CI_START="-0.010548675659010267" LOG_EFFECT_SIZE="0.17222057021341036" METHOD="MH" MODIFIED="2012-07-29 04:31:48 +1000" MODIFIED_BY="Tea Andabaka" NO="9" P_CHI2="0.7459912131613263" P_Q="1.0" P_Z="0.06476988775247401" Q="0.0" RANDOM="NO" SCALE="6.114896293974949" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3918" TOTAL_2="3952" WEIGHT="100.0" Z="1.846843069270281">
<NAME>Supplemental oxygen therapy for RSV infection</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.532256522433906" CI_START="0.9477362234457952" EFFECT_SIZE="1.5491646889106054" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="26" LOG_CI_END="0.4035076984363541" LOG_CI_START="-0.02331251987958785" LOG_EFFECT_SIZE="0.19009758927838313" MODIFIED="2012-07-29 04:02:29 +1000" MODIFIED_BY="Tea Andabaka" ORDER="43" O_E="0.0" SE="0.2507163090329397" STUDY_ID="STD-Carbonell_x002d_Estrany-2010" TOTAL_1="3306" TOTAL_2="3329" VAR="0.06285866761510052" WEIGHT="72.33191239195251"/>
<DICH_DATA CI_END="2.995171419900708" CI_START="0.5847069696638133" EFFECT_SIZE="1.3233660130718954" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.47642168301466403" LOG_CI_START="-0.2330617293737737" LOG_EFFECT_SIZE="0.12167997682044518" MODIFIED="2012-07-29 04:02:56 +1000" MODIFIED_BY="Tea Andabaka" ORDER="44" O_E="0.0" SE="0.4167540684365004" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="623" VAR="0.17368395355837526" WEIGHT="27.668087608047482"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="70.47620887326775" CI_START="-13.636208873267748" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="28.42" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.10" MODIFIED="2012-09-02 23:34:13 +1000" MODIFIED_BY="Tea Andabaka" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.18534708313868523" Q="0.0" RANDOM="NO" SCALE="182.19888355878223" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="3918" TOTAL_2="3952" UNITS="" WEIGHT="100.00000000000001" Z="1.3244697497218871">
<NAME>Days of supplemental oxygen therapy per 100 children</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="9.5" MEAN_2="4.1" MODIFIED="2012-07-29 04:11:04 +1000" MODIFIED_BY="Tea Andabaka" ORDER="45" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Carbonell_x002d_Estrany-2010" TOTAL_1="3306" TOTAL_2="3329" WEIGHT="0.0"/>
<CONT_DATA CI_END="70.47620887326775" CI_START="-13.636208873267748" EFFECT_SIZE="28.42" ESTIMABLE="YES" MEAN_1="42.06" MEAN_2="13.64" MODIFIED="2012-09-02 23:33:55 +1000" MODIFIED_BY="Tea Andabaka" ORDER="46" SD_1="510.65" SD_2="146.28" SE="21.45764371437524" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="623" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.7053250514616027" CI_END="1.0205545033193624" CI_START="0.9865774574419733" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0034221778821577" ESTIMABLE="YES" EVENTS_1="3529" EVENTS_2="3605" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.008836203426185268" LOG_CI_START="-0.005868812065045674" LOG_EFFECT_SIZE="0.001483695680569814" METHOD="MH" MODIFIED="2012-07-29 05:17:57 +1000" MODIFIED_BY="Tea Andabaka" NO="11" P_CHI2="0.8719507552209886" P_Q="1.0" P_Z="0.6924665681141733" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4063" TOTAL_2="4175" WEIGHT="100.00000000000001" Z="0.3955099672854621">
<NAME>Number of children reporting any AE</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.191405466762514" CI_START="0.914617543669181" EFFECT_SIZE="1.0438775510204081" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="56" LOG_CI_END="0.07605958852709209" LOG_CI_START="-0.03876047248776156" LOG_EFFECT_SIZE="0.01864955801966529" MODIFIED="2012-07-29 04:04:20 +1000" MODIFIED_BY="Tea Andabaka" ORDER="47" O_E="0.0" SE="0.06744587220859359" STUDY_ID="STD-Abarca-2009" TOTAL_1="70" TOTAL_2="66" VAR="0.004548945677977936" WEIGHT="1.62474454628582"/>
<DICH_DATA CI_END="1.0243123076791032" CI_START="0.9849660431012079" EFFECT_SIZE="1.0044465344629117" ESTIMABLE="YES" EVENTS_1="2837" EVENTS_2="2839" LOG_CI_END="0.010432391036884195" LOG_CI_START="-0.006578741632310042" LOG_EFFECT_SIZE="0.001926824702287042" MODIFIED="2012-07-29 04:04:38 +1000" MODIFIED_BY="Tea Andabaka" ORDER="48" O_E="0.0" SE="0.009992423536349456" STUDY_ID="STD-Carbonell_x002d_Estrany-2010" TOTAL_1="3298" TOTAL_2="3315" VAR="9.984852812979059E-5" WEIGHT="79.80965810426605"/>
<DICH_DATA CI_END="1.0255252334963276" CI_START="0.9634405650215797" EFFECT_SIZE="0.993998294970162" ESTIMABLE="YES" EVENTS_1="566" EVENTS_2="575" LOG_CI_END="0.010946350841284622" LOG_CI_START="-0.016175071957493358" LOG_EFFECT_SIZE="-0.002614360558104399" MODIFIED="2012-07-29 04:04:55 +1000" MODIFIED_BY="Tea Andabaka" ORDER="49" O_E="0.0" SE="0.015931258005210232" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="618" VAR="2.5380498162857514E-4" WEIGHT="16.126944249619484"/>
<DICH_DATA CI_END="1.1594798266764523" CI_START="0.8715621567955338" EFFECT_SIZE="1.0052655064703258" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="135" LOG_CI_END="0.06426319692457627" LOG_CI_START="-0.05970163507066233" LOG_EFFECT_SIZE="0.002280780926956975" MODIFIED="2012-07-29 04:05:12 +1000" MODIFIED_BY="Tea Andabaka" ORDER="50" O_E="0.0" SE="0.07281755594981809" STUDY_ID="STD-Fernandez-2010" TOTAL_1="83" TOTAL_2="176" VAR="0.005302396454504888" WEIGHT="2.4386530998286537"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8621305555554559" CI_END="1.3177345462505863" CI_START="0.7282532545713369" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9796144506733623" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="89" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.11982793172254849" LOG_CI_START="-0.13771756582942074" LOG_EFFECT_SIZE="-0.008944817053436136" METHOD="MH" MODIFIED="2012-07-29 05:18:13 +1000" MODIFIED_BY="Tea Andabaka" NO="12" P_CHI2="0.6498165109891808" P_Q="1.0" P_Z="0.89170816777497" Q="0.0" RANDOM="NO" SCALE="3.22" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="765" TOTAL_2="860" WEIGHT="100.00000000000001" Z="0.1361430849281059">
<NAME>Number of children reporting related AE</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9488085725305764" CI_START="0.45616568213386527" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.2897691813563819" LOG_CI_START="-0.34087739030115827" LOG_EFFECT_SIZE="-0.025554104472388168" MODIFIED="2012-07-29 04:05:42 +1000" MODIFIED_BY="Tea Andabaka" ORDER="51" O_E="0.0" SE="0.3704449179425157" STUDY_ID="STD-Abarca-2009" TOTAL_1="70" TOTAL_2="66" VAR="0.1372294372294372" WEIGHT="15.48603693482205"/>
<DICH_DATA CI_END="1.54176981116052" CI_START="0.7414839173211495" EFFECT_SIZE="1.069204152249135" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="51" LOG_CI_END="0.18801953765447366" LOG_CI_START="-0.1298982643179001" LOG_EFFECT_SIZE="0.029060636668286764" MODIFIED="2012-07-29 04:05:59 +1000" MODIFIED_BY="Tea Andabaka" ORDER="52" O_E="0.0" SE="0.1867464905970727" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="618" VAR="0.03487425175032256" WEIGHT="63.62333055953789"/>
<DICH_DATA CI_END="1.4954648956785688" CI_START="0.3602726142159742" EFFECT_SIZE="0.7340129749768304" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="26" LOG_CI_END="0.17477622292265374" LOG_CI_START="-0.44336874910948804" LOG_EFFECT_SIZE="-0.1342962630934172" MODIFIED="2012-07-29 04:06:20 +1000" MODIFIED_BY="Tea Andabaka" ORDER="53" O_E="0.0" SE="0.3631014164386405" STUDY_ID="STD-Fernandez-2010" TOTAL_1="83" TOTAL_2="176" VAR="0.13184263861974704" WEIGHT="20.89063250564007"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4057947006148312" CI_END="1.129049263543422" CI_START="0.9555026541548554" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0386575797573157" ESTIMABLE="YES" EVENTS_1="815" EVENTS_2="797" I2="11.914831523508305" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.05271289180831715" LOG_CI_START="-0.01976810224245147" LOG_EFFECT_SIZE="0.016472394782932855" METHOD="MH" MODIFIED="2012-07-29 05:18:27 +1000" MODIFIED_BY="Tea Andabaka" NO="13" P_CHI2="0.33318742202778984" P_Q="1.0" P_Z="0.3730029392287615" Q="0.0" RANDOM="NO" SCALE="6.8" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4063" TOTAL_2="4175" WEIGHT="99.99999999999999" Z="0.8908625202093648">
<NAME>Number of children reporting any SAE</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0548757204732198" CI_START="0.02703872742094624" EFFECT_SIZE="0.2357142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31278556074014596" LOG_CI_START="-1.568013752340847" LOG_EFFECT_SIZE="-0.6276140958003505" MODIFIED="2012-07-29 04:06:42 +1000" MODIFIED_BY="Tea Andabaka" ORDER="54" O_E="0.0" SE="1.1047908266105266" STUDY_ID="STD-Abarca-2009" TOTAL_1="70" TOTAL_2="66" VAR="1.2205627705627706" WEIGHT="0.5220794079359773"/>
<DICH_DATA CI_END="1.1762971293431448" CI_START="0.9349024161741782" EFFECT_SIZE="1.0486767988096504" ESTIMABLE="YES" EVENTS_1="506" EVENTS_2="485" LOG_CI_END="0.07051703716102967" LOG_CI_START="-0.029233717821374797" LOG_EFFECT_SIZE="0.020641659669827436" MODIFIED="2012-07-29 04:07:02 +1000" MODIFIED_BY="Tea Andabaka" ORDER="55" O_E="0.0" SE="0.05859408725086505" STUDY_ID="STD-Carbonell_x002d_Estrany-2010" TOTAL_1="3298" TOTAL_2="3315" VAR="0.003433267060761986" WEIGHT="61.3354150110785"/>
<DICH_DATA CI_END="1.1798086743044025" CI_START="0.936793751521598" EFFECT_SIZE="1.0513027128659682" ESTIMABLE="YES" EVENTS_1="304" EVENTS_2="292" LOG_CI_END="0.07181158490711387" LOG_CI_START="-0.028356014699933735" LOG_EFFECT_SIZE="0.021727785103590056" MODIFIED="2012-07-29 04:07:18 +1000" MODIFIED_BY="Tea Andabaka" ORDER="56" O_E="0.0" SE="0.0588389438467946" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="618" VAR="0.0034620213130062477" WEIGHT="36.842288844795476"/>
<DICH_DATA CI_END="1.5364381758151313" CI_START="0.18290858023634687" EFFECT_SIZE="0.5301204819277109" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="0.18651508952403958" LOG_CI_START="-0.7377659213038126" LOG_EFFECT_SIZE="-0.2756254158898864" MODIFIED="2012-07-29 04:07:34 +1000" MODIFIED_BY="Tea Andabaka" ORDER="57" O_E="0.0" SE="0.5429272410250728" STUDY_ID="STD-Fernandez-2010" TOTAL_1="83" TOTAL_2="176" VAR="0.2947699890470975" WEIGHT="1.3002167361900303"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9084900493049669" CI_END="2.4259409682088124" CI_START="0.32280075535633435" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8849268766331384" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.384880228726313" LOG_CI_START="-0.49106545769623716" LOG_EFFECT_SIZE="-0.05309261448496207" METHOD="MH" MODIFIED="2012-07-29 05:18:46 +1000" MODIFIED_BY="Tea Andabaka" NO="14" P_CHI2="0.6349271714362189" P_Q="1.0" P_Z="0.8121961951287221" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="765" TOTAL_2="860" WEIGHT="100.00000000000001" Z="0.23759375460956977">
<NAME>Number of children reporting related SAE</NAME>
<GROUP_LABEL_1>Palivizumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Motavizumab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors palivizumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors motavizumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.587873622928624" CI_START="0.013039781357177392" EFFECT_SIZE="0.3145539906103286" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.880120089042957" LOG_CI_START="-1.8847296905187794" LOG_EFFECT_SIZE="-0.5023048007379113" MODIFIED="2012-07-29 04:28:54 +1000" MODIFIED_BY="Tea Andabaka" ORDER="58" O_E="0.0" SE="1.6240864467417013" STUDY_ID="STD-Abarca-2009" TOTAL_1="70" TOTAL_2="66" VAR="2.637656786490085" WEIGHT="18.98898182131731"/>
<DICH_DATA CI_END="3.9496223525591176" CI_START="0.3717757221701784" EFFECT_SIZE="1.2117647058823529" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5965555720719192" LOG_CI_START="-0.42971897409016035" LOG_EFFECT_SIZE="0.08341829899087944" MODIFIED="2012-07-29 04:29:59 +1000" MODIFIED_BY="Tea Andabaka" ORDER="59" O_E="0.0" SE="0.6028387485565405" STUDY_ID="STD-Feltes-2011" TOTAL_1="612" TOTAL_2="618" VAR="0.36341455676121587" WEIGHT="61.21353672663746"/>
<DICH_DATA CI_END="8.680969823203132" CI_START="0.020458778734792845" EFFECT_SIZE="0.42142857142857143" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.9385682465287285" LOG_CI_START="-1.6891202946009158" LOG_EFFECT_SIZE="-0.37527602403609384" MODIFIED="2012-07-29 04:29:34 +1000" MODIFIED_BY="Tea Andabaka" ORDER="60" O_E="0.0" SE="1.5435172563276103" STUDY_ID="STD-Fernandez-2010" TOTAL_1="83" TOTAL_2="176" VAR="2.382445520581114" WEIGHT="19.797481452045247"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-10-16 04:04:41 +1000" MODIFIED_BY="Tea Andabaka">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-10-16 04:04:31 +1000" MODIFIED_BY="Tea Andabaka" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Palivizumab versus placebo, outcome: 1.1 Hospitalisation for RSV infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArYAAACwCAMAAADNG93qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-08-01 18:15:31 +1000" MODIFIED_BY="Tea Andabaka" NO="2" REF_ID="CMP-001.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Palivizumab versus placebo, outcome: 1.4 Admission to ICU.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArUAAACgCAMAAAAl+mRyAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-09-28 01:09:29 +1000" MODIFIED_BY="Tea Andabaka" NO="3" REF_ID="CMP-001.11" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Palivizumab versus placebo, outcome: 1.11 Number of children reporting any SAE.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAACQCAMAAAAldbPiAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2012-10-16 04:04:41 +1000" MODIFIED_BY="Tea Andabaka" NO="4" REF_ID="CMP-002.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Palivizumab versus motavizumab, outcome: 2.1 Hospitalisation for RSV infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvQAAACgCAMAAABUggjsAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2012-09-28 01:09:29 +1000" MODIFIED_BY="Tea Andabaka" NO="5" REF_ID="CMP-002.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Palivizumab versus motavizumab, outcome: 2.2 RSV-specific outpatient MALRI.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvQAAACgCAMAAABUggjsAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2012-09-28 01:10:19 +1000" MODIFIED_BY="Tea Andabaka" NO="6" REF_ID="CMP-002.07" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Palivizumab versus motavizumab, outcome: 2.7 Mechanical ventilation for RSV infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvQAAACgCAMAAABUggjsAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-03-16 00:20:27 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-06-30 20:04:48 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-06-30 20:04:11 +1000" MODIFIED_BY="[Empty name]">MEDLINE and CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-06-30 20:04:48 +1000" MODIFIED_BY="[Empty name]">
<P>1 Respiratory Syncytial Virus Infections/<BR/>2 respiratory syncytial viruses/ or respiratory syncytial virus, human/<BR/>3 (respiratory syncytial vir* or rsv).tw.<BR/>4 Respiratory Tract Infections/<BR/>5 (acute respiratory infection* or acute respiratory tract infection*).tw.<BR/>6 (lower respiratory tract infection* or lrti).tw.<BR/>7 exp Bronchiolitis/<BR/>8 bronchiolit*.tw.<BR/>9 pneumonia/ or pneumonia, viral/<BR/>10 pneumon*.tw.<BR/>11 or/1-10<BR/>12 palivizumab.tw,nm.<BR/>13 synagis.tw,nm.<BR/>14 exp Antibodies, Monoclonal/<BR/>15 (monoclonal antibod* or mab or mabs).tw.<BR/>16 Antiviral Agents/<BR/>17 Antibodies, Viral/<BR/>18 or/12-17<BR/>19 11 and 18</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-09-29 03:24:31 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-08-02 15:30:47 +1000" MODIFIED_BY="[Empty name]">Embase.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-09-29 03:24:31 +1000" MODIFIED_BY="[Empty name]">
<P>#21. #16 AND #20 524 29 Jul 2011<BR/>#20. #17 OR #18 OR #19 858,638 29 Jul 2011<BR/>#19. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR 'cross-over':ab,ti OR volunteer*:ab,ti OR allocat*;ti,ab OR<BR/>assign*:ab,ti OR ((singl* OR doubl*) NEAR/1 blind*):ab,ti AND [embase]/lim 818,196 29 Jul 2011<BR/>#18. 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp AND [embase]/lim 110,071 28 Jul 2011<BR/>#17. 'randomised controlled trial'/exp AND [embase]/lim 214,265 28 Jul 2011<BR/>#16. #10 AND #15 6,262 28 Jul 2011<BR/>#15. #11 OR #12 OR #13 OR #14 238,285 28 Jul 2011<BR/>#14. 'monoclonal antibody':ab,ti OR 'monoclonal antibodies':ab,ti OR mabs:ab,ti OR mab:ab,ti AND [embase]/lim 149,633 28 Jul 2011<BR/>#13. 'monoclonal antibody'/de OR 'virus antibody'/de OR 'antivirus agent'/de AND [embase]/lim 176,627 28 Jul 2011<BR/>#12. palivizumab:ab,ti OR synagis:ab,ti AND [embase]/lim 495 28 Jul 2011<BR/>#11. 'palivizumab'/de AND [embase]/lim 1,410 28 Jul 2011<BR/>#10. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 174,739 28 Jul 2011<BR/>#9. pneumon*:ab,ti AND [embase]/lim 104,459 28 Jul 2011<BR/>#8. 'pneumonia'/de OR 'virus pneumonia'/de AND [embase]/lim 67,722 28 Jul 2011<BR/>#7. bronchiolit*:ab,ti AND [embase]/lim 6,906 28 Jul 2011<BR/>#6. 'bronchiolitis'/exp AND [embase]/lim 9,404 28 Jul 2011<BR/>#5. 'acute respiratory infection':ab,ti OR 'acute respiratory infections':ab,ti OR 'lower respiratory tract infection':ab,ti OR 'lower<BR/>respiratory tract infections':ab,ti OR lrti:ab,ti AND [embase]/lim 5,440 28 Jul 2011<BR/>#4. 'respiratory tract infection'/de AND [embase]/lim 27,544 28 Jul 2011<BR/>#3. 'respiratory syncytial virus':ab,ti OR 'respiratory syncytial viruses':ab,ti OR rsv:ab,ti AND [embase]/lim 9,483 28 Jul 2011<BR/>#2. 'respiratory syncytial pneumovirus'/de AND [embase]/lim 8,983 28 Jul 2011<BR/>#1. 'respiratory syncytial virus infection'/de AND [embase]/lim 440 28 Jul 2011</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-08-02 15:45:23 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-08-02 15:36:56 +1000" MODIFIED_BY="[Empty name]">CINAHL (Ebsco) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-02 15:45:23 +1000" MODIFIED_BY="[Empty name]">
<P>S29 S19 and S28 72 <BR/>S28 S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 157323 <BR/>S27 (MH "Quantitative Studies") 6708 <BR/>S26 TI placebo* OR AB placebo* 17633 <BR/>S25 (MH "Placebos") 5979 <BR/>S24 TI random* OR AB random* 85911 <BR/>S23 TI (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or trebl* mask* or tripl* mask*) OR AB (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or trebl* mask* or tripl* mask*) 12936 <BR/>S22 TI clinic* trial* OR AB clinic* trial* 24108 <BR/>S21 PT clinical trial 48680 <BR/>S20 (MH "Clinical Trials+") 96829 <BR/>S19 S11 and S18 473 <BR/>S18 S12 or S13 or S14 or S15 or S16 or S17 17036 <BR/>S17 (MH "Antiviral Agents") 7987 <BR/>S16 (MH "Antibodies, Viral") 1337 <BR/>S15 TI (monoclonal antibod* or mab or mabs) OR AB (monoclonal antibod* or mab or mabs) 2004 <BR/>S14 (MH "Antibodies, Monoclonal+") 7068 <BR/>S13 TI (palivizumab or synagis) OR AB (palivizumab or synagis) 108 <BR/>S12 (MH "Palivizumab") 61 <BR/>S11 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 14405 <BR/>S10 (MH "Pneumonia, Viral") 182 <BR/>S9 TI pneumon* OR AB pneumon* 8786 <BR/>S8 (MH "Pneumonia") 4052 <BR/>S7 TI bronchiolit* OR AB bronchiolit* 622 <BR/>S6 (MH "Bronchiolitis+") 558 <BR/>S5 TI (acute respiratory infection* or acute respiratory tract infection* or lower respiratory tract infection* or lrti) OR AB (acute respiratory infection* or acute respiratory tract infection* or lower respiratory tract infection* or lrti) 836 <BR/>S4 (MH "Respiratory Tract Infections") 2921 <BR/>S3 TI (respiratory syncytial vir* or rsv) OR AB (respiratory syncytial vir* or rsv) 748 <BR/>S2 (MH "Respiratory Syncytial Viruses") 241 <BR/>S1 (MH "Respiratory Syncytial Virus Infections") 701 <BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-08-09 18:07:48 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-08-02 15:45:47 +1000" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-09 18:07:48 +1000" MODIFIED_BY="[Empty name]">
<P>&gt; Search &gt; (MH:"Respiratory Syncytial Virus Infections" OR "Infecciones por Virus Sincitial Respiratorio" OR "Infecções por Vírus Respiratório Sincicial" OR MH:"Respiratory Syncytial iruses" OR "Virus Sincitiales Respiratorios" OR "Vírus Sinciciais Respiratórios" OR MH:"Respiratory Syncytial Virus, Human" OR "Virus Sincitial Respiratorio Humano" OR "Vírus sincicial Respiratório Humano" OR "respiratory syncytial virus" OR "respiratory syncytical viruses" OR rsv OR MH:"Respiratory Tract Infections" OR "Infecciones del Sistema Respiratorio" OR "Infecções Respiratórias" OR "respiratory infection" OR "respiratory infections" OR "respiratory tract infections" OR "respiratory tract infection" OR "Infecciones del Tracto Respiratorio" OR "Infecciones Respiratorias" OR "Infecções do Trato Respiratório" OR "Infecções do Sistema Respiratório" OR MH:Bronchiolitis OR bronchiolit$ OR Bronquiolitis OR Bronquiolite OR MH:C08.127.446.135$ OR MH:C08.381.495.146.135$ OR C08.730.099.135$ OR MH:Pneumonia OR Neumonía OR pneumon$ OR Pulmonía OR "Inflamación Pulmonar" OR "Inflamação Pulmonar") AND (palivizumab OR synagis OR MH:"Antibodies, Monoclonal" OR "Anticuerpos Monoclonales" OR "Anticorpos Monoclonais" OR MH:D12.776.124.486.485.114.224$ OR MH:D12.776.124.790.651.114.224$ OR MH:D12.776.377.715.548.114.224$ OR "monoclonal antibodies" OR "monoclonal antibody" OR mab OR mabs OR MH:"Antiviral Agents" OR Antivirales OR Antivirais OR MH:"Antibodies, Viral" OR "Anticuerpos Antivirales" OR "Anticorpos Antivirais") &gt; clinical_trials</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2011-08-02 15:50:36 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2011-08-02 15:47:58 +1000" MODIFIED_BY="[Empty name]">Adverse effects search strategy in MEDLINE and EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-02 15:50:36 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">MEDLINE (Ovid)</HEADING>
<P>1 palivizumab.tw,nm. (502)<BR/>2 synagis.tw,nm. (74)<BR/>3 1 or 2 (507)<BR/>4 (ae or de or po or to).fs. (3302629)<BR/>5 (safe or safety or side effect* or undesirable effect* or treatment emergent or tolerability or toxicity or adrs).tw. (634946)<BR/>6 (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).tw. (176894)<BR/>7 4 or 5 or 6 (3675600)<BR/>8 3 and 7 (155)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">EMBASE.com</HEADING>
<P>#9. #7 OR #8 273 1 Aug 2011<BR/>#8. 'palivizumab'/exp/dd_ae,dd_to AND [embase]/lim 131 1 Aug 2011<BR/>#7. #3 AND #6 219 1 Aug 2011<BR/>#6. #4 OR #5 822,846 1 Aug 2011<BR/>#5. (adverse NEAR/2 (effect OR effects OR reaction OR reactions OR event OR events OR outcome OR outcomes)):ab,ti AND [embase]/lim 206,008 1 Aug 2011<BR/>#4. safe:ab,ti OR safety:ab,ti OR 'side effect':ab,ti OR 'side effects':ab,ti OR 'undesirable effect':ab,ti OR 'undesirable effects':ab,ti OR 'treatment emergent':ab,ti OR tolerability:ab,ti OR toxicity:ab,ti OR adrs:ab,ti AND [embase]/lim 700,278 1 Aug 2011<BR/>#3. #1 OR #2 1,426 1 Aug 2011<BR/>#2. palivizumab:ab,ti OR synagis:ab,ti AND [embase]/lim 495 1 Aug 2011<BR/>#1. 'palivizumab'/de AND [embase]/lim 1,410 1 Aug 2011</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2013-03-15 23:24:45 +1000" MODIFIED_BY="Tea Andabaka" NO="6">
<TITLE MODIFIED="2012-09-27 23:59:16 +1000" MODIFIED_BY="Tea Andabaka">Quality assessment of included economic evaluations by using the adapted Drummond checklist</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-15 23:24:45 +1000" MODIFIED_BY="Tea Andabaka">
<TABLE COLS="10" ROWS="35">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Study ID</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Well-defined question?</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Competing alternatives described?</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Effectiveness established?</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Relevant costs and consequences (conseq.) identified?</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Costs and conseq. measured accurately?</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Costs and conseq. valued credibly?</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Discounting performed?</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Incremental analysis of costs and conseq. performed?</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Sensitivity analysis performed?</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Bentley-2011" TYPE="STUDY">Bentley 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chirico-2009" TYPE="STUDY">Chirico 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Chiroli-2005" TYPE="STUDY">Chiroli 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-ElHassan-2006" TYPE="STUDY">ElHassan 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Embleton-2007" TYPE="STUDY">Embleton 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Garcia_x002d_Altes-2010" TYPE="STUDY">Garcia-Altes 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hampp-2011" TYPE="STUDY">Hampp 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Harris-2011" TYPE="STUDY">Harris 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hascoet-2008" TYPE="STUDY">Hascoet 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Joffe-1999" TYPE="STUDY">Joffe 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Kang-2009" TYPE="STUDY">Kang 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lanctot-2008" TYPE="STUDY">Lanctot 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lazaro-y-de-Mercado-2006" TYPE="STUDY">Lazaro y de Mercado 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lazaro-y-de-Mercado-2007" TYPE="STUDY">Lazaro y de Mercado 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lofland-2000" TYPE="STUDY">Lofland 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Mayen_x002d_Herrera-2011" TYPE="STUDY">Mayen-Herrera 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can't tell</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Neovius-2011" TYPE="STUDY">Neovius 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2007" TYPE="STUDY">Nuijten 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2009a" TYPE="STUDY">Nuijten 2009a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2009b" TYPE="STUDY">Nuijten 2009b</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nuijten-2010" TYPE="STUDY">Nuijten 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ravasio-2006" TYPE="STUDY">Ravasio 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Raya-Ortega-2006" TYPE="STUDY">Raya Ortega 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Resch-2008" TYPE="STUDY">Resch 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Resch-2012" TYPE="STUDY">Resch 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rietveld-2010" TYPE="STUDY">Rietveld 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Roeckl_x002d_Wiedmann-2003" TYPE="STUDY">Roeckl-Wiedmann 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Salinas_x002d_Escudero-2012" TYPE="STUDY">Salinas-Escudero 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Smart-2010" TYPE="STUDY">Smart 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Can&#8217;t tell</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tam-2009" TYPE="STUDY">Tam 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Vogel-2002" TYPE="STUDY">Vogel 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Weiner-2012" TYPE="STUDY">Weiner 2012</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Yount-2004" TYPE="STUDY">Yount 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2013-03-15 23:25:15 +1000" MODIFIED_BY="Tea Andabaka" NO="7">
<TITLE MODIFIED="2012-09-27 21:45:24 +1000" MODIFIED_BY="Tea Andabaka">GRADE approach for quality assessment of included RCTs</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-15 23:25:15 +1000" MODIFIED_BY="Tea Andabaka">
<P>The GRADE approach specifies four levels of quality.</P>
<OL>
<LI>High quality for randomised trials or double-upgraded observational studies.</LI>
<LI>Moderate quality for downgraded randomised trials or upgraded observational studies.</LI>
<LI>Low quality for double-downgraded randomised trials or observational studies.</LI>
<LI>Very low quality for triple-downgraded randomised trials or downgraded observational studies or case series/case reports.</LI>
</OL>
<P>Authors could downgrade randomised trial evidence by one or two levels depending on the presence of five factors.</P>
<OL>
<LI>Serious (- 1) or very serious (- 2) limitation to study quality.</LI>
<LI>Important inconsistency across the studies (- 1 or - 2).</LI>
<LI>Some (- 1) or major (- 2) uncertainty about directness.</LI>
<LI>Imprecise or sparse data (- 1 or - 2).</LI>
<LI>High probability of reporting bias (- 1).</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2013-03-15 23:25:33 +1000" MODIFIED_BY="Maria X Rojas" NO="8">
<TITLE MODIFIED="2012-05-08 05:57:07 +1000" MODIFIED_BY="Maria X Rojas">Money exchange rates</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-15 23:25:33 +1000" MODIFIED_BY="Maria X Rojas">
<TABLE COLS="3" ROWS="13">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>World currency</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Base year of the evaluation</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Exchange rate to Euros</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Canadian dollar (CAD)</P>
</TD>
<TD ALIGN="CENTER">
<P>2007</P>
</TD>
<TD ALIGN="CENTER">
<P>0.6994194213</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2010</P>
</TD>
<TD ALIGN="CENTER">
<P>0.7927647938</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Great British pound (GBP)</P>
</TD>
<TD ALIGN="CENTER">
<P>2003</P>
</TD>
<TD ALIGN="CENTER">
<P>1.4194561843</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2005</P>
</TD>
<TD ALIGN="CENTER">
<P>1.5060315583</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2006</P>
</TD>
<TD ALIGN="CENTER">
<P>1.4639767907</P>
</TD>
</TR>
<TR>
<TD>
<P>New Zealand dollar (NZD)</P>
</TD>
<TD ALIGN="CENTER">
<P>2000</P>
</TD>
<TD ALIGN="CENTER">
<P>0.4961650904</P>
</TD>
</TR>
<TR>
<TD>
<P>Swedish krona (SEK)</P>
</TD>
<TD ALIGN="CENTER">
<P>2009</P>
</TD>
<TD ALIGN="CENTER">
<P>0.0920369376</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="5">
<P>United States dollar (USD)</P>
</TD>
<TD ALIGN="CENTER">
<P>1995</P>
</TD>
<TD ALIGN="CENTER">
<P>Not available</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>1999</P>
</TD>
<TD ALIGN="CENTER">
<P>0.9704846756</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2002</P>
</TD>
<TD ALIGN="CENTER">
<P>1.0583130490</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2009</P>
</TD>
<TD ALIGN="CENTER">
<P>0.7205825931</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2010</P>
</TD>
<TD ALIGN="CENTER">
<P>0.8114656949</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2013-03-15 23:25:40 +1000" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2012-09-27 23:51:14 +1000" MODIFIED_BY="[Empty name]">GDP deflators for present value calculations</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-15 23:25:40 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="25">
<TR>
<TH VALIGN="BOTTOM">
<P>Country</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Base year of the evaluation</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P> GDP deflator for 2011 adjustment </P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Austria</P>
</TD>
<TD ALIGN="CENTER">
<P>2006</P>
</TD>
<TD ALIGN="CENTER">
<P>1.114357</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2010</P>
</TD>
<TD ALIGN="CENTER">
<P>1.032669</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Canada</P>
</TD>
<TD ALIGN="CENTER">
<P>2007</P>
</TD>
<TD ALIGN="CENTER">
<P>1.075445</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2010</P>
</TD>
<TD ALIGN="CENTER">
<P>1.029121</P>
</TD>
</TR>
<TR>
<TD>
<P>France</P>
</TD>
<TD ALIGN="CENTER">
<P>2006</P>
</TD>
<TD ALIGN="CENTER">
<P>1.082785</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Germany</P>
</TD>
<TD ALIGN="CENTER">
<P>2002</P>
</TD>
<TD ALIGN="CENTER">
<P>1.154669</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2006</P>
</TD>
<TD ALIGN="CENTER">
<P>1.089589</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>Italy</P>
</TD>
<TD ALIGN="CENTER">
<P>2004</P>
</TD>
<TD ALIGN="CENTER">
<P>1.151798</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2005</P>
</TD>
<TD ALIGN="CENTER">
<P>1.129224</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2006</P>
</TD>
<TD ALIGN="CENTER">
<P>1.106326</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2007</P>
</TD>
<TD ALIGN="CENTER">
<P>1.086535</P>
</TD>
</TR>
<TR>
<TD>
<P>Mexico</P>
</TD>
<TD ALIGN="CENTER">
<P>2009</P>
</TD>
<TD ALIGN="CENTER">
<P>1.077065</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Netherlands</P>
</TD>
<TD ALIGN="CENTER">
<P>2000</P>
</TD>
<TD ALIGN="CENTER">
<P>1.249521</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2006</P>
</TD>
<TD ALIGN="CENTER">
<P>1.092226</P>
</TD>
</TR>
<TR>
<TD>
<P>New Zealand</P>
</TD>
<TD ALIGN="CENTER">
<P>2000</P>
</TD>
<TD ALIGN="CENTER">
<P>1.340948</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Spain</P>
</TD>
<TD ALIGN="CENTER">
<P>2006</P>
</TD>
<TD ALIGN="CENTER">
<P>1.120584</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2008</P>
</TD>
<TD ALIGN="CENTER">
<P>1.04751</P>
</TD>
</TR>
<TR>
<TD>
<P>Sweden</P>
</TD>
<TD ALIGN="CENTER">
<P>2009</P>
</TD>
<TD ALIGN="CENTER">
<P>1.041534</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>UK</P>
</TD>
<TD ALIGN="CENTER">
<P>2003</P>
</TD>
<TD ALIGN="CENTER">
<P>1.237114</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2005</P>
</TD>
<TD ALIGN="CENTER">
<P>1.196183</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2006</P>
</TD>
<TD ALIGN="CENTER">
<P>1.168906</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>USA</P>
</TD>
<TD ALIGN="CENTER">
<P>1999</P>
</TD>
<TD ALIGN="CENTER">
<P>1.350378</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2002</P>
</TD>
<TD ALIGN="CENTER">
<P>1.25053</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>2010</P>
</TD>
<TD ALIGN="CENTER">
<P>1.031568</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-10" MODIFIED="2013-03-16 00:20:27 +1000" MODIFIED_BY="Tea Andabaka" NO="10">
<TITLE MODIFIED="2012-09-27 23:15:51 +1000" MODIFIED_BY="Tea Andabaka">Methods for present value calculations</TITLE>
<APPENDIX_BODY MODIFIED="2013-03-16 00:20:27 +1000" MODIFIED_BY="Tea Andabaka">
<P>Present value calculations are used to provide a unique measure to compare cash flows at different times. If the payments were made in the past, their value is enhanced to reflect that those payments could have earned interest in the elapsed time. The most common way of inflation adjustment uses the gross domestic product (GDP) deflator. The GDP is a monetary value of all the finished goods and services produced within country's borders in a specific time period, though GDP is usually calculated on an annual basis. It includes all of private and public consumption, government outlays, investments and exports less imports that occur within a defined territory.</P>
<P>In order to calculate the ICER present values at 2011 Euros, we performed two main steps: currency conversion and inflation adjustment.</P>
<P>Firstly, we converted the values reported in the study in their original currency to Euros at the same price year. When the information about the price year used was not stated by the authors, we took one year prior to the year of publication as a referent year. To be consistent through studies, all the exchange rates used were taken at the same month and day: 16 June (e.g. if value was reported in 2003 USD, to convert it in Euros we used the exchange rate for 16 June 2003). To do this, we used the XE Universal Currency Converter, as it contains historical rate tables for every world currency since 1995 to present date, and is available at <A HREF="http://www.xe.com/ucc/">http://www.xe.com/ucc/</A>. Money exchange rates used for currency conversions are presented in <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>.</P>
<P>Once the currencies were converted to Euros, we performed the inflation adjustments by using the following formula.</P>
<P>
<I>Present value in 2011 EUR = Reported value converted to EUR at base year x GDP deflator</I>
</P>
<P>The GDP deflator is the ratio of nominal GDP (the value of aggregate final output at current market prices) to real GDP (its value at base year prices) and can be considered the most comprehensive measure of inflation, since a wide array of goods and services are included in its construction.</P>
<P>
<I>GDP deflator = Nominal GDP</I>/<I>Real GDP</I>
</P>
<P>For calculating the GDP deflators, we considered not only the price years reported by authors, but also the country where the economic analysis was carried out. We retrieved the World Bank Consumer Price Indexes for these calculations (available at <A HREF="http://data.worldbank.org/indicator/FP.CPI.TOTL">http://data.worldbank.org/indicator/FP.CPI.TOTL</A>). GDP deflators used for inflation adjustments are given in <LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>